WO2005118857A2 - Methods and agents for screening for compounds capable of modulating vegf expression - Google Patents

Methods and agents for screening for compounds capable of modulating vegf expression Download PDF

Info

Publication number
WO2005118857A2
WO2005118857A2 PCT/US2004/020751 US2004020751W WO2005118857A2 WO 2005118857 A2 WO2005118857 A2 WO 2005118857A2 US 2004020751 W US2004020751 W US 2004020751W WO 2005118857 A2 WO2005118857 A2 WO 2005118857A2
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
utr
compound
seq
vegf
Prior art date
Application number
PCT/US2004/020751
Other languages
French (fr)
Other versions
WO2005118857A3 (en
Inventor
Liangxian Cao
Christopher Robert Trotta
Original Assignee
Ptc Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics, Inc. filed Critical Ptc Therapeutics, Inc.
Priority to CA2567111A priority Critical patent/CA2567111C/en
Priority to EP04809465A priority patent/EP1761638A4/en
Priority to JP2007515026A priority patent/JP2008507953A/en
Publication of WO2005118857A2 publication Critical patent/WO2005118857A2/en
Publication of WO2005118857A3 publication Critical patent/WO2005118857A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Definitions

  • VEGF Vascular Endothelial Growth Factor
  • VEGF is an important factor in the pathogenesis of cancers, diabetic retinopathy (DR), and exudative macular degeneration (reviewed in Tandle et al., Clin. Adv. in Hemat. and Oncol., 7(7) :41-48 (2003); Ferrara et al, Nat. Med., 5( 2,):1359-1364 (1999); Matter, supra; Carmeliet supra; Kerbel et al, Nat. Rev. Cancer, 2(10):121-139 (2002); Witmer et al, Prog. Retin. Eye Res., 22(l):l-29 (2003); Clark et al, Nat. Rev.
  • DR diabetic retinopathy
  • VEGF vascular endothelial growth factor
  • cytokines cytokines
  • growth factors steroid hormones and chemicals
  • mutations that modulate the activity of oncogenes such as ras or the tumor suppressor gene VHL (Maxwell et al, Nature, 399:211-215 (1999); Rak et al, Cancer Res., 60:490-498 (2000)).
  • VEGF expression is regulated after transcription by sequences in both the 5'- and 3 '-untranslated regions (UTRs) of its mRNA (Ikeda et al, J. Biol Chem., 270:19161-19166 (1995); Stein et al, Mol Cell. Biol, 75:3112-3119 (1998); Levy et al J. Biol. Chem., 271:2146-2153 (1996); Huez et al, Mol Cell Biol, 18:6118-6190 (1998); Akiri et al, Oncogene, 77:227-236 (1998)).
  • UTRs 5'- and 3 '-untranslated regions
  • the VEGF 5' UTR is unusually long and GC rich, and it contains an internal ribosomal entry site (IRES) that is reported to mediate a unique, cap-independent mode of translation initiation.
  • the VEGF 3' UTR harbors multiple AU-rich stability determinants that have been shown to be associated with VEGF mRNA turnover rates. Initiation of translation of the VEGF mRNA is reported to be unique under hypoxic conditions in that it is mediated via an internal ribosome entry site (IRES) within the VEGF 5' UTR (Stein et al, supra; Levy et al, supra; Huez et al, supra; Akiri et al, supra).
  • cap-dependent translation is dramatically impaired and the translation of the VEGF mRNA occurs through its cap-independent IRES. Initiation of translation of most eukaryotic mRNA is cap-dependent. IRES-mediated translation initiation becomes predominant when components of the translation initiation complex become rate-limiting, e.g., during hypoxia (Mitchell et al, Mol Cell, ll(3):151-lll (2003)).
  • IRES-mediated translation initiation becomes predominant when components of the translation initiation complex become rate-limiting, e.g., during hypoxia (Mitchell et al, Mol Cell, ll(3):151-lll (2003)).
  • Several investigators have used in vitro and bicistronic strategies, often in conjunction with deletion mutants, to study regulation of VEGF. Prats and colleagues reported the occurrence of cap-independent translation of human VEGF by virtue of an IRES.
  • IRES A a first IRES located within 300 nucleotides of the initiation codon and a second IRES located in the upstream half of the 5'-UTR.
  • IRES B a second IRES located in the upstream half of the 5'-UTR.
  • Keshet and colleagues reported an increase in IRES activity from a 163-nucleotide sequence derived from a VEGF 5' UTR, which is possibly an artifact from RT-PCR amplification, relative to the entire full-length VEGF 5' UTR. Stein et al, supra. Goodall and colleagues reported a deletion analysis of IRES residues toward the 3' end of the mouse VEGF 5' UTR, and speculated that, for optimal IRES activity, the upstream half of the VEGF 5' UTR is necessary. Miller et al, supra.
  • the present invention provides, for the first time, a negative regulator of post- transcriptional regulation (NeRP) located in the 5' UTR of VEGF. Removal of a NeRP from the VEGF 5' UTR results in increased translation of an operably linked gene dependent on the presence of a PTCRE of the present invention.
  • NeRP post- transcriptional regulation
  • the present invention includes a nucleic acid construct comprising a nucleic acid sequence encoding a reporter polypeptide, where the nucleic acid sequence encoding a reporter polypeptide is operably linked to a NeRP, the NeRP is operably linked to a PTCRE, the PTCRE is not SEQ ID NO: 3, and expression of the reporter polypeptide is capable of being modulated relative to in an absence of the NeRP.
  • the present invention also includes a nucleic acid molecule comprising a nucleic acid sequence encoding a reporter polypeptide and a VEGF 5' UTR nucleic acid sequence in an absence of SEQ ID NO: 4.
  • the present invention also includes a nucleic acid molecule comprising a nucleic acid sequence encoding a reporter polypeptide operably linked to a VEGF 5' UTR in an absence ofSEQ ID NO: 4.
  • the present invention also includes a nucleic acid molecule comprising a nucleic acid sequence encoding a reporter polypeptide, where the nucleic acid sequence encoding a reporter polypeptide is operably linked downstream of a UTR containing a NeRP, and the UTR is not operably upstream of SEQ ID NO: 3.
  • the present invention also includes a heterogeneous population of nucleic acid molecules, where the heterogeneous population comprises a reporter nucleic acid sequence, and the nucleic acid sequence encoding a reporter polypeptide is operably linked to a VEGF 5' UTR in an absence of NeRPl (SEQ ID NO: 4).
  • the present invention also includes a substantially purified nucleic acid molecule comprising between 95% and 99% sequence identity with a nucleic acid molecule of SEQ ID NO: 3, a fragment thereof, or a complement of either.
  • the present invention also includes a substantially purified nucleic acid molecule consisting of SEQ ID NO: 3, a fragment thereof, or a complement of either.
  • the present invention also includes a substantially purified nucleic acid molecule consisting of a first nucleic acid sequence linked to a heterologous nucleic acid sequence encoding a polypeptide, where the first nucleic acid sequence is selected from the group consisting of SEQ ID NO: 3, a fragment thereof, and a complement of either.
  • the present invention also includes a substantially purified nucleic acid molecule comprising between 95% and 99%) sequence identity with a nucleic acid molecule of SEQ ID NO: 4, a fragment thereof, or a complement of either.
  • the present invention also includes a substantially purified nucleic acid molecule of a nucleic acid sequence selected from a group consisting of SEQ ID NO: 4, a fragment thereof, and a complement of either.
  • the present invention also includes a substantially purified nucleic acid molecule consisting of a first nucleic acid sequence linked to a heterologous nucleic acid sequence encoding a polypeptide, where the first nucleic acid sequence is selected from the group consisting of SEQ ID NO: 4, a fragment thereof, and a complement of either.
  • the present invention also includes a method of making a nucleic acid construct to screen for a compound comprising: a) providing a main ORF downstream of a promoter in the nucleic acid construct; b) operably linking a VEGF 5' UTR in an absence of SEQ ID NO: 4 upstream of the main ORF; and c) operably linking a VEGF 3' UTR downstream of the main ORF.
  • the present invention also includes a method of screening in vivo for a compound that modulates UTR-dependent expression comprising: a) providing a cell having a nucleic acid molecule comprising a promoter upstream from a VEGF 5' UTR in an absence of SEQ ID NO: 4, where the VEGF 5' UTR in an absence of SEQ ID NO: 4 is upstream from a nucleic acid sequence encoding a reporter polypeptide, and the nucleic acid sequence encoding a reporter polypeptide is upstream from a VEGF 3' UTR; b) contacting the cell with a compound; c) producing a nucleic acid molecule that contains a nucleic acid sequence encoding a reporter polypeptide and does not contain SEQ ID NO: 4; and d) detecting the reporter polypeptide.
  • the present invention also includes a method of screening in vitro for a compound that modulates UTR-affected expression comprising: a) providing an in vitro translation system; b) contacting the in vitro translation system with a compound and a nucleic acid molecule comprising a VEGF 5' UTR in an absence of SEQ ID NO: 4, where the VEGF 5' UTR in an absence of SEQ ID NO: 4 is upstream from a nucleic acid sequence encoding a reporter polypeptide and the nucleic acid sequence encoding a reporter polypeptide is upstream from a VEGF 3' UTR; and c) detecting the reporter polypeptide in vitro.
  • the present invention also includes a method of expressing a nucleic acid molecule in a cell comprising: a) providing a nucleic acid molecule to a cell, where the nucleic acid molecule comprises a nucleic acid sequence encoding a reporter polypeptide flanked by VEGF UTRs in an absence of SEQ ID NO: 4; and b) detecting the reporter polypeptide.
  • the present invention also includes a method of screening for a compound that modulates protein expression through a main ORF-independent, UTR-affected mechanism comprising: a) growing a stable cell line having a reporter gene operably linked to a VEGF 5' UTR in an absence of SEQ ID NO: 4; b) comparing the stable cell line in a presence of a compound relative to the stable cell line in an absence of the compound; and c) selecting for the compound that modulates protein expression through a main ORF-independent, UTR- affected mechanism.
  • the present invention also includes a method of screening for a compound that modulates protein expression through a main ORF-independent, UTR-affected mechanism comprising: a) growing a stable cell line having a main ORF operably linked to a VEGF 5' UTR in an absence of SEQ ID NO: 4; b) comparing the stable cell line in the presence of a compound relative to the stable cell line in the absence of the compound; and c) selecting for the compound that modulates protein expression through a main ORF-independent, UTR- affected mechanism.
  • the present invention also includes a method of screening for a compound that modulates protein expression through a VEGF-independent, UTR-affected mechanism comprising: a) substituting in vivo a VEGF gene with a reporter gene, where a UTR consisting of SEQ ID NO: 3 is operably linked to the reporter gene, and the substitution occurs in a differentiated cell; b) growing the differentiated cell; and c) selecting for the compound that modulates protein expression of the reporter gene through a main ORF- independent, UTR-affected mechanism.
  • the present invention also includes a method of screening for a compound that modulates protein expression through a main ORF-independent, UTR-affected mechanism comprising: a) substituting in vivo a main ORF with a reporter gene, where a 5' UTR is operably linked to the reporter gene and consists of SEQ ID NO: 3, and the substitution occurs in a differentiated cell; b) growing the differentiated cell; and c) selecting for the compound that modulates protein expression of the reporter gene through a main ORF- independent, UTR-affected mechanism.
  • the present invention also includes a method of screening for a compound that modulates protein expression through a UTR-affected mechanism comprising: a) providing a stable cell line having a reporter gene operably linked to a VEGF 5' UTR in an absence of SEQ ID NO: 4, where the stable cell line mimics post-transcriptional regulation of a VEGF gene found in vivo in presence of the compound; b) maintaining the stable cell line; and c) selecting for the compound that modulates protein expression of the reporter gene through a UTR-affected mechanism.
  • the present invention also includes a method of screening for a compound that modulates protein expression through a UTR-affected mechanism comprising: a) providing a stable cell line having a main ORF encoding a reporter polypeptide operably linked to a VEGF 5' UTR in an absence of SEQ ID NO: 4, where the stable cell line mimics post- transcriptional regulation of a VEGF gene found in vivo in a presence of a compound; b) maintaining the stable cell line; and c) selecting for the compound that modulates protein expression of the main ORF through a UTR-affected mechanism.
  • the present invention also includes a method of screening for a compound that modulates protein expression through a UTR-affected mechanism mediating the effect of a NeRP comprising: a) growing a stable cell line having a reporter gene operably linked to a 5' VEGF UTR in an absence of a NeRP 1 (SEQ ID NO: 4); b) comparing the stable cell line in a presence of a compound relative to in an absence of the compound, where the compound does not modulate UTR-dependent expression if the 5' VEGF UTR in an absence of a NeRPl (SEQ ID NO: 4) is operably linked to a reporter gene; and c) selecting for the compound that modulates protein expression of the reporter gene through a UTR-affected mechanism mediating the effect of a NeRP.
  • the present invention also includes a method of screening for a compound that modulates protein expression through a UTR-affected mechanism mediating the effect of a NeRP comprising: a) growing a stable cell line having a main ORF encoding a reporter polypeptide operably linked to a 5' VEGF UTR in an absence of a NeRPl (SEQ ID NO: 4); b) comparing the stable cell line in the presence of a compound relative to that in the absence of the compound, where the compound does not modulate UTR-dependent expression if the 5' VEGF UTR in an absence of a NeRPl (SEQ ID NO: 4) is operably linked to a main ORF; and c) selecting for the compound that modulates protein expression of the main ORF through a UTR-affected mechanism mediating the effect of a NeRP .
  • the present invention also includes a method of screening for a compound that modulates protein expression through a UTR-affected mechanism mediating the effect of a NeRP comprising: a) growing a stable cell line having a reporter gene operably linked to a UTR having a NeRPl (SEQ ID NO: 4); b) comparing the stable cell line in a presence of a compound relative to in an absence of the compound, where the compound modulates UTR- dependent expression if a NeRPl (SEQ ID NO: 4) is operably linked to a reporter gene; and c) selecting for the compound that modulates protein expression of the reporter gene through a UTR-affected mechanism mediating the effect of a NeRP.
  • the present invention also includes a method of screening for a compound that modulates protein expression through a UTR-affected mechanism mediating the effect of a NeRP comprising: a) growing a stable cell line having a main ORF encoding a reporter polypeptide operably linked to a UTR having a NeRPl (SEQ ID NO: 4); b) comparing the stable cell line in a presence of a compound relative to in an absence of the compound, where the compound modulates UTR-dependent expression if a NeRPl (SEQ ID NO: 4) is operably linked to a main ORF encoding a reporter polypeptide; and c) selecting for the compound that modulates protein expression of the main ORF encoding a reporter polypeptide through a UTR-affected mechanism mediating the effect of the NeRP.
  • Figure 1 sets forth a sequence alignment of VEGF 5' UTR for mouse, rat, and human.
  • Figure 2 sets forth an example of a compound that inhibits VEGF expression over a concentration range.
  • Figure 3 sets forth an example of UTR-dependent inhibition of VEGF expression, where VEGF expression is dependent on one or more VEGF UTRs.
  • Figure 4A sets forth an example of effective inhibition of VEGF production in tumor tissue.
  • Figure 4B sets forth the inhibition of human VEGF production in vivo by a compound.
  • Figure 5 sets forth a schematic of a 5' VEGF UTR and restriction sites therein. VEGF 5 'UTR is amplified from human genomic DNA by two separate PCR reactions.
  • FIG. 6 sets forth a schematic representation of dicistronic plasmids that can be used for transf ection experiments.
  • P21uc/5UTR- ⁇ NeRPl is a dicistronic plasmid containing VEGF 5'UTRl, in which nucleotides 337 to 1083 of the VEGF cDNA are fused to the firefly luciferase coding sequence;
  • P21uc/5UTR-FL is generated by subcloning VEGF 5'UTR2 into the plasmid p21uc/vegf5utrl between Sal I and B ⁇ mHI;
  • plasmid p21uc/5UTR- ⁇ 51-476 is derived from p21uc/5UTR-FL by removing the Nhe /fragment (nt 51 to 746);
  • plasmid p21uc/5UTR- ⁇ 476-1038 is derived from p21uc/vegf5utr-fl by removing the sequence from B ⁇ mHI site to the 3'end of 5'UTR;
  • P21uc-e can be used as a negative control in this study.
  • Figure 7 sets forth results identifying the presence of a VEGF IRES domain (a PTCRE) and a NeRP in the VEGF mRNA 5'UTR. Reporter gene expression is analyzed by monitoring luciferase activity.
  • SEQ ID NO 1 sets forth a full-length VEGF 5' UTR.
  • SEQ ID NO 2 sets forth an open reading frame encoding VEGF.
  • SEQ ID NO 3 sets forth a PTCREl, a 702 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 4 sets forth aNeRPl, a 336 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 5 sets forth a PTCRE2, a 485 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 6 sets forth a PTCRE3, a 556 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 7 sets forth a PTCRE4, a 294 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 8 sets forth a PTCRE5, a 194 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 9 sets forth a NeRP2, a 476 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 10 sets forth aNeRP3, a 554 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 11 sets forth a NeRP4, a 51 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 12 sets forth a eRP5, a 91 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 13 sets forth a NeRP6, a 335 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 14 sets forth a NeRP7, a 332 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 15 sets forth a NeRP ⁇ , a 331 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 16 sets forth aNeRP9, a 330 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 17 sets forth a NeRP 10, a 329 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 18 sets forth a NeRPl 1 , a 328 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO 19 sets forth a NeRP 12, a 327 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO: 20 sets forth a NeRP13, a 326 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO: 21 sets forth aNeRP14, a 316 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO: 22 sets forth a NeRP15, a 306 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO: 23 sets forth a NeRP 16, a 296 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO: 24 sets forth a NeRP17, a 286 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO: 25 sets forth a NeRP 18, a 276 nucleotide region of a VEGF 5' UTR.
  • SEQ ID NO: 26 sets forth a NeRP19, a 266 nucleotide region of a VEGF 5' UTR.
  • the term “construct” refers to an artificially manipulated nucleic acid molecule.
  • heterologous refers to ingredients or constituents of dissimilar or diverse origin.
  • the term “mammalian cancer cell” or “mammalian tumor cell” refers to a cell derived from a mammal that proliferates inappropriately.
  • the term “main ORF-independent mechanism” refers to a cellular pathway or process, wherein at least one step relates to gene expression and is not dependent on the nucleic acid sequence of the main open reading frame.
  • reporter gene refers to any gene whose expression can be measured.
  • RNA induced gene silencing or RNA interference (RNAi) refers to the mechanism of double-stranded RNA (dsRNA) introduced into a system to reduce protein expression of specific genetic sequence.
  • dsRNA double-stranded RNA
  • specifically bind means that a compound binds to another compound in a manner different from a similar type of compounds, e.g. in terms of affinity, avidity, and the like. In a non-limiting example, more binding occurs in the presence of a competing reagent, such as casein.
  • antibodies that specifically bind a target protein should provide a detection signal at least 2-, 5-, 10-, or 20- fold higher relative to a detection signal provided with other molecules when used in Western blots or other immunochemical assays.
  • a nucleic acid can specifically bind its complementary nucleic acid molecule.
  • a transcription factor can specifically bind a particular nucleic acid sequence.
  • the term "secondary structure” means the alpha-helical, beta-sheet, random coil, beta turn structures and helical nucleic acid structures that occur in proteins, polypeptides, nucleic acids, compounds comprising modified nucleic acids, compounds comprising modified amino acids, and other types of compounds as a result of, at least, the compound's composition.
  • non-peptide therapeutic agent and analogous terms include, but are not limited to organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds but excluding proteins, polypeptides and nucleic acids).
  • UTR refers to the untranslated region of a mRNA.
  • the term "untranslated region-dependent expression” or “UTR- dependent expression” refers to the regulation of gene expression through UTRs at the level of mRNA expression, i.e., after transcription of the gene has begun until the protein or the RNA product(s) encoded by the gene has degraded or excreted.
  • the term "vector” refers to a nucleic acid molecule used to introduce a nucleic acid sequence in a cell or organism. The entirety of the International Application PCT/US04/01643, filed January 21, 2004, including the sequence listing, is hereby incorporated by reference.
  • the present invention includes and utilizes the fact that an untranslated region (UTR) is capable of modulating expression of a gene and that such modulation of expression is capable of being altered or modulated by the addition of compounds.
  • a UTR is a region of a RNA that is not translated into protein.
  • a UTR is a flanking region of the RNA transcript that is not translated into the targeted protein, and can include a 5' UTR that has a short, putative open reading frame.
  • the UTR is a 5' UTR, i.e., upstream of the coding region, or a 3' UTR, i.e., downstream of the coding region.
  • the present invention includes and provides agents and methods useful in screening for a compound capable of modulating gene expression and also hybrid molecules.
  • Nucleic Acid Agents and Constructs One skilled in the art may refer to general reference texts for detailed descriptions of known teclmiques discussed herein or equivalent techniques. These texts include Ausubel et al, Current Protocols in Molecular Biology, John Wiley and Sons, Inc.
  • UTRs The present invention includes nucleic acid molecules with UTRs that comprise or consist of a post-transcriptional regulatory element (PTCRE) including SEQ ID NO: 3, a negative regulator of a PTCRE (NeRP) including SEQ ID NO: 4, and fragments and complements of all.
  • PTCRE post-transcriptional regulatory element
  • NeRP negative regulator of a PTCRE
  • a PTCRE of the present invention can differ from any of the residues in SEQ ID NO: 3 in that the nucleic acid sequence has been deleted, substituted, or added in a manner that does not alter the function.
  • a PTCRE of the present invention consists or comprises SEQ ID NO: 5, and fragments and complements of all.
  • a PTCRE of the present invention consists or comprises SEQ ID NOs: 6-8, and fragments and complements of all.
  • a PTCRE of the present invention can differ from any of the residues in an untranslated region selected from the group consisting of a nucleic acid sequence consisting or comprising SEQ ID NO: 3 and SEQ ID NOs: 5-8 in that the nucleic acid sequence has been deleted, substituted, or added in a manner that does not alter the function.
  • a NeRP of the present invention can differ from any of the residues in SEQ ID NO: 4 in that the nucleic acid sequence has been deleted, substituted, or added in a manner that does not alter the function.
  • a NeRP of the present invention consists or comprises SEQ ID NO: 9, and fragments and complements of all.
  • a NeRP of the present invention consists or comprises SEQ ID NOs: 10- 12, and fragments and complements of all.
  • a NeRP of the present invention can differ from any of the residues in a UTR selected from the group consisting of a nucleic acid sequence consisting or comprising SEQ ID NO: 4 and SEQ ID NOs: 9-12 in that the nucleic acid sequence has been deleted, substituted, or added in a manner that does not alter the function.
  • a NeRP is not a full-length sequence of a target UTR.
  • a NeRP is not a full-length VEGF 5' UTR.
  • a NeRP can be a nucleic acid sequence with a single base deletion at any location of SEQ ID NO: 4. Therefore, a NeRP of the invention may be 335 bases. In another embodiment, a NeRP includes a nucleic acid sequence with two or more bases deleted from any location of SEQ ID NO: 4. In another embodiment, a NeRP includes 3, 4, 5, 6, 7, 8, 9 or 10 residue deletions at any location of SEQ ID NO: 4. In another embodiment, a NeRP includes the remaining nucleic acid sequence resulting from the deletion of 20, 30, 40, 50, 60, or 70 residues from any location of SEQ ID NO: 4.
  • a NeRP of the present invention may be produced by contiguous, noncontiguous, or a combination of contiguous deletions and noncontiguous deletions of SEQ ID NO: 4 in a manner that does not alter the function of the NeRP.
  • a nucleic acid molecule which includes a NeRP and a PTCRE
  • the secondary structure of the remaining nucleic acid molecule is altered in a manner comparable to the alteration in the secondary structure of a full-length VEGF 5' UTR when SEQ ID NO: 4 is deleted.
  • a NeRP of the present invention has a secondary structure comparable to the secondary structure of SEQ ID NO: 4.
  • the presence of a NeRP can be detected by the deletion, insertion or alteration of one or more pseudoknots from a larger nucleic acid molecule.
  • the deletion, insertion or alteration of a stem-loop structure from a larger nucleic acid molecule of the present invention results in a NeRP of the present invention.
  • the present invention also includes a NeRP that has a tertiary structure comparable to the tertiary structure formed by SEQ ID NO: 4.
  • Tertiary structure can be determined by, for example, crystallography and phylogenetic covariation (as reviewed in Martin I, et al, Biochim Biophys Ada. 2003 Jul 11;1614(1):97-103; Heinemann TJ., et al, Biol Chem. 1996 Jul-Aug;377(7-8):447-54).
  • the present invention provides nucleic acid molecules that hybridize to the above- described nucleic acid molecules.
  • the nucleic acid molecule hybridizes to a nucleic acid molecule selected from the group consisting of a nucleic acid sequence consisting or comprising SEQ ID NOs: 3-12, and complements thereof.
  • Nucleic acid hybridization is a technique well known to those of skill in the art of DNA manipulation.
  • the hybridization properties of a nucleic acid molecule are an indication of their similarity or identity.
  • the nucleic acid molecules preferably hybridize, under moderate or high stringency conditions, with a nucleic acid sequence selected from SEQ ID NO: 5 and complements thereof. Fragments of these sequences are also contemplated.
  • the nucleic acid molecules preferably hybridize, under moderate or high stringency conditions, with a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5 and its complement.
  • the hybridization conditions typically involve nucleic acid hybridization in about 0.1X to about 10X SSC (diluted from a 20X SSC stock solution containing 3 M sodium chloride and 0.3M sodium citrate, pH 7.0 in distilled water), about 2.5X to about 5X Denhardt's solution (diluted from a 50X stock solution containing 1% (w/v) bovine serum albumin, 1% (w/v) Ficoll ® (Amersham Biosciences Inc., Piscataway, NJ), and 1% (w/v) polyvinylpyrrolidone in distilled water), about 10 mg/ml to about 100 mg/ml salmon sperm DNA, and about 0.02% (w/v) to about 0.1% (w/v) SDS, with an incubation at about 20° C to about 70° C for several hours to overnight.
  • 10X SSC diluted from a 20X SSC stock solution containing 3 M sodium chloride and 0.3M sodium citrate, pH 7.0 in distilled water
  • the moderate stringency hybridization conditions are provided by 6X SSC, 5X Denhardt's solution, 100 mg/ml salmon sperm DNA, and 0.1% (w/v) SDS, with an incubation at 55° C for several hours.
  • the moderate stringency wash conditions are about 0.02% (w/v) SDS, with an incubation at about 55° C overnight.
  • the high stringency hybridization conditions are about 2X SSC, about 3X Denhardt's solution, and about 10 mg/ml salmon sperm DNA.
  • the high stringency wash conditions are about 0.05% (w/v) SDS, with an incubation at about 65° C overnight.
  • the nucleic acid molecule comprises a nucleic acid sequence that is greater than 85% identical, and more preferably greater than 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 3-12, complements thereof, and fragments of any of these sequences.
  • the percent identity is preferably determined using the "Best Fit” or "Gap” program of the Sequence Analysis Software PackageTM (Version 10; Genetics Computer Group, Inc., University of Wisconsin Biotechnology Center, Madison, WI).
  • “Gap” utilizes the algorithm of Needleman and Wunsch to find the alignment of two sequences that maximizes the number of matches and minimizes the number of gaps.
  • “BestFit” performs an optimal alignment of the best segment of similarity between two sequences and inserts gaps to maximize the number of matches using the local homology algorithm of Smith and Waterman. The percent identity calculations may also be performed using the Megalign program of the LASERGENE bioinformatics computing suite (default parameters, DNASTAR Inc., Madison, Wisconsin). The percent identity is most preferably determined using the "Best Fit” program using default parameters.
  • Fragment nucleic acid molecules can contain significant portions of, or indeed most of, SEQ ID NO: 3.
  • the fragments are between about 160 and 250 consecutive residues, about 260 and about 350 consecutive residues, about 360 and about 400 consecutive residues, or about 460 and 500 consecutive residues long of a nucleic molecule of the present invention.
  • the fragment comprises at least 170, 300, 500, or 600 consecutive residues of SEQ ID NO: 3.
  • a fragment nucleic acid molecule is capable of selectively hybridizing to SEQ ID NO: 3.
  • a PTCRE comprises or consists of SEQ ID NO: 3.
  • a PTCRE comprises or consists of a fragment of SEQ ID NO: 3.
  • a PTCRE can share identity with between particular mammals, including, but not limited to human, mouse, and rat.
  • a PTCRE is unique to a human VEGF 5' UTR PTCRE, a non-limiting example of which is SEQ ID NO: 3.
  • Fragment nucleic acid molecules can contain significant portions of SEQ ID NO: 4.
  • nucleic acid molecules can comprise or consist of significant portions of SEQ ID NO: 4.
  • the fragments are between about 40 and about 90 consecutive residues, about 100 and about 150 consecutive residues, about 160 and about 250 consecutive residues, or about 260 and 325 consecutive residues long of a nucleic molecule of the present invention.
  • the fragment comprises at least 90, 150, 250, or 325 consecutive residues of SEQ ID NO: 4.
  • a fragment nucleic acid molecule is capable of selectively hybridizing to SEQ ID NO: 4.
  • a NeRP comprises or consists of SEQ ID NO: 4.
  • a NeRP comprises or consists of a fragment of SEQ ID NO: 4.
  • a NeRP can share identity with between particular mammals, including, but not limited to human, mouse, and rat.
  • a NeRP is unique to a human VEGF 5' UTR NeRP, a non-limiting example of which is SEQ ID NO: 4.
  • nucleic acid molecules of the present invention Any of a variety of methods may be used to obtain one or more of the above- described nucleic acid molecules of the present invention. Automated nucleic acid synthesizers may be employed for this purpose. In lieu of such synthesis, the disclosed nucleic acid molecules may be used to define a pair of primers that can be used with the polymerase chain reaction (PCR) to amplify and obtain any desired nucleic acid molecule or fragment. Short nucleic acid sequences having the ability to specifically hybridize to complementary nucleic acid sequences may be produced and utilized in the present invention, e.g., as probes to identify the presence of a complementary nucleic acid sequence in a given sample.
  • PCR polymerase chain reaction
  • the short nucleic acid sequences may be used as oligonucleotide primers to amplify or mutate a complementary nucleic acid sequence using PCR technology. These primers may also facilitate the amplification of related complementary nucleic acid sequences (e.g., related sequences from other species). Use of these probes or primers may greatly facilitate the identification of transgenic cells or organisms that contain the presently disclosed structural nucleic acid sequences. Such probes or primers may also, for example, be used to screen cDNA, mRNA, or genomic libraries for additional nucleic acid sequences related to or sharing homology with the presently disclosed promoters and structural nucleic acid sequences.
  • the probes may also be PCR probes, which are nucleic acid molecules capable of initiating a polymerase activity while in a double-stranded structure with another nucleic acid.
  • a primer or probe is generally complementary to a portion of a nucleic acid sequence that is to be identified, amplified, or mutated and of sufficient length to form a stable and sequence-specific duplex molecule with its complement.
  • the primer or probe preferably is about 10 to about 200 residues long, more preferably is about 10 to about 100 residues long, even more preferably is about 10 to about 50 residues long, and most preferably is about 14 to about 30 residues long.
  • the primer or probe may, for example without limitation, be prepared by direct chemical synthesis, by PCR (U.S. Patent Nos.
  • sequence comparisons can be done to find nucleic acid molecules of the present invention based on secondary structure homology.
  • GeneBee available on the world wide web at genebee.msu.su/services/rna2_reduced.html
  • Vienna RNA Package available on the world wide web at tbi.univie.ac.at/ ⁇ ivo/RNA/
  • SstmctView available on the world wide web at the Stanford Medical Informatics website, under: projects/helix/sstructview/home.html and described in "RNA Secondary Structure as a Reusable Interface to Biological Information Resources.” 1997. Gene vol. 190GC59-70).
  • comparisons of secondary structure are preformed in Le et al , A common RNA structural motif involved in the internal initiation of translation of cellular mRNAs. 1997. Nuc. Acid. Res. vol. 25(2):362-369.
  • the present invention includes and provides nucleic acid constructs. It is understood that any of the constructs and other nucleic acid agents of the present invention can be either DNA or RNA.
  • a construct can be a nucleic acid molecule having a UTR, a coding sequence, or both.
  • a construct is composed of at least one UTR of the present invention, a sequence encoding a reporter polypeptide, and a vector.
  • any of the nucleic acid molecules of the present invention can be used in combination with a method of the present invention.
  • Vectors Exogenous genetic material may be introduced into a host cell by use of a vector or construct designed for such purpose.
  • a vector or construct of the present invention includes, without limitation, linear or closed circular plasmids.
  • a vector system may be a single vector or plasmid or two or more vectors or plasmids that together contain the total DNA to be introduced into the genome of the host.
  • a vector contains a promoter functional in mammalian cells or bacteria or both. Means for preparing vectors or constructs are well known in the art.
  • Vectors suitable for replication in mammalian cells may include viral replicons, or sequences that insure integration of the appropriate sequences encoding HCV epitopes into the host genome.
  • vaccinia virus another vector used to express foreign DNA is vaccinia virus.
  • heterologous DNA is generally inserted into a gene that is non-essential to the virus, for example, the thymidine kinase gene (tk), which also provides a selectable marker.
  • tk thymidine kinase gene
  • Expression of the HCV polypeptide then occurs in cells or animals that are infected with the live recombinant vaccinia virus.
  • plasmid vectors containing replicon and control sequences that are derived from species compatible with the host cell are used in connection with bacterial hosts.
  • the vector ordinarily carries a replication site, as well as marking sequences that are capable of providing phenotypic selection in transformed cells. For example, E.
  • an expression vector can be a high-level mammalian expression vector designed to randomly integrate into the genome, for example, pCMRl.
  • an expression vector can be a high-level mammalian expression vector designed to site-specifically integrate into the genome of cells.
  • pMCPl can site-specifically integrate into the genome of cells genetically engineered to contain the FRT site-specific recombination site via the Flp recombinase (see, e.g., Craig, 1988, Ann. Rev. Genet. 22: 77-105; and Sauer, 1994, Curr. Opin. Biotechnol 5: 521-527).
  • Promoters A construct can include a promoter, e.g., a recombinant vector typically comprises, in a 5' to 3' orientation: a promoter to direct the transcription of a nucleic acid molecule of interest.
  • a construct can include a mammalian promoter and can be used to express a nucleic acid molecule of choice.
  • a mammalian promoter refers to a promoter functional in a mammalian cell derived from a mammalian cell or both. A number of promoters that are active in mammalian cells have been described in the literature. A promoter can be selected on the basis of the cell type into which the vector will be inserted.
  • a preferred promoter of the present invention is a VEGF promoter. In addition to VEGF promoters described previously, other promoter sequences can be utilized in a construct or other nucleic acid molecule.
  • Suitable promoters include, but are not limited to, those described herein.
  • Suitable promoters for mammalian cells are known in the art and include viral promoters, such as those from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), cytomegalovirus (CMV), and bovine papilloma virus (BPV), and the parvovirus B19p6 promoter as well as mammalian cell-derived promoters.
  • viral promoters such as those from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), cytomegalovirus (CMV), and bovine papilloma virus (BPV)
  • SV40 Simian Virus 40
  • RSV Rous sarcoma virus
  • ADV adenovirus
  • CMV cytomegalovirus
  • BBV bovine papilloma virus
  • sequences encoding a reporter gene can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence.
  • preferred promoters include tissue-specific promoters and inducible promoters.
  • Other preferred promoters include the hematopoietic stem cell-specific, e.g., CD34, glucose-6-phosphotase, interleukin-1 alpha, CD1 lc integrin gene, GM-CSF, interleukin-5R alpha, interleukin-2, c-fos, h-ras and DMD gene promoters.
  • promoters include the herpes thymidine kinase promoter, and the regulatory sequences of the metallothionein gene.
  • Inducible promoters suitable for use with bacteria hosts include the ⁇ -lactamase and lactose promoter systems, the arabinose promoter system, alkaline phosphatase, a tryptophan (trp) promoter system and hybrid promoters such as the tac promoter.
  • trp tryptophan
  • Promoters for use in bacterial systems also generally contain a Shine-Dalgarno sequence operably linked to the DNA encoding the polypeptide of interest.
  • a promoter can also be selected on the basis of their regulatory features, e.g., enhancement of transcriptional activity, inducibility, tissue specificity, and developmental stage-specificity.
  • a promoter can work in vitro, for example the T7-promoter.
  • Particularly preferred promoters can also be used to express a nucleic acid molecule of the present invention in a nonhuman mammal. Additional promoters that may be utilized are described, for example, in Bernoist and Chambon, Nature 290:304-310 (1981); Yamamoto et al, Cell 22:787-797 (1980); Wagner et al, PNAS 78:1441-1445 (1981); Brinster et al, Nature 296:39-42 (1982).
  • reporter gene is any gene whose expression can be measured.
  • a reporter gene does not have any UTRs.
  • a reporter gene is a contiguous open reading frame.
  • a reporter gene can have a previously determined reference range of detectable expression.
  • Constructs of the invention can comprise one or more reporter genes fused to one or more UTRs. For example, specific RNA sequences, RNA structural motifs, and/or RNA structural elements that are known or suspected to modulate UTR-dependent expression of a target gene can be fused to the reporter gene.
  • a reporter gene of the present invention encoding a protein, a fragment thereof, or a polypeptide can also be linked to a propeptide encoding region.
  • a propeptide is an amino acid sequence found at the amino terminus of a proprotein or proenzyme. Cleavage of the propeptide from the proprotein yields a mature biochemically active protein. The resulting polypeptide is known as a propolypeptide or proenzyme (a zymogen in some cases). Propolypeptides are generally inactive and can be converted to mature active polypeptides by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide or proenzyme.
  • a reporter gene can express a selectable or screenable marker.
  • Selectable markers may also be used to select for organisms or cells that contain exogenous genetic material. Examples of such include, but are not limited to: a neo gene, which codes for kanamycin resistance and can be selected for using kanamycin, GUS, neomycin phosphotransferase II (nptll), or an antibiotic resistance coding sequence. Screenable markers can be used to monitor expression.
  • Exemplary screenable markers include: green fluorescent protein (GFP), luciferase (LUX), a ⁇ -glucuronidase or uidA gene (GUS) which encodes an enzyme for which various chromogenic substrates are known; a ⁇ -lactamase gene, a gene which encodes an enzyme for which various chromogenic substrates are known (e.g., PAD AC, a chromogenic cephalosporin); a luciferase gene; a tyrosinase gene, which encodes an enzyme capable of oxidizing tyrosine to DOP A and dopaquinone which in turn condenses to melanin; and ⁇ -galactosidase, which can turn a chromogenic ⁇ -galactose substrate.
  • GFP green fluorescent protein
  • LUX luciferase
  • GUS uidA gene
  • selectable or screenable marker genes are also genes that encode a secretable marker whose secretion can be detected as a means of identifying or selecting for transfonned cells. Examples include markers that encode a secretable antigen that can be identified by antibody interaction, or even secretable enzymes, which can be detected utilizing their inherent properties. Secretable proteins fall into a number of classes, including small, diffusible proteins which are detectable, (e.g., by ELISA), or small active enzymes which are detectable in extracellular solution (e.g., ⁇ -amylase, ⁇ -lactamase, phosphinothricin transferase). Other possible selectable or screenable marker genes, or both, are apparent to those of skill in the art.
  • a reporter gene can express a fusion protein.
  • the fusion protein can be a fusion of any reporter gene operably linked to another gene, or fragment thereof.
  • the expressed fusion protein can provide a "tagged" epitope to facilitate detection of the fusion protein, such as GST, GFP, FLAG, or polyHIS.
  • Such fusions preferably encode between 1 and 50 amino acids, more preferably between 5 and 30 additional amino acids, and even more preferably between 5 and 20 amino acids.
  • a fusion protein can be a fusion protein that includes in whole or in part of a VEGF protein sequence.
  • the fusion can provide regulatory, enzymatic, cell signaling, or intercellular transport functions.
  • a sequence encoding a signal peptide can be added to direct a fusion protein to a particular organelle within a eukaryotic cell.
  • fusion partners preferably encode between 1 and 1000 additional amino acids, more preferably between 5 and 500 additional amino acids, and even more preferably between 10 and 250 amino acids.
  • the present invention also provides for a reporter gene flanked by one or more untranslated regions (e.g., the 5' UTR, 3' UTR, or both the 5' UTR and 3' UTR of the target gene).
  • the present invention provides for a reporter gene flanked by one or more UTRs of a target gene, where the UTR contains one or more mutations (e.g., one or more substitutions, deletions and/or additions).
  • the reporter gene is flanked by both 5' and 3' UTRs so that compounds that interfere with an interaction between the 5' and 3' UTRs can be identified.
  • a stable hairpin secondary structure is inserted into the UTR, preferably the 5' UTR of the target gene.
  • the addition of a stable hairpin secondary structure in the 5' UTR can be used to separate cap-dependent from cap-independent translation (see, e.g., Muhlrad et al, 1995, Mol Cell. Biol 15(4):2145-56, the disclosure of which is incorporated by reference in its entirety).
  • an intron is inserted into a UTR (preferably, the 5' UTR) or at the 5' end of an ORF of a target gene.
  • an intron e.g., the human elongation factor one alpha (EF-1 alpha) first intron
  • EF-1 alpha human elongation factor one alpha
  • both a stable hairpin secondary structure and an intron are added to the reporter gene construct.
  • the stable hairpin secondary structure is cloned into the 5' UTR and the intron is added at the 5' end of the main ORF of the reporter gene.
  • the reporter gene can be positioned such that the translation of that reporter gene is dependent upon the mode of translation initiation, such as, but not limited to, cap-dependent translation or cap-independent translation (i.e., translation via an internal ribosome entry site).
  • the reporter gene can be positioned such that the reporter protein is translated only in the presence of a compound that shifts the reading frame of the UTR so that the formerly untranslated open reading frame is then translated.
  • the reporter gene constructs can be monocistronic or multicistronic.
  • a multicistronic reporter gene construct may encode 2, 3, 4, 5, 6, 7, 8, 9, 10 or more, or in the range of 2-5, 5- 10 or 10-20 reporter genes.
  • a dicistronic reporter gene construct comprising, in the following order going downstream, a promoter, a first reporter gene, a 5' UTR of a target gene, a second reporter gene and optionally, a 3' UTR of a target gene.
  • the transcription of both reporter genes is capable of being driven by the promoter.
  • the present invention includes the translation of the mRNA from the first reporter gene by a cap-dependent scanning mechanism and the translation of the mRNA from the second reporter gene by a cap-independent mechanism, for example by an IRES.
  • the IRES -dependent translation of a mRNA of the second reporter gene can be normalized against the cap-dependent translation.
  • Reporter genes can be expressed in vitro or in vivo. In vivo expression can be in a suitable bacterial or eukaryotic host. Suitable methods for expression are described by Sambrook et al, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); Haymes et al, Nucleic Acid Hybridization, A Practical Approach, IRL Press, Washington, DC (1985); or similar texts. Fusion protein or peptide molecules of the invention are preferably produced via recombinant means.
  • linked means physically linked, operably linked, flanked, or any of these in combination.
  • physically linked means that the physically linked nucleic acid sequences are located on the same nucleic acid molecule, for example a promoter can be physically linked to a reporter gene as part of a construct.
  • a physical linkage can be proximal, and either direct or indirect.
  • the promoter is operably linked and physically linked to a nucleic acid sequence of the present invention.
  • a preferred embodiment of the present invention also provides for specific nucleic acid molecules containing a reporter gene flanked by one or more UTRs of a target gene.
  • the one or more UTRs of a target gene can be physically linked, operably linked, or operably and physically linked to the reporter gene.
  • the present invention also provides for a reporter gene flanked by one or more UTRs of a target gene, where one or more of the UTRs contains one or more mutations (e.g., one or more of each substitution, deletion, addition, or any combination of each).
  • a reporter gene is flanked by a 5' UTR of a VEGF gene containing one or more deletions.
  • a reporter gene is flanked by and operably linked to a 5' VEGF UTR in the absence of a NeRP.
  • the reporter gene is flanked by both 5' and 3' UTRs of one or more target genes so that compounds that interfere with an interaction between the 5' and 3' UTRs can be identified.
  • the reporter gene is flanked by a 5' and 3' UTRs of one target gene, and the reporter gene is physically, operably, or physically and operably linked to the UTRs of one target gene.
  • a reporter gene is proximally linked, either directly or indirectly, to one or more UTRs of a target gene.
  • the last nucleic acid residue of the reporter gene is chemically bonded to the first nucleic acid residue of the UTR of a target gene. If the reporter gene is proximally linked indirectly to a UTR of a target gene, the last nucleic acid residue of the reporter gene is not chemically bonded to the first nucleic acid residue of the UTR of a target gene and the last nucleic acid residue of the reporter gene can be about 3 or greater than 5 but less than 20. If the reporter gene is directly linked to a UTR of a target gene at any time during reporter gene processing, such as after a splicing event, the reporter gene is directly linked to the UTR.
  • UTRs Agents and constructs of the invention include nucleic acid molecules with an untranslated region (UTR).
  • a UTR refers to a UTR of an mRNA, . e. the region of the mRNA that is not translated into protein.
  • a UTR contains one or more regulatory elements that modulate UTR-dependent regulation of gene expression.
  • a UTR is a 5' UTR, i.e., upstream of the coding region, or a 3' UTR, i.e., downstream of the coding region.
  • the 5' UTR includes a VEGF promoter.
  • the 5' UTR includes a VEGF promoter and a PTCRE.
  • a "main ORF” is a nucleic acid sequence, including sequence contained in deoxyribonucleic acid and ribonucleic acid molecules, having an open reading frame that can be translated. Examples of a main ORF include a reporter gene, a target gene, and a control gene.
  • a "target gene” can be any gene.
  • a target gene is a gene operatively linked downstream of a VEGF 5' UTR containing an upstream open reading frame (“uORF").
  • a target gene can be a VEGF main ORF.
  • a target gene is a gene containing a uORF.
  • a target gene is a gene having greater than 50% identity greater than 200 residues with respect to a VEGF gene.
  • a "control gene" can be any gene.
  • a control gene is a gene operatively linked downstream of a VEGF 5' UTR that does not contain a NeRP.
  • a UTR of the present invention can be operatively, physically, or operatively and physically linked to a reporter gene.
  • a UTR of the present invention is physically linked to a reporter gene.
  • a UTR of the present invention is a VEGF 5' UTR physically linked upstream of a reporter gene.
  • VEGF 5' UTR contains or consists of SEQ ID NO: 3 and is physically linked downstream of a reporter gene.
  • a VEGF 5' UTR does not contain or consist of a NeRP and is physically and operatively linked upstream of a reporter gene.
  • VEGF 5' UTR does not contain or consist of a NeRP and does contain or consist of a PTCRE and is physically and operatively linked upstream of a reporter gene.
  • a UTR of the present invention is physically linked upstream to a reporter gene and another UTR is physically linked downstream of the reporter gene.
  • a UTR of the present invention contains or consists of SEQ ID NO: 3 and is physically and operatively linked upstream of a reporter gene and a VEGF 3' UTR is physically and operatively linked downstream of a reporter gene.
  • a UTR of the present invention is physically linked to reporter gene containing an intron.
  • a UTR of the present invention containing SEQ ID NO: 3 is physically linked to a reporter gene containmg an intron.
  • a UTR of the present invention is physically linked upstream of a reporter gene and contains an intron internal to the UTR.
  • a UTR of the present invention is physically linked upstream of a reporter gene and a UTR is physically linked downstream of the reporter gene.
  • a VEGF 5' UTR of the present invention containing a SEQ ID NO: 3 is physically linked upstream of a reporter gene and a VEGF 3' UTR is physically linked downstream of the reporter gene.
  • a PTCRE is a post-transcriptional regulatory element that modulates expression of a target gene.
  • a PTCRE is not a full-length sequence of a target UTR.
  • a PTCRE is not a full-length VEGF 5' UTR.
  • a PTCRE in one target gene can have primary nucleic acid sequence similarity to a PTCRE in a different target gene. Alternatively, there may not be any primary nucleic acid sequence similarity in PTCREs of similar function.
  • a PTCRE in one target gene can have a secondary, tertiary, or secondary and tertiary structure similar to a PTCRE in a different target gene.
  • PTCREs include, but are not limited to, IRES elements, upstream ORFs, and AREs.
  • a PTCRE is a nucleic acid sequence in a UTR, which modulates UTR-dependent expression.
  • a PTCRE can be a nucleic acid sequence selected from the group consisting of an iron response element ("IRE”), Internal ribosome entry site (“IRES”), upstream open reading frame (“uORF”), male specific lethal element (“MSL-2”), G quartet element, and 5 '-terminal oligopyrimidine tract (“TOP”), AU-rich element (“ARE”), selenocysteine insertion sequence (“SECIS”), histone stem loop, cytoplasmic polyadenylation element (“CPE”), nanos translational control element, amyloid precursor protein element (“APP”), translational regulation element (“TGE”)/direct repeat element (“DRE”), Bruno element (“BRE”), or a 15-lipoxygenase differentiation control element (“15-LOX-DICE”).
  • IRE iron response element
  • IRES Internal ribosome entry site
  • UORF upstream open reading frame
  • MSL-2 male specific lethal element
  • MSL-2 G quartet element
  • TOP 5 '-terminal oligopyrim
  • a PTCRE is not an IRES from VEGF. In another embodiment, PTCRE is not be an IRES. In a preferred embodiment, a PTCRE is SEQ ID NO: 3. In a most preferred embodiment, a PTCRE is not a NeRP and the PTCRE does not contain or consist of a NeRP.
  • a NeRP is a nucleic acid sequence in a UTR, which modulates PTCRE-dependent expression in a NeRP-dependent mechanism. In one embodiment of the present invention, a NeRP regulates an IRES. In a preferred embodiment, a NeRP suppresses IRES-dependent expression of a gene. In a most preferred embodiment, a NeRP is SEQ ID NO: 4.
  • a NeRP can modulate PTCRE-dependent expression, where the PTCRE suppresses gene expression, so that the NeRP is capable of increasing gene expression by a NeRP-dependent mechanism.
  • a NeRP mimics an IRES.
  • a NeRP of the present invention can differ from any of the residues in SEQ ID NO: 4 in that the nucleic acid sequence has been deleted, substituted, or added in a manner that does not alter the function.
  • a NeRP of the present invention consists or comprises SEQ ID NO: 9, and fragments and complements of all.
  • a NeRP of the present invention consists or comprises SEQ ID NOs: 10-12, and fragments and complements of all.
  • PTCREs of the present invention can be located in any position within a construct and not limited to the 5' UTR region of a construct.
  • a PTCRE of the present invention can be operatively, physically, or operatively and physically linked to a UTR.
  • a PTCRE of the present invention is a UTR of the present invention.
  • NeRPs of the present invention can be located in any position within a construct and not limited to the VEGF 5' UTR region of a construct.
  • a NeRP of the present invention can be operatively, physically, or operatively and physically linked to a UTR.
  • a NeRP of the present invention is upstream of a PTCRE of the present invention.
  • a PTCRE of the present invention is located between about 1 to about 100 residues upstream from the initiation codon of an open reading frame in a mRNA, between about 150 to about 250 residues upstream from the initiation codon, or between about 300 to about 500 residues upstream from the initiation codon.
  • the untranslated region is about 1 residue upstream from the initiation codon.
  • a NeRP of the present invention is between about 1000 to about 500 residues upstream from a PTCRE, between about 500 to about 100 residues upstream from a PTCRE, or between about 100 to about 60 residues upstream from a PTCRE.
  • a PTCRE is within about 1000 residues upstream from the 5' end of a main ORF, about 500 residues upstream from the 5' end of a main ORF, or within about 200 residues upstream from the 5' end of a main ORF, or about 100 residues upstream from the 5' end of a main ORF.
  • a PTCRE is within the main ORF and between about 1000 to about 500 residues upstream from the 3' end of a main ORF, between about 500 to about 100 residues upstream from the 3' end of a main ORF, or between about 100 to about 60 residues upstream from the 3 ' end of a main ORF. In a most preferred embodiment, the PTCRE is within 30 residues upstream from the 5' end of a main ORF. Constructs of the present invention can have more or fewer components than described above.
  • constructs of the present invention can include genetic elements, including but not limited to, 3' transcriptional terminators, 3' polyadenylation signals, other untranslated nucleic acid sequences, transit or targetmg sequences, selectable or screenable markers, promoters, enhancers, and operators, as desired.
  • Constructs of the present invention can also contain a promoterless gene that may utilize an endogenous promoter upon insertion into a host cell chromosome.
  • sequences encoding nucleic acid molecules of the present invention can be cloned into a vector for the production of an mRNA probe.
  • RNA probes are known in the art, are commercially available, and can be used to synthesize RNA probes in vitro by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (for example, Amersham Biosciences Inc., Piscataway, NJ; and Promega Co, Madison, WI).
  • Modulation of Gene Expression by Nucleic Acid Molecules of the Present Invention Modulation of gene expression can result in more or less gene expression.
  • Many approaches for modulating gene expression using nucleic acid molecules of the present invention are known to one skilled in the art.
  • over-expression of a gene product can be the result from transfection of a construct of the present invention into a mammalian cell.
  • down-regulation can be the result from transfection of a construct of the present invention into a mammalian cell.
  • Other non-limiting examples include anti-sense techniques like RNA interference (RNAi), transgenic animals, hybrids, and ribozymes. The following examples are provided by way of illustration, and are not intended to be limiting of the present invention.
  • UTR-dependent expression refers to the regulation of gene expression through UTRs at the level of mRNA expression, i.e., after transcription of the gene has begun until the protein or the RNA product(s) encoded by the gene has degraded.
  • the term “UTR-dependent expression” refers to the regulation of mRNA stability or translation.
  • the term “UTR-dependent expression” refers to the regulation of gene expression through regulatory elements present in an UTR(s). Altering the sequence of a PTCRE within a UTR of target gene may change the amount of UTR-dependent expression observed for that target gene.
  • a "UTR-affected mechanism” is a cellular mechanism that discriminates between UTRs based on their nucleic acid sequence or based on properties that are a function of their sequence such as the secondary, tertiary, or quaternary structure or other associated factors. Modulation of the UTR-dependent expression of a target gene can be due to a change in how a UTR-affected mechanism acts on the target gene.
  • a UTR in a target gene can contain an IRES, which affects target gene expression via a UTR- affected mechanism.
  • a UTR-affected mechanism can be a main ORF- independent mechanism.
  • a "main ORF-independent mechanism” refers to a cellular pathway or process, wherein at least one step relates to gene expression and is not dependent on the nucleic acid sequence of the main open reading frame.
  • a UTR-affected mechanism is a main ORF-independent, UTR-affected mechanism.
  • one or more mutations may be introduced into the UTRs operably linked to a reporter gene and the effect on the expression of the reporter gene in a reporter gene-based assay described herein can be determined.
  • a reporter gene construct comprising the 5' UTR of a target gene may be mutated by deleting a fragment of the 5' UTR of the target gene or substituting a fragment of the 5' UTR of the target gene with a fragment of the 5' UTR of another gene and measuring the expression of the reporter gene in the presence and absence of a compound that has been identified in a screening assays of the present invention or of an assay well known to the skilled artisan.
  • the deletion of a fragment of the 5' UTR of the target gene or the substitution of a fragment of the 5' UTR of the target gene with a fragment of the 5' UTR of another gene affects the ability of the compound to modulate the expression of the reporter gene
  • the fragment of the 5' UTR deleted or substituted plays a role in the regulation of the reporter gene expression and the regulation, at least in part, in an UTR-dependent manner.
  • the possibility that a particular compound is functioning solely by modulating the expression of a target gene in an UTR-independent manner can be determined by changing the vector utilized as a reporter construct.
  • the UTRs flanked by a reporter gene from the first reporter construct in which an effect on reporter gene expression was detected following exposure to a compound may be inserted into a new reporter construct that has, e.g., different transcriptional regulation elements (e.g., a different promoter) and a different selectable marker.
  • the level of reporter gene expression in the presence of the compound can be compared to the level of reporter gene expression in the absence of the compound or in the presence of a control (e.g., PBS). If there is no change in the level of expression of the reporter gene in the presence of the compound relative to the absence of the compound or in the presence of a control, then the compound probably is functioning in an UTR-independent manner.
  • RNA binding assays RNA binding assays, subtraction assays, and expressed protein concentration and activity assays are examples of methods to determine UTR-dependent expression of a gene.
  • a hybrid of a compound and a PTCRE or a NeRP of the present invention is a hybrid formed between two non-identical molecules.
  • a hybrid can be formed between two nucleic acid molecules.
  • a hybrid can be formed between two ribonucleic acid molecules, between a ribonucleic acid molecule and a deoxyribonucleic acid molecule, or between derivatives of either.
  • a hybrid can be formed between a nucleic acid of the present invention and a non-nucleic acid molecule.
  • a hybrid can be formed between a nucleic acid molecule and a non-nucleic acid molecule, for example, a polypeptide or a non-peptide therapeutic agent.
  • Ribozymes In one aspect of the present invention, the activity or expression of a gene is regulated by designing trans-cleaving catalytic RNAs (ribozymes) specifically directed to a nucleic acid molecule of the present invention, for example, SEQ ID NO: 3 and SEQ ID NOs: 5-8.
  • the activity or expression of a gene is regulated by designing trans- cleaving catalytic RNAs (ribozymes) specifically directed to a nucleic acid molecule of the present invention, for example, SEQ ID NO: 4 and SEQ ID NOs: 9-12.
  • Ribozymes are RNA molecules possessing endoribonuclease activity. Ribozymes are specifically designed for a particular target, and the target message contains a specific nucleotide sequence. They are engineered to cleave any RNA species site-specifically in the background of cellular RNA. The cleavage event renders the mRNA unstable and prevents protein expression.
  • ribozymes can be used to inhibit expression of a gene of unknown function for the purpose of determining its function in an in vitro or in vivo context, by detecting a phenotypic effect.
  • One commonly used ribozyme motif is the hammerhead, for which the substrate sequence requirements are minimal. Design of the hammerhead ribozyme, and the therapeutic uses of ribozymes, are disclosed in Usman et al, Current Opin. Strict. Biol 6:527-533 (1996). Ribozymes can also be prepared and used as described in Long et al, FASEBJ. 7:25 (1993); Symons, .4 Rev. Biochem.
  • ribozyme fragments in a hairpin structure are described by Chowrira and Burke, Nucleic Acids Res. 20:2835 (1992). Ribozymes can also be made by rolling transcription as described in Daubendiek and Kool, Nat. Biotechnol 15(3):273-277 (1997). The hybridizing region of the ribozyme may be modified or may be prepared as a branched structure as described in Horn and Urdea, Nucleic Acids Res. 11:6959-61 (1989).
  • ribozymes may also be chemically altered in ways familiar to those skilled in the art, and chemically synthesized ribozymes can be administered as synthetic oligonucleotide derivatives modified by monomeric units.
  • liposome mediated delivery of ribozymes improves cellular uptake, as described in Birikli et al, Eur. J. Biochem. 245:1-16 (1997).
  • Ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes”) such as the one which occurs naturally in Tetrahymena thermophila (known as the IVS, or L-19 IVS RNA) and which has been extensively described by Thomas Cech and collaborators (Zaug et al, Science 224:574-578 (1984); Zaug and Cech, Science 231:470-475 (1986); Zaug et al, Nature, 324:429-433 (1986); W0 88/04300; Been and Cech, Cell 47:207-216 (1986)).
  • Cech-type ribozymes such as the one which occurs naturally in Tetrahymena thermophila (known as the IVS, or L-19 IVS RNA) and which has been extensively described by Thomas Cech and collaborators (Zaug et al, Science 224:574-578 (1984); Zaug and Cech, Science 231:470-475 (1986); Zaug
  • the Cech-type ribozymes have an eight base pair active site which hybridizes to a target RNA sequence whereafter cleavage of the target RNA takes place.
  • the invention encompasses those Cech-type ribozymes which target eight base-pair active site sequences that are present in a target gene.
  • Ribozymes can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.) and should be delivered to cells which express the target gene in vivo.
  • a preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Because ribozymes, unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency. Using the nucleic acid sequences of the invention and methods known in the art, ribozymes are designed to specifically bind and cut the corresponding mRNA species. Ribozymes thus provide a means to inhibit the expression of any of the proteins encoded by the disclosed nucleic acids or their full-length genes.
  • ribozymes corresponding to that nucleotide sequence can be tested in vitro for efficacy in cleaving the target transcript. Those ribozymes that effect cleavage in vitro are further tested in vivo.
  • the ribozyme can also be used to generate an animal model for a disease, as described in Birikh et al, Eur. J. Biochem. 245:1-16 (1997).
  • An effective ribozyme is used to determine the function of the gene of interest by blocking its transcription and detecting a change in the cell.
  • an effective ribozyme is designed and delivered in a gene therapy for blocking transcription and expression of the gene.
  • Therapeutic and functional genomic applications of ribozymes begin with knowledge of a portion of the coding sequence of the gene to be inhibited. Thus, for many genes, a partial nucleic acid sequence provides adequate sequence for constructing an effective ribozyme.
  • a target cleavage site is selected in the target sequence, and a ribozyme is constructed based on the 5' and 3' nucleotide sequences that flank the cleavage site.
  • Retroviral vectors are engineered to express monomeric and multimeric hammerhead ribozymes targetmg the mRNA of the target coding sequence.
  • ribozymes are tested in vitro for an ability to cleave the target mRNA.
  • a cell line is stably transduced with the retroviral vectors expressing the ribozymes, and the transduction is confirmed by Northern blot analysis and reverse-transcription polymerase chain reaction
  • RT-PCR RT-PCR
  • the cells are screened for inactivation of the target mRNA by such indicators as reduction of expression of disease markers or reduction of the gene product of the target mRNA.
  • Nucleic acid molecules that may be used in cell transformation or transfection can be any of the nucleic acid molecules of the present invention.
  • Nucleic acid molecules of the present invention can be introduced into a cell or organism.
  • the cell is selected from the group consisting of cells that do not express VEGF, cells that express VEGF, or cells that express VEGF conditionally.
  • the cell is a cancer cell, more preferably a cancer cell where VEGF is overexpressed relative to a non- transformed cell.
  • a host cell strain can be chosen for its ability to modulate the expression of the inserted sequences, to process an expressed reporter gene in the desired fashion, or based on the expression levels of an endogenous or heterologous VEGF gene.
  • Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC, Manassas, VA), such as HeLa cells, Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells and a number of other cell lines.
  • ATCC American Type Culture Collection
  • VA Manassas
  • suitable mammalian host cell lines include those shown below in Table 1.
  • Table 1 Mammalian Host Cell Lines
  • cells of the present invention can be cells of an organism.
  • the organism is a mammal.
  • the mammal is a human.
  • the organism is a non-human mammal, preferably a mouse, rat, or a chimpanzee.
  • cells can be pluripotent or differentiated.
  • a nucleic acid of the present invention can be naturally occurring in the cell or can be introduced using techniques such as those described in the art. There are many methods for introducing transforming DNA segments into cells, but not all are suitable for delivering DNA to eukaryotic cells.
  • Suitable methods include any method by which DNA can be introduced into a cell, such as by direct delivery of DNA, by desiccation/inhibition-mediated DNA uptake, by electroporation, by agitation with silicon carbide fibers, by acceleration of DNA coated particles, by chemical transfection, by lipofection or liposome-mediated transfection, by calcium chloride-mediated DNA uptake, etc.
  • DNA can be introduced into a cell, such as by direct delivery of DNA, by desiccation/inhibition-mediated DNA uptake, by electroporation, by agitation with silicon carbide fibers, by acceleration of DNA coated particles, by chemical transfection, by lipofection or liposome-mediated transfection, by calcium chloride-mediated DNA uptake, etc.
  • Lipofectamine ® Invitrogen Co., Carlsbad, CA
  • Fugene ® Hoffmann-La Roche Inc., Nutley, NJ
  • the transfected nucleic acids of the present invention may be expressed transciently or stably.
  • Such transfected cells can be in a two- or three-dimensional cell culture system or in an organism.
  • the construct may be an autonomously replicating construct, i.e., a construct that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome.
  • the construct may contain any means for assuring self-replication.
  • the construct may further comprise an origin of replication enabling the construct to replicate autonomously in the host cell in question.
  • the construct may be one which, when introduced into the cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. This integration may be the result of homologous or non-homologous recombination. Integration of a construct or nucleic acid into the genome by homologous recombination, regardless of the host being considered, relies on the nucleic acid sequence of the construct.
  • the construct contains nucleic acid sequences for directing integration by homologous recombination into the genome of the host.
  • nucleic acid sequences enable the construct to be integrated into the host cell genome at a precise location or locations in one or more chromosomes.
  • These nucleic acid sequences may be any sequence that is homologous with a host cell target sequence and, furthermore, may or may not encode proteins. Stable expression is preferred for long-term, high-yield production of recombinant proteins.
  • cell lines that stably express a reporter gene can be transformed using expression constructs that can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate construct. Following the introduction of the construct, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to a selective medium. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully express the introduced construct. Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. See, for example, Animal Cell Culture, R.I. Freshney, ed., 1986. Any number of selection systems can be used to recover transformed cell lines.
  • herpes simplex virus thymidine kinase (Wigler et al, 1977. Cell vol.11:223-32) and adenine phosphoribosyltransferase (Lowy etal, 1980 Cell vol. 22:817-23.) genes which can be employed in tk ' or aprf cells, respectively.
  • antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection.
  • dhfr confers resistance to methotrexate (Wigler et al, 1980. Proc. Natl. Acad. Sci. vol.
  • npt confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin et al, 1981. J Mol. Biol vol.150: 1-14), and als and at confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. Additional selectable genes have been described. For example, trpB allows cells to utilize indole in place of tryptophan, and hisD allows cells to utilize histinol in place of histidine (Hartman & Mulligan, 1988. Proc. Natl Acad. Sci. vol. 85:8047-51).
  • Visible markers such as anthocyanins, ⁇ -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific construct system (Rhodes et al, 1995. Methods Mol. Biol. vol. 55:121-131).
  • a reporter gene is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding a reporter gene is inserted within a marker gene sequence, transformed cells containing sequences that encode a reporter gene can be identified by the absence of marker gene function.
  • a marker gene can be placed in tandem with a sequence encoding a reporter gene under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of a reporter gene.
  • host cells which contain a reporter gene and which express a reporter gene e can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques that include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein.
  • the presence of a reporter gene can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding a reporter gene.
  • Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding a reporter gene to detect transformants that contain a reporter gene.
  • Screening Methods of the Present Invention Compound The present invention includes methods for screening compounds capable of modulating gene expression. Any compound can be screened in an assay of the present invention.
  • a compound includes a nucleic acid or a non-nucleic acid, such as a polypeptide or a non-peptide therapeutic agent.
  • a nucleic acid can be a polynucleotide, a polynucleotide analog, a nucleotide, or a nucleotide analog.
  • a compound can be an antisense oligonucleotide, which are nucleotide sequences complementary to a specific DNA or RNA sequence of the present invention.
  • an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used.
  • Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both.
  • Nucleic acid molecules, including antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a cell.
  • Nucleic acid molecules can be anti- sense or sense and double- or single-stranded.
  • nucleic acid molecules can be interfering RNA (RNAi) or microRNA (miRNA).
  • the dsRNA is 20-25 residues in length, termed small interfering RNAs (siRNA).
  • Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non- phosphodiester internucleotide linkages such alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters. See Brown, 1994 Meth. Mol. Biol vol. 20:1-8; Sonveaux, 1994. Meth Mol. Biol. Vol.
  • a compound can be a peptide, polypeptide, polypeptide analog, amino acid, or amino acid analog.
  • a compound can be synthesized manually or by an automated synthesizer.
  • a compound can be a member of a library of compounds.
  • the compound is selected from a combinatorial library of compounds comprising peptoids; random biooligomers; diversomers such as hydantoins, benzodiazepines and dipeptides; vinylogous polypeptides; nonpeptidal peptidomimetics; oligocarbamates; peptidyl phosphonates; peptide nucleic acid libraries; antibody libraries; carbohydrate libraries; and small organic molecule libraries.
  • the small organic molecule libraries are libraries of benzodiazepines, isoprenoids, thiazolidinones, metathiazanones, pyrrolidines, morpholino compounds, or diazepindiones.
  • a compound in another embodiment, can have a molecular weight less than about 10,000 grams per mole, less than about 5,000 grams per mole, less than about 1,000 grams per mole, less than about 500 grams per mole, less than about 100 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.
  • Compounds can be evaluated comprehensively for cytotoxicity. The cytotoxic effects of the compounds can be studied using cell lines, including for example 293 (kidney), HuH7 (liver), and Hela cells over about 4, 10, 16, 24, 36 or 72-hour periods.
  • a number of primary cells such as normal fibroblasts and peripheral blood mononuclear cells (PBMCs) can be grown in the presence of compounds at various concentrations for about 4 days.
  • PBMCs peripheral blood mononuclear cells
  • Fresh compound can be added every other day to maintain a constant level of exposure with time.
  • the effect of each compound on cell-proliferation can be determined by CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega Co, Madison, WI) and [ 3 H]- Thymidine incorporation.
  • Treatment of some cells with some of the compounds may have cytostatic effects.
  • a selective index ratios of CC5 0 in cytotoxicity assays to the EC50 in ELISA or FACS or the reporter gene assays
  • Compounds exhibiting substantial selective indices can be of interest and can be analyzed further in the functional assays.
  • the structure of a compound can be determined by any well-known method such as mass spectroscopy, NMR, vibrational spectroscopy, or X-ray crystallography as part of a method of the present invention.
  • Compounds can be pharmacologic agents already known in the art or can be compounds previously unknown to have any pharmacological activity.
  • the compounds can be naturally occurring or designed in the laboratory. They can be isolated from microorganisms, animals, or plants, and can be produced recombinantly, or synthesized by chemical methods known in the art.
  • compounds can be obtained using any of the numerous combinatorial library methods known in the art, including but not limited to, biological libraries, spatially addressable parallel solid phase or solution phase libraries, synthetic library methods requiring deconvolution, the "one-bead one-compound” library method, and synthetic library methods using affinity chromatography selection.
  • Methods for the synthesis of molecular libraries are well known in the art (see, for example, DeWitt et al., Proc. Natl. Acad. Sci. U.S.A. 90, 6909, 1993; Erb et al. Proc. Natl. Acad. Sci. U.S.A. 91, 11422, 1994; Zuckermann et al, J. Med. Chem.
  • Methods of the present invention for screening compounds can select for compounds capable of modulating gene expression, which are capable of directly binding to a ribonucleic acid molecule transcribed from a target gene.
  • a compound identified in accordance with the methods of the present invention may be capable of binding to one or more trans-acting factors (such as, but not limited to, proteins) that modulate UTR- dependent expression of a target gene.
  • a compound identified in accordance with the methods of invention may disrupt an interaction between the 5' UTR and the 3' UTR.
  • Compounds can be tested using in vitro assays (e.g., cell-free assays) or in vivo assays (e.g., cell-based assays) well known to one of skill in the art or as provided in the present invention.
  • a compound that modulates expression of a target gene can be determined from the methods provided in the present invention.
  • a UTR of the present invention includes UTRs capable of modulating gene expression in the presence, in the absence, or in the presence and absence of a compound.
  • the effect of a compound on the expression of one or more genes can be determined utilizing assays well known to one of skill in the art or provided by the present invention to assess the specificity of a particular compound's effect on the UTR-dependent expression of a target gene.
  • a compound has specificity for a plurality of genes.
  • a compound identified utilizing the methods of the present invention is capable of specifically effect the expression of only one gene or, alternatively, a group of genes within the same signaling pathway.
  • Compounds identified in the assays of the present invention can be tested for biological activity using host cells containing or engineered to contain the target RNA element involved in UTR-dependent gene expression coupled to a functional readout system. Screening assays The present invention includes and provides for assays capable of screening for compounds capable of modulating gene expression.
  • an assay is an in vitro assay.
  • an assay is an in vivo assay.
  • an assay measures translation.
  • the assay includes a nucleic acid molecule of the present invention or a construct of the present invention.
  • a nucleic acid molecule or construct of the present invention include, without limitation, SEQ ID NOs: 3- 12, or a sequence that differs from any of the residues in SEQ ID NOs: 3-12 in that the nucleic acid sequence has been deleted, substituted, or added in a manner that does not alter the function.
  • the present invention also provides fragments and complements of all the nucleic acid molecules of the present invention.
  • the activity or expression of a reporter gene is modulated. Modulated means increased or decreased during any point before, after, or during translation.
  • activity or expression of a reporter gene is modulated during translation.
  • inhibition of translation of the reporter gene would modulate expression.
  • expression level of a reporter gene is modulated if the steady-state level of the expressed protein decreased even though translation was not inhibited.
  • a change in the half-life of a mRNA can modulate expression.
  • modulated activity or expression of a reporter gene means increased or decreased during any point before or during translation.
  • the activity or expression of a reporter gene or a target gene is modulated by greater than 30%, 40%, 50%, 60%, 70%, 80% or 90%) in the presence of a compound. In a highly preferred aspect, more of an effect is observed in VEGF- dependent cancer cells.
  • the activity or expression of a reporter gene is modulated without altering the activity of a control gene for general, indiscriminate translation activity.
  • indiscriminate translation activity refers to modulation in translation levels or activity that is random or unsystematic.
  • One assay for modulation in general, indiscriminate translation activity uses a general translational inhibitor, for example puromycin, which is an inhibitor that causes release of nascent peptide and mRNA from ribosomes.
  • Expression of a reporter gene can be detected with, for example, techniques know in the art. Translation or transcription of a reporter gene can be detected in vitro or in vivo.
  • either the compound or the reporter gene can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase.
  • a detectable label such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase.
  • High-throughput screening can be done by exposing nucleic acid molecules of the present invention to a library of compounds and detecting gene expression with assays known in the art, including, for example without limitation, those described above.
  • cancer cells such as HeLa cells, expressing a nucleic acid molecule of the present invention are treated with a library of compounds.
  • Percent inhibition of reporter gene activity can be obtained with all the library compounds can be analyzed using, for example without limitation, a scattergram generated by SpotFire ® (SpotFire, Inc., Somerville, MA).
  • the high-throughput screen can be followed by subsequent selectivity screens.
  • a subsequent selectivity screen can include detection of reporter gene expression in cells expressing, for example, a reporter gene linked to a PTCRE or flanked by a 5' and 3' UTR of the same gene, either of which contains a PTCRE or a NeRP or both of the present invention.
  • a subsequent selectivity screen can include detection of reporter gene expression in cells in the presence of a various concentrations of compounds.
  • a compound has been identified to modulate UTR-dependent expression of a target gene and preferably, the structure of the compound has been identified by the methods described in the present invention and well known in the art, the compounds are tested for biological activity in further assays and/or animal models. Further, a lead compound may be used to design congeners or analogs.
  • labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays.
  • Means for producing labeled hybridization or PCR probes for detecting sequences related to PTCREs or NeRPs of the present invention include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide.
  • Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.
  • an assay is an in vitro assay.
  • an in vitro assay that measures translation.
  • the in vitro assay includes a nucleic acid molecule of the present invention or a construct of the present invention.
  • a reporter gene of the present invention can encode a fusion protein or a fusion protein comprising a domain that allows the expressed reporter gene to be bound to a solid support.
  • glutathione-S -transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, which are then combined with the compound or the compound and the non-adsorbed expressed reporter gene; the mixture is then incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components.
  • Binding of the interactants can be determined either directly or indirectly, as described above.
  • the complexes can be dissociated from the solid support before binding is determined.
  • Other techniques for immobilizing an expressed reporter gene or compound on a solid support also can be used in the screening assays of the invention.
  • either an expressed reporter gene or compound can be immobilized utilizing conjugation of biotin and streptavidin.
  • Biotinylated expressed reporter genes or compounds can be prepared from biotin-NHS(N-hydroxysuccinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL) and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemicals, Rockford, IL).
  • biotinylation kit Pierce Chemicals, Rockford, IL
  • streptavidin-coated 96 well plates Piereptavidin-coated 96 well plates
  • antibodies which specifically bind to an expressed reporter gene or compound, but which do not interfere with a desired binding or catalytic site can be derivatized to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation.
  • Methods for detecting such complexes include immunodetection of complexes using antibodies which specifically bind to an expressed reporter gene or compound, enzyme-linked assays which rely on detecting an activity of an expressed reporter gene, electrophoretic mobility shift assays (EMSA), and SDS gel electrophoresis under reducing or non-reducing conditions.
  • a reporter gene in vitro can be detected following the use of a reticulocyte lysate translation system, for example the TNT Coupled Reticulocyte Lysate System (Promega Co., Madison, WI).
  • RNA 100 ng
  • RNA 100 ng
  • reaction mixtures containing 70% reticulocyte lysate, 20 ⁇ M amino acids and RNase inhibitor (0.8 units/ ⁇ l).
  • 20 ⁇ l of Luclite can be added and luminescence can be read on the View-Lux.
  • Different concentrations of compounds can be added to the reaction in a final DMSO concentration of 2%> and the EC 50 values calculated.
  • Puromycin can be used as control for general indiscriminate translation inhibition.
  • In vitro transcripts encoding a reporter gene linked to specific UTRs from target genes, including GAPDH, XIAP, TNF- ⁇ , and HIF-l ⁇ , can also be used.
  • capped RNA can be translated in translation extracts prepared from specialized cells or cancer cell lines, for example without limitation, HT1080 cells (a human fibrosarcoma cell line). Briefly, the cells can be washed with PBS and swollen in hypotonic buffer (10 mM Hepes, pH 7.4, 15 mM KC1, 1.5 mM Mg(OAc) 2 , 2 mM DTT and 0.5 mM Pefabloc (Pentapharm Ltd. Co., Switzerland) for 5 minutes on ice. The cells can be lysed using a Dounce homogenizer (100 strokes), and the extracts can be spun for 10 minutes at 10,000 x g.
  • hypotonic buffer 10 mM Hepes, pH 7.4, 15 mM KC1, 1.5 mM Mg(OAc) 2 , 2 mM DTT and 0.5 mM Pefabloc (Pentapharm Ltd. Co., Switzerland)
  • the cells can be lysed using a Dounce homogenizer (100 strokes),
  • the translation reaction can be capped RNA (50 ng) in a reaction mixture containing 60%» clarified translation extract, 15 ⁇ M total amino acids, 0.2 mg/ml Creatine phosho-kinase, which are all in IX translation buffer (15 mM Hepes, pH 7.4, 85 mM KOAc, 1.5 mM Mg(OAc) 2 , 0.5 mM ATP, 0.075 mM GTP, 18 mM creatine diphosphate and 1.5 mM DTT). After incubation of the translation reaction for 90 min at 37°C, activity of the protein encoded by the reporter gene can be detected.
  • luciferase For activity of luciferase, encoded by the luciferase gene serving as the reporter gene, addition of 20 ⁇ l of LucLite ® (Packard Instrument Co., Inc., Meriden, CT) can be used. Capped and uncapped RNAs can be synthesized in vitro using the T7 polymerase transcription kits (Ambion Inc., Austin, TX).
  • Capped RNAs from a variety of nucleic acid molecules of the present invention including without limitation, constructs with VEGF linked to a PTCRE of the present invention, constructs with a reporter gene linked only to a vector, constructs with GAPDH linked to a PTCRE, constructs with a HIF-l ⁇ linked to a PTCRE, and constructs with a HIF-l ⁇ not linked to a PTCRE, can be used in a similar in vitro system to study the influence of cell-type specific factors on translation.
  • the present invention includes and provides for assays capable of screening for compounds capable of modulating gene expression.
  • an assay is an in vivo assay.
  • a preferred aspect of the present invention is an assay that measures translation.
  • an in vivo assay includes a nucleic acid molecule of the present invention or a construct of the present invention and can include the use of a cell or a cell or tissue within an organism.
  • an in vivo assay includes a nucleic acid molecule of the present invention present in a cell or a cell or tissue within an organism.
  • in vivo translation of a reporter gene can be detected.
  • a reporter gene is transfected into a cancer cell obtained from a cell line available at the (American Type Culture Collection (ATCC), Manassas, VA), for example HeLa, MCF-7, and COS-7, BT474.
  • a cancer cell has an altered genome relative to a similarly derived normal, primary cell, and the mammalian cancer cell proliferates under conditions where such a primary cell would not. Screening for compounds that modulate reporter gene expression can be carried out in an intact cell. Any cell that comprises a reporter gene can be used in a cell-based assay system.
  • a reporter gene can be naturally occurring in the cell or can be introduced using techniques such as those described above (see Cells and Organisms).
  • a cell line is chosen based on its expression levels of naturally occurring VEGF. Modulation of reporter gene expression by a compound can be determined in vitro as described above or in vivo as described below. To detect expression of endogenous protein, a variety of protocols for detecting and measuring the expression of a reporter gene are known in the art. For example, Enzyme- Linked Immunosorbent Assays (ELIS As), western blots using either polyclonal or monoclonal antibodies specific for an expressed reporter gene, Fluorescence-Activated Cell Sorter (FACS), electrophoretic mobility shift assays (EMSA), or radioimmunoassay (RIA) can be performed to quantify the level of specific proteins in lysates or media derived from cells treated with the compounds.
  • ELIS As Enzyme- Linked Immunosorbent Assays
  • FACS Fluorescence-Activated Cell Sorter
  • ESA electrophoretic mobility shift assays
  • RIA radioimmunoassay
  • a phenotypic or physiological readout can be used to assess UTR-dependent activity of the target RNA in the presence and absence of the lead compound.
  • labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays.
  • Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides having a PTCRE or a NeRP of the present invention include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide.
  • sequences having a PTCRE or a NeRP of the present invention can be cloned into a vector for the production of a mRNA probe.
  • vectors are known in the art, are commercially available, and can be used to synthesize RNA probes in vitro by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Biosciences Inc., Piscataway, NJ; and Promega Co, Madison, WI).
  • Suitable reporter molecules or labels which can be used for ease of detection include radionucleotides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.
  • Therapeutic Uses The present invention also provides for methods for treating, preventing or ameliorating one or more symptoms of a disease or disorder associated with the aberrant expression of a target gene, said method comprising administering to a subject in need thereof a therapeutically or prophylactically effective amount of a compound, or a pharmaceutically acceptable salt thereof, identified according to the methods described herein.
  • a target gene is aberrantly expressed.
  • a target gene can be aberrantly overexpressed or expressed at an aberrantly low level.
  • the invention provides for a method of treating or preventing a disease or disorder or ameliorating a symptom thereof, said method comprising administering to a subject in need thereof an effective amount of a compound, or a pharmaceutically acceptable salt thereof, identified according to the methods described herein, wherein said effective amount increases the expression of a target gene beneficial in the treatment or prevention of said disease or disorder.
  • the invention also provides for a method of treating or preventing a disease or disorder or ameliorating a symptom thereof, said method comprising administering to a subject in need thereof an effective amount of a compound, or a pharmaceutically acceptable salt thereof, identified according to the methods described herein, wherein said effective amount decreases the expression of a target gene whose expression is associated with or has been linked to the onset, development, progression or severity of said disease or disorder.
  • the disease or disorder is a proliferative disorder, an inflammatory disorder, an infectious disease, a genetic disorder, an autoimmune disorder, a cardiovascular disease, or a central nervous system disorder.
  • the infectious disease can be caused by a fungal infection, a bacterial infection, a viral infection, or an infection caused by another type of pathogen.
  • the invention provides pharmaceutical compositions that can be administered to a patient to achieve a therapeutic effect.
  • Pharmaceutical compositions of the invention can comprise, for example, ribozymes or antisense oligonucleotides, antibodies that specifically bind to a PTCRE or NeRP of the present invention, or mimetics, activators, inhibitors of PTCRE or NeRP activity, or a nucleic acid molecule of the present invention.
  • compositions can be administered alone or in combination with at least one other agent, such as stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.
  • agent such as stabilizing compound
  • the compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones.
  • these pharmaceutical compositions can contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • compositions of the invention can be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means.
  • Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
  • compositions for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen.
  • disintegrating or solubilizing agents can be added, such as the cross- linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.
  • Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol.
  • Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers.
  • the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
  • suitable liquids such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
  • Pharmaceutical formulations suitable for parenteral administration can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline.
  • Aqueous injection suspensions can contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds can be prepared as appropriate oily injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or tiiglycerides, or liposomes.
  • Non-lipid polycationic amino polymers also can be used for delivery.
  • the suspension also can contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • compositions of the present invention can be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
  • the pharmaceutical composition can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.
  • the preferred preparation can be a lyophilized powder which can contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use. Further details on techniques for formulation and administration can be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.). After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration.
  • a therapeutically effective dose refers to that amount of active ingredient that increases or decreases reporter gene activity relative to reporter gene activity that occurs in the absence of the therapeutically effective dose.
  • the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dog, or pigs. The animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • Therapeutic efficacy and toxicity e.g., ED 50 (the dose therapeutically effective in 50%) of the population) and LD 50 (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals.
  • the dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD 5 o/ED 50 .
  • Pharmaceutical compositions that exhibit large therapeutic indices are preferred.
  • the data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use.
  • the dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
  • the dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect.
  • Factors that can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy.
  • Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation. Normal dosage amounts can vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration.
  • Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors.
  • polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.
  • the reagent is a single-chain antibody
  • polynucleotides encoding the antibody can be constructed and introduced into a cell either ex vivo or in vivo using well-established techniques including, but not limited to, transferrin-polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, "gene gun,” and DEAE- or calcium phosphate-mediated transfection.
  • Effective in vivo dosages of an antibody are in the range of about 5 ⁇ g to about 50 ⁇ g/kg, about 50 ⁇ g to about 5 mg/kg, about 100 ⁇ g to about 500 ⁇ g/kg of patient body weight, and about 200 to about 250 ⁇ g/kg of patient body weight.
  • effective in vivo dosages are in the range of about 100 ng to about 200 ng, 500 ng to about 50 mg, about 1 ⁇ g to about 2 mg, about 5 ⁇ g to about 500 ⁇ g, and about 20 ⁇ g to about 100 ⁇ g of DNA.
  • the reagent is preferably an antisense oligonucleotide or a ribozyme.
  • Polynucleotides that express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described above.
  • a reagent reduces expression of a reporter gene or the activity of a reporter gene by at least about 10, preferably about 50, more preferably about 75, 90, or 100%) relative to the absence of the reagent.
  • any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles.
  • the combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described above.
  • a reagent which affects translation can be administered to a human cell, either in vitro or in vivo, to specifically reduce translational activity of a specific gene.
  • the reagent preferably binds to a 5' UTR of a gene.
  • the reagent preferably binds to a PTCRE or NeRP of the present invention.
  • the reagent is a compound.
  • an antibody can be added to a preparation of stem cells which have been removed from the body. The cells can then be replaced in the same or another human body, with or without clonal propagation, as is known in the art.
  • the reagent is delivered using a liposome.
  • the liposome is stable in the animal into which it has been administered for at least about 30 minutes, more preferably for at least about 1 hour, and even more preferably for at least about 24 hours.
  • a liposome comprises a lipid composition that is capable of targeting a reagent, particularly a polynucleotide, to a particular site in an animal, such as a human.
  • the lipid composition of the liposome is capable of targeting to a specific organ of an animal, such as the lung, liver, spleen, heart brain, lymph nodes, and skin.
  • a liposome useful in the present invention comprises a lipid composition that is capable of fusing with the plasma membrane of the targeted cell to deliver its contents to the cell.
  • the transfection efficiency of a liposome is about 0.5 ⁇ g of DNA per 16 nmole of liposome delivered to about 10 6 cells, more preferably about 1.0 ⁇ g of DNA per 16 mnole of liposome delivered to about 10 6 cells, and even more preferably about 2.0 ⁇ g of DNA per 16 nmol of liposome delivered to about 10 6 cells.
  • a liposome is between about 100 and 500 nm, more preferably between about 150 and 450 nm, and even more preferably between about 200 and 400 nm in diameter.
  • Suitable liposomes for use in the present invention include those liposomes standardly used in, for example, gene delivery methods known to those of skill in the art. More preferred liposomes include liposomes having a polycationic lipid composition and/or liposomes having a cholesterol backbone conjugated to polyethylene glycol.
  • a liposome comprises a compound capable of targeting the liposome to a particular cell type, such as a cell-specific ligand exposed on the outer surface of the liposome.
  • a liposome with a reagent such as an antisense oligonucleotide or ribozyme can be achieved using methods that are standard in the art (see, for example, U.S. Pat. No. 5,705,151).
  • a reagent such as an antisense oligonucleotide or ribozyme
  • from about 0.1 ⁇ g to about 10 ⁇ g of polynucleotide is combined with about 8 nmol of liposomes, more preferably from about 0.5 ⁇ g to about 5 ⁇ g of polynucleotides are combined with about 8 nmol liposomes, and even more preferably about 1.0 ⁇ g of polynucleotides is combined with about 8 nmol liposomes.
  • antibodies can be delivered to specific tissues in vivo using receptor-mediated targeted delivery.
  • Receptor-mediated DNA delivery techniques are taught in, for example, Findeis et al. Trends in Biotechnol. 11, 202-05 (1993); Chiou et al., Gene Therapeutics: Methods And Applications Of Direct Gene Transfer (J. A. Wolff, ed.) (1994); Wu & Wu, J. Biol. Chem. 263, 621-24 (1988); Wu et al., J. Biol. Chem. 269, 542-46 (1994); Zenke et al., Proc. Natl. Acad. Sci. U.S.A. 87, 3655-59 (1990); Wu et al., J. Biol.
  • Agents of the present invention can also be used in diagnostic assays for detecting diseases and abnormalities or susceptibility to diseases and abnormalities related to the presence of mutations in the nucleic acid sequences that encode a PTCRE or NeRP of the present invention. For example, differences can be determined between the cDNA or genomic sequence encoding a PTCRE or NeRP in individuals afflicted with a disease and in normal individuals. If a mutation is observed in some or all of the afflicted individuals but not in normal individuals, then the mutation is likely to be the causative agent of the disease.
  • the direct DNA sequencing method can reveal sequence differences between a reference gene and a gene having mutations.
  • cloned DNA segments can be employed as probes to detect specific DNA segments.
  • the sensitivity of this method is greatly enhanced when combined with PCR.
  • a sequencing primer can be used with a double-stranded PCR product or a single-stranded template molecule generated by a modified PCR.
  • the sequence determination is performed by conventional procedures using radiolabeled nucleotides or by automatic sequencing procedures using fluorescent tags.
  • genetic testing based on DNA sequence differences can be carried out by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Small sequence deletions and insertions can be visualized, for example, by high-resolution gel electrophoresis.
  • DNA fragments of different sequences can be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific melting or partial melting temperatures (see, e.g., Myers et al., Science 230, 1242, 1985). Sequence changes at specific locations can also be revealed by nuclease protection assays, such as RNase and SI protection or the chemical cleavage method (e.g., Cotton et al., Proc. Natl. Acad. Sci. USA 85, 4397-4401, 1985).
  • the detection of a specific DNA sequence can be performed by methods such as hybridization, RNase protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes and Southern blotting of genomic DNA.
  • mutations can also be detected by in situ analysis.
  • Altered levels of a PTCRE or NeRP of the present invention can also be detected in various tissues.
  • one or more genes having a PTCRE or a NeRP can be detected by assays used to detect levels of particular nucleic acid sequence, such as Southern hybridization, northern hybridization, and PCR.
  • assays can be used to detect levels of a reporter polypeptide regulated by a PTCRE or a NeRP or of a polypeptide encoded by a gene having a PTCRE or a NeRP.
  • assays are well known to those of skill in the art and include radioimmunoassays, competitive binding assays, western blot analysis, and ELISA assays.
  • a sample from a subject such as blood or a tissue biopsy derived from a host, may be the material on which these assays are conducted.
  • a monocistronic reporter construct (pLuc/vegf5'+3'UTR) is under the transcriptional control of the CMV promoter and contains a VEGF IRES driving the luciferase reporter, which nucleic acid sequences are both upstream of a VEGF 3' -UTR.
  • Stable cell lines are generated by transfecting 293 cells with the pLuc/vegf5'+3'UTR.
  • a stable cell line is cultured under hygromycin B selection to create clonal cell lines consistent with protocols well known in the art.
  • clonal cell lines are screened for luciferase activity.
  • the luciferase activity of several clonal cell lines (hereafter "clones") are compared and normalized against total protein content. Clones are maintained under hygromycin B selection for more than three months with intermittent monitoring of luciferase activity. Clones are stable and maintain a high level of luciferase expression. Many clones, for example, about twenty, may be compared to each other with respect to luciferase activity. In comparison to clones B9, D3, and H6, clone B9 exhibits the highest level of luciferase activity.
  • PTHTS post-transcriptional, high-throughput screening
  • Bright-Glow (Promega Co., Madison, WI) is used as a substrate to measure firefly luciferase activity. Active compounds are identified by reporting the average percent inhibition of the duplicate runs followed by rejecting those compounds that did not provide satisfactory reproducibility. The average percent inhibition of compounds that provide satisfactory reproducibility is within a range of about 10%>, about 25% or about 35%> in duplicate runs. Data is analyzed as a normal distribution, which is apparent from graphical and statistical analysis of skewness and kurtosis. Hits are then reported at about a 99% confidence level, usually representing a selection of 3 standard deviations from the mean, or a hit lower limit of observed inhibition about equal to 50%. These selection criteria result in a hit rate of about 1%.
  • the conditioned media is assayed by ELISA.
  • concentration of VEGF is calculated from the standard ELISA curve of each assay.
  • the assays are performed in duplicate at a compound concentration of about 7 ⁇ M.
  • a threshold of about 50%o inl ibition for a compound is selected as a criterion for further investigation.
  • Further evaluation of about 100 to about 150 compounds is conducted from about 700 to about 800 initial PTHTS hits.
  • the activity of the identified compounds is confirmed by repeating the experiments described above.
  • the identified compounds are then acquired as dry powders and analyzed further.
  • the purity and molecular weight of the identified compounds are confirmed by LC-MS.
  • a dose-response analysis is performed using an ELISA assay and using conditions essentially as described above.
  • a dose-response cytotoxicity assay is performed under the same conditions as the ELISA to ensure that the inhibition of VEGF expression is not due to cytotoxicity as measured by CellTiter-Glo ® (Promega, Inc., Madison, WI).
  • Dose-response curves are plotted using percentage inliibition versus concentration of the compound. For each compound, the maximal inhibition is set as 100%) and the minimal inhibition is set as 0%> to generate EC 50 and CC 50 values.
  • a compound from PTHTS shows a sigmoidal curve over a compound concentration range from about lO ⁇ nM to about 10 nM when plotted against the percent inhibition of VEGF expression on the y-axis (see Figure 2).
  • the same compound from PTHTS shows a convex curve over the same compound concentration range plotted against the percent of cytotoxicity.
  • the ELISA EC 50 (50%> inhibition of VEGF expression) for this particular compound is about 7 nM, while its CC 50 (50%> cytotoxicity) is greater than about 2000 nM. Subsets of compounds that show similar efficacy/cytotoxicity windows are also identified.
  • the B9 cell line harbors the firefly luciferase reporter driven by the CMV promoter and flanked by the 5'- and 3 '-UTRs of VEGF transcripts.
  • Use of the B9 cell line with the PTHTS identifies compounds that specifically target the function of VEGF UTRs to modulate expression.
  • Cell line B12 harbors the luciferase reporter in the absence of operably linked VEGF UTRs.
  • Compounds that inhibit luciferase activity in both the B9 and B 12 cell lines are general transcription or general translation inhibitors or luciferase enzyme inhibitors.
  • the dose-response curves of an identified compound show a concave curve in B9 cells and a sigmoidal curve in B12 cells when the percent luciferase inhibition of each is plotted over a compound concentration range from about lO ⁇ nM to about 10 4 nM on the x-axis (see Figure 3).
  • the difference between the two cell lines (B9 and B12) shows that inhibition of VEGF production by this compound is through the VEGF UTRs, i.e., by a post-transcriptional control mechanism.
  • a control experiment is performed with a general translation inhibitor, puromycin. Puromycin treatment does not change the difference of inhibition in luciferase expression in these two cell lines.
  • Example 2 Example 2.
  • TNF- ⁇ TNF- ⁇
  • FGF-2 G- CSF
  • IGF-1 PDGF
  • HIF-l ⁇ HIF-l ⁇
  • ELISA assays analyze levels of expression of these factors using commercially available kits from R&D Systems (Minneapolis, MN). UTR-specific PTHTS identified compounds are tested for their ability to inhibit the expression of a subset of these proteins, including G-CSF, TNF ⁇ , FGF-2, and IGF-1.
  • Identified compounds that are very potent inhibitors of VEGF production as assayed in HeLa cells have EC5 0 values ranging from low nM to high nM.
  • a general translation inhibitor (puromycin) results in similar inhibition for all these cytokines, with EC 50 values ranging from about 0.2 to about 2 ⁇ M.
  • Lead compounds are further characterized and optimized.
  • Analogs are synthesized and identified compounds exhibit excellent potency in the VEGF ELISA assay (EC 50 values ranging from 0.5 nM to 50 nM).
  • an analog exhibits low nM potency.
  • several analogs are synthesized and a subset of identified compounds are very active (EC 50 values ranging from 1 to 50 nM) in the VEGF ELISA assay. Activity of a very potent analog is improved about 500-fold compared to its parent (EC 50 of 1 nM vs. 500 nM).
  • Identified compounds are active as inhibitors of hypoxia-inducible VEGF production in retinal pigment epithelial cells and macrophage cells.
  • PTHTS identified compounds are VEGF-specific inhibitors for the treatment of ocular neo vascular disorders.
  • the effect of the identified compounds on retinal pigment epithelial cells and macrophage cells are tested in two cell lines: ARPE-19, a human retinal pigment epithelial cell line, and RAW264, a mouse macrophage cell line. Both cell lines produce high levels of VEGF under hypoxic conditions. A subset of identified compounds is active in these two cell lines.
  • Compound 1 inhibits VEGF production in both macrophage (a non-limiting example of which is RAW264.7) and retinal pigment epithelial cells (a non-limiting example of which is ARPE-19). In selectivity studies, as shown in Table 2, Compound 1 specifically inhibits VEGF expression relative to that of other factors (FGF-2, IGF-1, GCSF, TNF ⁇ ).
  • Example 4 Identified compounds are active in inhibition of VEGF expression and tumor growth in vivo.
  • a pharmacodynamic model assesses intratumor VEGF levels and selects compounds for in vivo efficacy. Preliminary data demonstrates that several of our compounds effectively inhibit VEGF production in tumor tissues (see Figure 4A).
  • HT1080 cells a human fibrosarcoma cell line
  • mice are implanted subcutaneously in nude mice. After seven days, mice are administrated compounds orally at 20mg/kg/day for two weeks. The tumors are then excised from the mice and homogenized in Tris-HCl buffer containing proteinase inhibitors (Moulder, S.L., et al, Cancer Res.
  • Intratumor VEGF levels are subsequently measured using a human VEGF ELISA kit (R&D System, Minneapolis, MN). Protein concentrations of the homogenates are measured with a Bio-RadTM Protein assay kit and intratumor VEGF levels are normalized to the protein concentrations. Treatment with the identified compounds significantly reduces intratumor VEGF protein levels compared to the vehicle control. In addition, treatment with the identified compound for two weeks inhibits tumor growth as compared to the vehicle-treated control groups (see Figure 4B).
  • Example 5 Mapping of Functional Domains in a 5' VEGF UTR VEGF-5UTR1 and 5UTR2 are amplified from human genomic DNA.
  • the full-length 5' UTR is generated by ligation of the two fragments (see Figure 5).
  • P21uc/VEGF5UTR-FL is generated by inserting the full-length 5' UTR into a dicistronic plasmid (p21uc) between Sal land Sm ⁇ l I sites.
  • Other vectors are derived from p21uc/VEGF5UTR-FL by deleting relevant sequences. All these plasmids are tested in 293 cells by transient transfection.
  • Figure 6 shows the relative fire-fly luciferase activity (normalized against Renilla luciferase) for each of the VEGF 5' UTR fragments. Similar results are obtained from repeating such experiments.

Abstract

The invention relates to the fields of screening assays and compounds and methods for altering protein expression and levels of protein. In particular, the invention includes assays to screen for agents capable of modulating expression of VEGF and agents capable of modulating VEGF expression.

Description

TITLE OF THE INVENTION Methods and Agents for Screening for Compounds Capable of Modulating VEGF Expression
BACKGROUND OF THE INVENTION Aberrant angiogenesis plays a role in the pathogenesis of numerous diseases, including malignant, ischemic, inflammatory and immune disorders (reviewed in Matter, Drug Discovery Today, (5:1005-1024 (2001); Yancopoulos et al, Nature, 407:242-248(2000); Carmeliet, Nat. Med, 9(6):653-660 (2003); Ferrara, Semin. Oncol, 29(6 Suppl 16):10-14 (2002)). Vascular Endothelial Growth Factor (VEGF), an angiogenesis regulator, plays a central role in angiogenesis. In particular, VEGF is an important factor in the pathogenesis of cancers, diabetic retinopathy (DR), and exudative macular degeneration (reviewed in Tandle et al., Clin. Adv. in Hemat. and Oncol., 7(7) :41-48 (2003); Ferrara et al, Nat. Med., 5( 2,):1359-1364 (1999); Matter, supra; Carmeliet supra; Kerbel et al, Nat. Rev. Cancer, 2(10):121-139 (2002); Witmer et al, Prog. Retin. Eye Res., 22(l):l-29 (2003); Clark et al, Nat. Rev. Drug Discovery, 2:448-459 (2003); Ferrara (2002), supra; Thomas, J Biol. Chem., 271:603-606 (1996); Gerber et al, Development, 126:1149-1 59 (1999); which are hereby incorporated by reference), the last two of which are leading causes of blindness in the United States. The expression of VEGF is regulated by a number of factors and agents including cytokines, growth factors, steroid hormones and chemicals, and mutations that modulate the activity of oncogenes such as ras or the tumor suppressor gene VHL (Maxwell et al, Nature, 399:211-215 (1999); Rak et al, Cancer Res., 60:490-498 (2000)). In part, VEGF expression is regulated after transcription by sequences in both the 5'- and 3 '-untranslated regions (UTRs) of its mRNA (Ikeda et al, J. Biol Chem., 270:19161-19166 (1995); Stein et al, Mol Cell. Biol, 75:3112-3119 (1998); Levy et al J. Biol. Chem., 271:2146-2153 (1996); Huez et al, Mol Cell Biol, 18:6118-6190 (1998); Akiri et al, Oncogene, 77:227-236 (1998)). The VEGF 5' UTR is unusually long and GC rich, and it contains an internal ribosomal entry site (IRES) that is reported to mediate a unique, cap-independent mode of translation initiation. The VEGF 3' UTR harbors multiple AU-rich stability determinants that have been shown to be associated with VEGF mRNA turnover rates. Initiation of translation of the VEGF mRNA is reported to be unique under hypoxic conditions in that it is mediated via an internal ribosome entry site (IRES) within the VEGF 5' UTR (Stein et al, supra; Levy et al, supra; Huez et al, supra; Akiri et al, supra). Under hypoxic conditions, cap-dependent translation is dramatically impaired and the translation of the VEGF mRNA occurs through its cap-independent IRES. Initiation of translation of most eukaryotic mRNA is cap-dependent. IRES-mediated translation initiation becomes predominant when components of the translation initiation complex become rate-limiting, e.g., during hypoxia (Mitchell et al, Mol Cell, ll(3):151-lll (2003)). Several investigators have used in vitro and bicistronic strategies, often in conjunction with deletion mutants, to study regulation of VEGF. Prats and colleagues reported the occurrence of cap-independent translation of human VEGF by virtue of an IRES. From these studies, they postulated the presence of two IRESs, a first IRES (IRES A) located within 300 nucleotides of the initiation codon and a second IRES (IRES B) located in the upstream half of the 5'-UTR. Huez et al, supra. In Stein et al, supra., deletion mutants in dicistronic and monocistronic constructs were used to identify sequences of the VEGF 5' UTR required for maximal IRES activity. Keshet and colleagues reported an increase in IRES activity from a 163-nucleotide sequence derived from a VEGF 5' UTR, which is possibly an artifact from RT-PCR amplification, relative to the entire full-length VEGF 5' UTR. Stein et al, supra. Goodall and colleagues reported a deletion analysis of IRES residues toward the 3' end of the mouse VEGF 5' UTR, and speculated that, for optimal IRES activity, the upstream half of the VEGF 5' UTR is necessary. Miller et al, supra. The present invention provides, for the first time, a negative regulator of post- transcriptional regulation (NeRP) located in the 5' UTR of VEGF. Removal of a NeRP from the VEGF 5' UTR results in increased translation of an operably linked gene dependent on the presence of a PTCRE of the present invention.
SUMMARY OF THE INVENTION The present invention includes a nucleic acid construct comprising a nucleic acid sequence encoding a reporter polypeptide, where the nucleic acid sequence encoding a reporter polypeptide is operably linked to a NeRP, the NeRP is operably linked to a PTCRE, the PTCRE is not SEQ ID NO: 3, and expression of the reporter polypeptide is capable of being modulated relative to in an absence of the NeRP. The present invention also includes a nucleic acid molecule comprising a nucleic acid sequence encoding a reporter polypeptide and a VEGF 5' UTR nucleic acid sequence in an absence of SEQ ID NO: 4. The present invention also includes a nucleic acid molecule comprising a nucleic acid sequence encoding a reporter polypeptide operably linked to a VEGF 5' UTR in an absence ofSEQ ID NO: 4. The present invention also includes a nucleic acid molecule comprising a nucleic acid sequence encoding a reporter polypeptide, where the nucleic acid sequence encoding a reporter polypeptide is operably linked downstream of a UTR containing a NeRP, and the UTR is not operably upstream of SEQ ID NO: 3. The present invention also includes a heterogeneous population of nucleic acid molecules, where the heterogeneous population comprises a reporter nucleic acid sequence, and the nucleic acid sequence encoding a reporter polypeptide is operably linked to a VEGF 5' UTR in an absence of NeRPl (SEQ ID NO: 4). The present invention also includes a substantially purified nucleic acid molecule comprising between 95% and 99% sequence identity with a nucleic acid molecule of SEQ ID NO: 3, a fragment thereof, or a complement of either. The present invention also includes a substantially purified nucleic acid molecule consisting of SEQ ID NO: 3, a fragment thereof, or a complement of either. The present invention also includes a substantially purified nucleic acid molecule consisting of a first nucleic acid sequence linked to a heterologous nucleic acid sequence encoding a polypeptide, where the first nucleic acid sequence is selected from the group consisting of SEQ ID NO: 3, a fragment thereof, and a complement of either. The present invention also includes a substantially purified nucleic acid molecule comprising between 95% and 99%) sequence identity with a nucleic acid molecule of SEQ ID NO: 4, a fragment thereof, or a complement of either. The present invention also includes a substantially purified nucleic acid molecule of a nucleic acid sequence selected from a group consisting of SEQ ID NO: 4, a fragment thereof, and a complement of either. The present invention also includes a substantially purified nucleic acid molecule consisting of a first nucleic acid sequence linked to a heterologous nucleic acid sequence encoding a polypeptide, where the first nucleic acid sequence is selected from the group consisting of SEQ ID NO: 4, a fragment thereof, and a complement of either. The present invention also includes a method of making a nucleic acid construct to screen for a compound comprising: a) providing a main ORF downstream of a promoter in the nucleic acid construct; b) operably linking a VEGF 5' UTR in an absence of SEQ ID NO: 4 upstream of the main ORF; and c) operably linking a VEGF 3' UTR downstream of the main ORF. The present invention also includes a method of screening in vivo for a compound that modulates UTR-dependent expression comprising: a) providing a cell having a nucleic acid molecule comprising a promoter upstream from a VEGF 5' UTR in an absence of SEQ ID NO: 4, where the VEGF 5' UTR in an absence of SEQ ID NO: 4 is upstream from a nucleic acid sequence encoding a reporter polypeptide, and the nucleic acid sequence encoding a reporter polypeptide is upstream from a VEGF 3' UTR; b) contacting the cell with a compound; c) producing a nucleic acid molecule that contains a nucleic acid sequence encoding a reporter polypeptide and does not contain SEQ ID NO: 4; and d) detecting the reporter polypeptide. The present invention also includes a method of screening in vitro for a compound that modulates UTR-affected expression comprising: a) providing an in vitro translation system; b) contacting the in vitro translation system with a compound and a nucleic acid molecule comprising a VEGF 5' UTR in an absence of SEQ ID NO: 4, where the VEGF 5' UTR in an absence of SEQ ID NO: 4 is upstream from a nucleic acid sequence encoding a reporter polypeptide and the nucleic acid sequence encoding a reporter polypeptide is upstream from a VEGF 3' UTR; and c) detecting the reporter polypeptide in vitro. The present invention also includes a method of expressing a nucleic acid molecule in a cell comprising: a) providing a nucleic acid molecule to a cell, where the nucleic acid molecule comprises a nucleic acid sequence encoding a reporter polypeptide flanked by VEGF UTRs in an absence of SEQ ID NO: 4; and b) detecting the reporter polypeptide. The present invention also includes a method of screening for a compound that modulates protein expression through a main ORF-independent, UTR-affected mechanism comprising: a) growing a stable cell line having a reporter gene operably linked to a VEGF 5' UTR in an absence of SEQ ID NO: 4; b) comparing the stable cell line in a presence of a compound relative to the stable cell line in an absence of the compound; and c) selecting for the compound that modulates protein expression through a main ORF-independent, UTR- affected mechanism. The present invention also includes a method of screening for a compound that modulates protein expression through a main ORF-independent, UTR-affected mechanism comprising: a) growing a stable cell line having a main ORF operably linked to a VEGF 5' UTR in an absence of SEQ ID NO: 4; b) comparing the stable cell line in the presence of a compound relative to the stable cell line in the absence of the compound; and c) selecting for the compound that modulates protein expression through a main ORF-independent, UTR- affected mechanism. The present invention also includes a method of screening for a compound that modulates protein expression through a VEGF-independent, UTR-affected mechanism comprising: a) substituting in vivo a VEGF gene with a reporter gene, where a UTR consisting of SEQ ID NO: 3 is operably linked to the reporter gene, and the substitution occurs in a differentiated cell; b) growing the differentiated cell; and c) selecting for the compound that modulates protein expression of the reporter gene through a main ORF- independent, UTR-affected mechanism. The present invention also includes a method of screening for a compound that modulates protein expression through a main ORF-independent, UTR-affected mechanism comprising: a) substituting in vivo a main ORF with a reporter gene, where a 5' UTR is operably linked to the reporter gene and consists of SEQ ID NO: 3, and the substitution occurs in a differentiated cell; b) growing the differentiated cell; and c) selecting for the compound that modulates protein expression of the reporter gene through a main ORF- independent, UTR-affected mechanism. The present invention also includes a method of screening for a compound that modulates protein expression through a UTR-affected mechanism comprising: a) providing a stable cell line having a reporter gene operably linked to a VEGF 5' UTR in an absence of SEQ ID NO: 4, where the stable cell line mimics post-transcriptional regulation of a VEGF gene found in vivo in presence of the compound; b) maintaining the stable cell line; and c) selecting for the compound that modulates protein expression of the reporter gene through a UTR-affected mechanism. The present invention also includes a method of screening for a compound that modulates protein expression through a UTR-affected mechanism comprising: a) providing a stable cell line having a main ORF encoding a reporter polypeptide operably linked to a VEGF 5' UTR in an absence of SEQ ID NO: 4, where the stable cell line mimics post- transcriptional regulation of a VEGF gene found in vivo in a presence of a compound; b) maintaining the stable cell line; and c) selecting for the compound that modulates protein expression of the main ORF through a UTR-affected mechanism. The present invention also includes a method of screening for a compound that modulates protein expression through a UTR-affected mechanism mediating the effect of a NeRP comprising: a) growing a stable cell line having a reporter gene operably linked to a 5' VEGF UTR in an absence of a NeRP 1 (SEQ ID NO: 4); b) comparing the stable cell line in a presence of a compound relative to in an absence of the compound, where the compound does not modulate UTR-dependent expression if the 5' VEGF UTR in an absence of a NeRPl (SEQ ID NO: 4) is operably linked to a reporter gene; and c) selecting for the compound that modulates protein expression of the reporter gene through a UTR-affected mechanism mediating the effect of a NeRP. The present invention also includes a method of screening for a compound that modulates protein expression through a UTR-affected mechanism mediating the effect of a NeRP comprising: a) growing a stable cell line having a main ORF encoding a reporter polypeptide operably linked to a 5' VEGF UTR in an absence of a NeRPl (SEQ ID NO: 4); b) comparing the stable cell line in the presence of a compound relative to that in the absence of the compound, where the compound does not modulate UTR-dependent expression if the 5' VEGF UTR in an absence of a NeRPl (SEQ ID NO: 4) is operably linked to a main ORF; and c) selecting for the compound that modulates protein expression of the main ORF through a UTR-affected mechanism mediating the effect of a NeRP . The present invention also includes a method of screening for a compound that modulates protein expression through a UTR-affected mechanism mediating the effect of a NeRP comprising: a) growing a stable cell line having a reporter gene operably linked to a UTR having a NeRPl (SEQ ID NO: 4); b) comparing the stable cell line in a presence of a compound relative to in an absence of the compound, where the compound modulates UTR- dependent expression if a NeRPl (SEQ ID NO: 4) is operably linked to a reporter gene; and c) selecting for the compound that modulates protein expression of the reporter gene through a UTR-affected mechanism mediating the effect of a NeRP. The present invention also includes a method of screening for a compound that modulates protein expression through a UTR-affected mechanism mediating the effect of a NeRP comprising: a) growing a stable cell line having a main ORF encoding a reporter polypeptide operably linked to a UTR having a NeRPl (SEQ ID NO: 4); b) comparing the stable cell line in a presence of a compound relative to in an absence of the compound, where the compound modulates UTR-dependent expression if a NeRPl (SEQ ID NO: 4) is operably linked to a main ORF encoding a reporter polypeptide; and c) selecting for the compound that modulates protein expression of the main ORF encoding a reporter polypeptide through a UTR-affected mechanism mediating the effect of the NeRP.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 sets forth a sequence alignment of VEGF 5' UTR for mouse, rat, and human. Figure 2 sets forth an example of a compound that inhibits VEGF expression over a concentration range. Figure 3 sets forth an example of UTR-dependent inhibition of VEGF expression, where VEGF expression is dependent on one or more VEGF UTRs. Figure 4A sets forth an example of effective inhibition of VEGF production in tumor tissue. Figure 4B sets forth the inhibition of human VEGF production in vivo by a compound. Figure 5 sets forth a schematic of a 5' VEGF UTR and restriction sites therein. VEGF 5 'UTR is amplified from human genomic DNA by two separate PCR reactions. In the overlap region of 5'UTRl and 5'UTR2, a unique enzyme site BamHI is used to assemble the full-length 5 'UTR in subsequent cloning. Figure 6 sets forth a schematic representation of dicistronic plasmids that can be used for transf ection experiments. P21uc/5UTR-ΔNeRPl is a dicistronic plasmid containing VEGF 5'UTRl, in which nucleotides 337 to 1083 of the VEGF cDNA are fused to the firefly luciferase coding sequence; P21uc/5UTR-FL is generated by subcloning VEGF 5'UTR2 into the plasmid p21uc/vegf5utrl between Sal I and BαmHI; plasmid p21uc/5UTR-Δ51-476 is derived from p21uc/5UTR-FL by removing the Nhe /fragment (nt 51 to 746); plasmid p21uc/5UTR-Δ476-1038 is derived from p21uc/vegf5utr-fl by removing the sequence from BαmHI site to the 3'end of 5'UTR; plasmid p21uc/5UTR-Δ 1-476 is derived from p21uc/5UTR-FL by removing the sequence from BαmHI to the 5 'end of 5'UTR. P21uc-e can be used as a negative control in this study. Figure 7 sets forth results identifying the presence of a VEGF IRES domain (a PTCRE) and a NeRP in the VEGF mRNA 5'UTR. Reporter gene expression is analyzed by monitoring luciferase activity.
Description of the Nucleic Acid Sequences
SEQ ID NO 1 sets forth a full-length VEGF 5' UTR. SEQ ID NO 2 sets forth an open reading frame encoding VEGF. SEQ ID NO 3 sets forth a PTCREl, a 702 nucleotide region of a VEGF 5' UTR. SEQ ID NO 4 sets forth aNeRPl, a 336 nucleotide region of a VEGF 5' UTR. SEQ ID NO 5 sets forth a PTCRE2, a 485 nucleotide region of a VEGF 5' UTR. SEQ ID NO 6 sets forth a PTCRE3, a 556 nucleotide region of a VEGF 5' UTR. SEQ ID NO 7 sets forth a PTCRE4, a 294 nucleotide region of a VEGF 5' UTR. SEQ ID NO 8 sets forth a PTCRE5, a 194 nucleotide region of a VEGF 5' UTR. SEQ ID NO 9 sets forth a NeRP2, a 476 nucleotide region of a VEGF 5' UTR. SEQ ID NO 10 sets forth aNeRP3, a 554 nucleotide region of a VEGF 5' UTR. SEQ ID NO 11 sets forth a NeRP4, a 51 nucleotide region of a VEGF 5' UTR. SEQ ID NO 12 sets forth a eRP5, a 91 nucleotide region of a VEGF 5' UTR. SEQ ID NO 13 sets forth a NeRP6, a 335 nucleotide region of a VEGF 5' UTR. SEQ ID NO 14 sets forth a NeRP7, a 332 nucleotide region of a VEGF 5' UTR. SEQ ID NO 15 sets forth a NeRPδ, a 331 nucleotide region of a VEGF 5' UTR. SEQ ID NO 16 sets forth aNeRP9, a 330 nucleotide region of a VEGF 5' UTR. SEQ ID NO 17 sets forth a NeRP 10, a 329 nucleotide region of a VEGF 5' UTR. SEQ ID NO 18 sets forth a NeRPl 1 , a 328 nucleotide region of a VEGF 5' UTR. SEQ ID NO 19 sets forth a NeRP 12, a 327 nucleotide region of a VEGF 5' UTR. SEQ ID NO: 20 sets forth a NeRP13, a 326 nucleotide region of a VEGF 5' UTR. SEQ ID NO: 21 sets forth aNeRP14, a 316 nucleotide region of a VEGF 5' UTR. SEQ ID NO: 22 sets forth a NeRP15, a 306 nucleotide region of a VEGF 5' UTR. SEQ ID NO: 23 sets forth a NeRP 16, a 296 nucleotide region of a VEGF 5' UTR. SEQ ID NO: 24 sets forth a NeRP17, a 286 nucleotide region of a VEGF 5' UTR. SEQ ID NO: 25 sets forth a NeRP 18, a 276 nucleotide region of a VEGF 5' UTR. SEQ ID NO: 26 sets forth a NeRP19, a 266 nucleotide region of a VEGF 5' UTR.
Definitions As used herein, the term "construct" refers to an artificially manipulated nucleic acid molecule. As used herein, the term "heterologous" refers to ingredients or constituents of dissimilar or diverse origin. As used herein, the term "mammalian cancer cell" or "mammalian tumor cell" refers to a cell derived from a mammal that proliferates inappropriately. As used herein, the term "main ORF-independent mechanism" refers to a cellular pathway or process, wherein at least one step relates to gene expression and is not dependent on the nucleic acid sequence of the main open reading frame. As used herein, the term "reporter gene" refers to any gene whose expression can be measured. As used herein, the term "RNA induced gene silencing, or RNA interference (RNAi)" refers to the mechanism of double-stranded RNA (dsRNA) introduced into a system to reduce protein expression of specific genetic sequence. As used herein, the term "specifically bind" means that a compound binds to another compound in a manner different from a similar type of compounds, e.g. in terms of affinity, avidity, and the like. In a non-limiting example, more binding occurs in the presence of a competing reagent, such as casein. In another non-limiting example, antibodies that specifically bind a target protein should provide a detection signal at least 2-, 5-, 10-, or 20- fold higher relative to a detection signal provided with other molecules when used in Western blots or other immunochemical assays. In an alternative non-limiting example, a nucleic acid can specifically bind its complementary nucleic acid molecule. In another non-limiting example, a transcription factor can specifically bind a particular nucleic acid sequence. As used herein, the term "secondary structure" means the alpha-helical, beta-sheet, random coil, beta turn structures and helical nucleic acid structures that occur in proteins, polypeptides, nucleic acids, compounds comprising modified nucleic acids, compounds comprising modified amino acids, and other types of compounds as a result of, at least, the compound's composition. As used herein, the term "non-peptide therapeutic agent" and analogous terms include, but are not limited to organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds but excluding proteins, polypeptides and nucleic acids). As used herein, the term "UTR" refers to the untranslated region of a mRNA. As used herein, the term "untranslated region-dependent expression" or "UTR- dependent expression" refers to the regulation of gene expression through UTRs at the level of mRNA expression, i.e., after transcription of the gene has begun until the protein or the RNA product(s) encoded by the gene has degraded or excreted. As used herein, the term "vector" refers to a nucleic acid molecule used to introduce a nucleic acid sequence in a cell or organism. The entirety of the International Application PCT/US04/01643, filed January 21, 2004, including the sequence listing, is hereby incorporated by reference.
DETAILED DESCRIPTION OF THE INVENTION The present invention includes and utilizes the fact that an untranslated region (UTR) is capable of modulating expression of a gene and that such modulation of expression is capable of being altered or modulated by the addition of compounds. In a preferred embodiment, a UTR is a region of a RNA that is not translated into protein. In a more preferred embodiment, a UTR is a flanking region of the RNA transcript that is not translated into the targeted protein, and can include a 5' UTR that has a short, putative open reading frame. In a most preferred embodiment, the UTR is a 5' UTR, i.e., upstream of the coding region, or a 3' UTR, i.e., downstream of the coding region. Moreover, the present invention includes and provides agents and methods useful in screening for a compound capable of modulating gene expression and also hybrid molecules. Nucleic Acid Agents and Constructs One skilled in the art may refer to general reference texts for detailed descriptions of known teclmiques discussed herein or equivalent techniques. These texts include Ausubel et al, Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (1995); Sambrook et al, Molecular Cloning, A Laboratory Manual (2d ed.), Cold Spring Harbor Press, Cold Spring Harbor, New York (1989); Birren et al, Genome Analysis: A Laboratory Manual, volumes 1 through 4, Cold Spring Harbor Press, Cold Spring Harbor, New York (1997- 1999). These texts can, of course, also be referred to in making or using an aspect of the invention. UTRs The present invention includes nucleic acid molecules with UTRs that comprise or consist of a post-transcriptional regulatory element (PTCRE) including SEQ ID NO: 3, a negative regulator of a PTCRE (NeRP) including SEQ ID NO: 4, and fragments and complements of all. A PTCRE of the present invention can differ from any of the residues in SEQ ID NO: 3 in that the nucleic acid sequence has been deleted, substituted, or added in a manner that does not alter the function. In another aspect of the present invention, a PTCRE of the present invention consists or comprises SEQ ID NO: 5, and fragments and complements of all. In another aspect of the present invention, a PTCRE of the present invention consists or comprises SEQ ID NOs: 6-8, and fragments and complements of all. A PTCRE of the present invention can differ from any of the residues in an untranslated region selected from the group consisting of a nucleic acid sequence consisting or comprising SEQ ID NO: 3 and SEQ ID NOs: 5-8 in that the nucleic acid sequence has been deleted, substituted, or added in a manner that does not alter the function. A NeRP of the present invention can differ from any of the residues in SEQ ID NO: 4 in that the nucleic acid sequence has been deleted, substituted, or added in a manner that does not alter the function. In another aspect of the present invention, a NeRP of the present invention consists or comprises SEQ ID NO: 9, and fragments and complements of all. In another aspect of the present invention, a NeRP of the present invention consists or comprises SEQ ID NOs: 10- 12, and fragments and complements of all. A NeRP of the present invention can differ from any of the residues in a UTR selected from the group consisting of a nucleic acid sequence consisting or comprising SEQ ID NO: 4 and SEQ ID NOs: 9-12 in that the nucleic acid sequence has been deleted, substituted, or added in a manner that does not alter the function. In one aspect, a NeRP is not a full-length sequence of a target UTR. In a preferred aspect, a NeRP is not a full-length VEGF 5' UTR. In one embodiment, a NeRP can be a nucleic acid sequence with a single base deletion at any location of SEQ ID NO: 4. Therefore, a NeRP of the invention may be 335 bases. In another embodiment, a NeRP includes a nucleic acid sequence with two or more bases deleted from any location of SEQ ID NO: 4. In another embodiment, a NeRP includes 3, 4, 5, 6, 7, 8, 9 or 10 residue deletions at any location of SEQ ID NO: 4. In another embodiment, a NeRP includes the remaining nucleic acid sequence resulting from the deletion of 20, 30, 40, 50, 60, or 70 residues from any location of SEQ ID NO: 4. In light of the specification, a NeRP of the present invention may be produced by contiguous, noncontiguous, or a combination of contiguous deletions and noncontiguous deletions of SEQ ID NO: 4 in a manner that does not alter the function of the NeRP. In a preferred embodiment, when a nucleic acid molecule, which includes a NeRP and a PTCRE, has been deleted, substituted, or added to in a manner that removes the negative regulation of a PTCRE, the secondary structure of the remaining nucleic acid molecule is altered in a manner comparable to the alteration in the secondary structure of a full-length VEGF 5' UTR when SEQ ID NO: 4 is deleted. In a more preferred embodiment, a NeRP of the present invention has a secondary structure comparable to the secondary structure of SEQ ID NO: 4. In an embodiment of the present invention, the presence of a NeRP can be detected by the deletion, insertion or alteration of one or more pseudoknots from a larger nucleic acid molecule. In another embodiment, the deletion, insertion or alteration of a stem-loop structure from a larger nucleic acid molecule of the present invention results in a NeRP of the present invention. Programs such as mfold, (see the world wide web at bioweb.pasteur.fr/seqanal/interfaces/mfold-simple.html) genebee (see the world wide web at genebee.msu.su/) may be used to ascertain the secondary structure of SEQ ID NO: 4 and other nucleic acid molecules of the present invention. Other programs or methods well known to those of skill in the art can also be employed. The present invention also includes a NeRP that has a tertiary structure comparable to the tertiary structure formed by SEQ ID NO: 4. Tertiary structure can be determined by, for example, crystallography and phylogenetic covariation (as reviewed in Martin I, et al, Biochim Biophys Ada. 2003 Jul 11;1614(1):97-103; Heinemann TJ., et al, Biol Chem. 1996 Jul-Aug;377(7-8):447-54). The present invention provides nucleic acid molecules that hybridize to the above- described nucleic acid molecules. In a preferred aspect, the nucleic acid molecule hybridizes to a nucleic acid molecule selected from the group consisting of a nucleic acid sequence consisting or comprising SEQ ID NOs: 3-12, and complements thereof. Nucleic acid hybridization is a technique well known to those of skill in the art of DNA manipulation. The hybridization properties of a nucleic acid molecule are an indication of their similarity or identity. The nucleic acid molecules preferably hybridize, under moderate or high stringency conditions, with a nucleic acid sequence selected from SEQ ID NO: 5 and complements thereof. Fragments of these sequences are also contemplated. In another aspect, the nucleic acid molecules preferably hybridize, under moderate or high stringency conditions, with a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5 and its complement. The hybridization conditions typically involve nucleic acid hybridization in about 0.1X to about 10X SSC (diluted from a 20X SSC stock solution containing 3 M sodium chloride and 0.3M sodium citrate, pH 7.0 in distilled water), about 2.5X to about 5X Denhardt's solution (diluted from a 50X stock solution containing 1% (w/v) bovine serum albumin, 1% (w/v) Ficoll® (Amersham Biosciences Inc., Piscataway, NJ), and 1% (w/v) polyvinylpyrrolidone in distilled water), about 10 mg/ml to about 100 mg/ml salmon sperm DNA, and about 0.02% (w/v) to about 0.1% (w/v) SDS, with an incubation at about 20° C to about 70° C for several hours to overnight. In a preferred aspect, the moderate stringency hybridization conditions are provided by 6X SSC, 5X Denhardt's solution, 100 mg/ml salmon sperm DNA, and 0.1% (w/v) SDS, with an incubation at 55° C for several hours. The moderate stringency wash conditions are about 0.02% (w/v) SDS, with an incubation at about 55° C overnight. In a more preferred aspect, the high stringency hybridization conditions are about 2X SSC, about 3X Denhardt's solution, and about 10 mg/ml salmon sperm DNA. The high stringency wash conditions are about 0.05% (w/v) SDS, with an incubation at about 65° C overnight. In an embodiment, the nucleic acid molecule comprises a nucleic acid sequence that is greater than 85% identical, and more preferably greater than 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 3-12, complements thereof, and fragments of any of these sequences. The percent identity is preferably determined using the "Best Fit" or "Gap" program of the Sequence Analysis Software Package™ (Version 10; Genetics Computer Group, Inc., University of Wisconsin Biotechnology Center, Madison, WI). "Gap" utilizes the algorithm of Needleman and Wunsch to find the alignment of two sequences that maximizes the number of matches and minimizes the number of gaps. "BestFit" performs an optimal alignment of the best segment of similarity between two sequences and inserts gaps to maximize the number of matches using the local homology algorithm of Smith and Waterman. The percent identity calculations may also be performed using the Megalign program of the LASERGENE bioinformatics computing suite (default parameters, DNASTAR Inc., Madison, Wisconsin). The percent identity is most preferably determined using the "Best Fit" program using default parameters. Fragment nucleic acid molecules can contain significant portions of, or indeed most of, SEQ ID NO: 3. In an embodiment, the fragments are between about 160 and 250 consecutive residues, about 260 and about 350 consecutive residues, about 360 and about 400 consecutive residues, or about 460 and 500 consecutive residues long of a nucleic molecule of the present invention. In another embodiment, the fragment comprises at least 170, 300, 500, or 600 consecutive residues of SEQ ID NO: 3. In a particularly preferred embodiment, a fragment nucleic acid molecule is capable of selectively hybridizing to SEQ ID NO: 3. In one embodiment, a PTCRE comprises or consists of SEQ ID NO: 3. In another embodiment, a PTCRE comprises or consists of a fragment of SEQ ID NO: 3. In a preferred embodiment, a PTCRE can share identity with between particular mammals, including, but not limited to human, mouse, and rat. In another preferred embodiment, a PTCRE is unique to a human VEGF 5' UTR PTCRE, a non-limiting example of which is SEQ ID NO: 3. Fragment nucleic acid molecules can contain significant portions of SEQ ID NO: 4. In another embodiment of the present invention, nucleic acid molecules can comprise or consist of significant portions of SEQ ID NO: 4. In an embodiment, the fragments are between about 40 and about 90 consecutive residues, about 100 and about 150 consecutive residues, about 160 and about 250 consecutive residues, or about 260 and 325 consecutive residues long of a nucleic molecule of the present invention. In another embodiment, the fragment comprises at least 90, 150, 250, or 325 consecutive residues of SEQ ID NO: 4. In a preferred embodiment, a fragment nucleic acid molecule is capable of selectively hybridizing to SEQ ID NO: 4. In one embodiment, a NeRP comprises or consists of SEQ ID NO: 4. In another embodiment, a NeRP comprises or consists of a fragment of SEQ ID NO: 4. In a preferred embodiment, a NeRP can share identity with between particular mammals, including, but not limited to human, mouse, and rat. In another preferred embodiment, a NeRP is unique to a human VEGF 5' UTR NeRP, a non-limiting example of which is SEQ ID NO: 4. Any of a variety of methods may be used to obtain one or more of the above- described nucleic acid molecules of the present invention. Automated nucleic acid synthesizers may be employed for this purpose. In lieu of such synthesis, the disclosed nucleic acid molecules may be used to define a pair of primers that can be used with the polymerase chain reaction (PCR) to amplify and obtain any desired nucleic acid molecule or fragment. Short nucleic acid sequences having the ability to specifically hybridize to complementary nucleic acid sequences may be produced and utilized in the present invention, e.g., as probes to identify the presence of a complementary nucleic acid sequence in a given sample. Alternatively, the short nucleic acid sequences may be used as oligonucleotide primers to amplify or mutate a complementary nucleic acid sequence using PCR technology. These primers may also facilitate the amplification of related complementary nucleic acid sequences (e.g., related sequences from other species). Use of these probes or primers may greatly facilitate the identification of transgenic cells or organisms that contain the presently disclosed structural nucleic acid sequences. Such probes or primers may also, for example, be used to screen cDNA, mRNA, or genomic libraries for additional nucleic acid sequences related to or sharing homology with the presently disclosed promoters and structural nucleic acid sequences. The probes may also be PCR probes, which are nucleic acid molecules capable of initiating a polymerase activity while in a double-stranded structure with another nucleic acid. A primer or probe is generally complementary to a portion of a nucleic acid sequence that is to be identified, amplified, or mutated and of sufficient length to form a stable and sequence-specific duplex molecule with its complement. The primer or probe preferably is about 10 to about 200 residues long, more preferably is about 10 to about 100 residues long, even more preferably is about 10 to about 50 residues long, and most preferably is about 14 to about 30 residues long. The primer or probe may, for example without limitation, be prepared by direct chemical synthesis, by PCR (U.S. Patent Nos. 4,683,195 and 4,683,202), or by excising the nucleic acid specific fragment from a larger nucleic acid molecule. Various methods for determining the sequence of PCR probes and PCR techniques exist in the art. Computer- generated searches using programs such as Primer3 (www-genome.wi.mit. edu/cgi- bin/primer/primer3.cgi), STSPipeline (www-genome.wi.mit.edu/cgi-bin www- STS_Pipeline), or GeneUp (Pesole et al, BioTechniques 25:112-123, 1998), for example, can be used to identify potential PCR primers. Furthermore, sequence comparisons can be done to find nucleic acid molecules of the present invention based on secondary structure homology. Several methods and programs are available to predict and compare secondary structures of nucleic acid molecules, for example, GeneBee (available on the world wide web at genebee.msu.su/services/rna2_reduced.html); the Vienna RNA Package (available on the world wide web at tbi.univie.ac.at/~ivo/RNA/); SstmctView (available on the world wide web at the Stanford Medical Informatics website, under: projects/helix/sstructview/home.html and described in "RNA Secondary Structure as a Reusable Interface to Biological Information Resources." 1997. Gene vol. 190GC59-70). For example, comparisons of secondary structure are preformed in Le et al , A common RNA structural motif involved in the internal initiation of translation of cellular mRNAs. 1997. Nuc. Acid. Res. vol. 25(2):362-369.
Constructs of the Present Invention The present invention includes and provides nucleic acid constructs. It is understood that any of the constructs and other nucleic acid agents of the present invention can be either DNA or RNA. In a preferred embodiment, a construct can be a nucleic acid molecule having a UTR, a coding sequence, or both. In another embodiment, a construct is composed of at least one UTR of the present invention, a sequence encoding a reporter polypeptide, and a vector. Moreover, any of the nucleic acid molecules of the present invention can be used in combination with a method of the present invention. Vectors Exogenous genetic material may be introduced into a host cell by use of a vector or construct designed for such purpose. Any of the nucleic acid sequences of the present invention can be incorporated into a vector or construct of the present invention. A vector or construct of the present invention includes, without limitation, linear or closed circular plasmids. A vector system may be a single vector or plasmid or two or more vectors or plasmids that together contain the total DNA to be introduced into the genome of the host. In a preferred embodiment, a vector contains a promoter functional in mammalian cells or bacteria or both. Means for preparing vectors or constructs are well known in the art. Vectors suitable for replication in mammalian cells may include viral replicons, or sequences that insure integration of the appropriate sequences encoding HCV epitopes into the host genome. For example, another vector used to express foreign DNA is vaccinia virus. Such heterologous DNA is generally inserted into a gene that is non-essential to the virus, for example, the thymidine kinase gene (tk), which also provides a selectable marker. Expression of the HCV polypeptide then occurs in cells or animals that are infected with the live recombinant vaccinia virus. In general, plasmid vectors containing replicon and control sequences that are derived from species compatible with the host cell are used in connection with bacterial hosts. The vector ordinarily carries a replication site, as well as marking sequences that are capable of providing phenotypic selection in transformed cells. For example, E. coli is typically transformed using a construct with a backbone derived from a vector, such as pBR322, which contains genes for ampicillin and tetracycline resistance and thus provides easy means for identifying transformed cells. The pBR322 plasmid, or other microbial plasmid or phage, also generally contains, or is modified to contain, promoters that can be used by the microbial organism for expression of the selectable marker genes. In a preferred embodiment of the present invention, an expression vector can be a high-level mammalian expression vector designed to randomly integrate into the genome, for example, pCMRl. In another preferred embodiment of the present invention, an expression vector can be a high-level mammalian expression vector designed to site-specifically integrate into the genome of cells. For example, pMCPl can site-specifically integrate into the genome of cells genetically engineered to contain the FRT site-specific recombination site via the Flp recombinase (see, e.g., Craig, 1988, Ann. Rev. Genet. 22: 77-105; and Sauer, 1994, Curr. Opin. Biotechnol 5: 521-527). Promoters A construct can include a promoter, e.g., a recombinant vector typically comprises, in a 5' to 3' orientation: a promoter to direct the transcription of a nucleic acid molecule of interest. In a preferred aspect of the present invention, a construct can include a mammalian promoter and can be used to express a nucleic acid molecule of choice. As used herein, a "mammalian promoter" refers to a promoter functional in a mammalian cell derived from a mammalian cell or both. A number of promoters that are active in mammalian cells have been described in the literature. A promoter can be selected on the basis of the cell type into which the vector will be inserted. A preferred promoter of the present invention is a VEGF promoter. In addition to VEGF promoters described previously, other promoter sequences can be utilized in a construct or other nucleic acid molecule. Suitable promoters include, but are not limited to, those described herein. Suitable promoters for mammalian cells are known in the art and include viral promoters, such as those from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), cytomegalovirus (CMV), and bovine papilloma virus (BPV), and the parvovirus B19p6 promoter as well as mammalian cell-derived promoters. A number of viral-based expression systems can be used to express a reporter gene in mammalian host cells. For example, if an adenovirus is used as an expression vector, sequences encoding a reporter gene can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Other examples of preferred promoters include tissue-specific promoters and inducible promoters. Other preferred promoters include the hematopoietic stem cell-specific, e.g., CD34, glucose-6-phosphotase, interleukin-1 alpha, CD1 lc integrin gene, GM-CSF, interleukin-5R alpha, interleukin-2, c-fos, h-ras and DMD gene promoters. Other promoters include the herpes thymidine kinase promoter, and the regulatory sequences of the metallothionein gene. Inducible promoters suitable for use with bacteria hosts include the β-lactamase and lactose promoter systems, the arabinose promoter system, alkaline phosphatase, a tryptophan (trp) promoter system and hybrid promoters such as the tac promoter. However, other known bacterial inducible promoters are suitable. Promoters for use in bacterial systems also generally contain a Shine-Dalgarno sequence operably linked to the DNA encoding the polypeptide of interest. A promoter can also be selected on the basis of their regulatory features, e.g., enhancement of transcriptional activity, inducibility, tissue specificity, and developmental stage-specificity. A promoter can work in vitro, for example the T7-promoter. Particularly preferred promoters can also be used to express a nucleic acid molecule of the present invention in a nonhuman mammal. Additional promoters that may be utilized are described, for example, in Bernoist and Chambon, Nature 290:304-310 (1981); Yamamoto et al, Cell 22:787-797 (1980); Wagner et al, PNAS 78:1441-1445 (1981); Brinster et al, Nature 296:39-42 (1982). Reporter genes As used herein, a "reporter gene" is any gene whose expression can be measured. In a preferred embodiment, a reporter gene does not have any UTRs. In a more preferred embodiment, a reporter gene is a contiguous open reading frame. In another preferred embodiment, a reporter gene can have a previously determined reference range of detectable expression. Constructs of the invention can comprise one or more reporter genes fused to one or more UTRs. For example, specific RNA sequences, RNA structural motifs, and/or RNA structural elements that are known or suspected to modulate UTR-dependent expression of a target gene can be fused to the reporter gene. A reporter gene of the present invention encoding a protein, a fragment thereof, or a polypeptide, can also be linked to a propeptide encoding region. A propeptide is an amino acid sequence found at the amino terminus of a proprotein or proenzyme. Cleavage of the propeptide from the proprotein yields a mature biochemically active protein. The resulting polypeptide is known as a propolypeptide or proenzyme (a zymogen in some cases). Propolypeptides are generally inactive and can be converted to mature active polypeptides by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide or proenzyme. A reporter gene can express a selectable or screenable marker. Selectable markers may also be used to select for organisms or cells that contain exogenous genetic material. Examples of such include, but are not limited to: a neo gene, which codes for kanamycin resistance and can be selected for using kanamycin, GUS, neomycin phosphotransferase II (nptll), or an antibiotic resistance coding sequence. Screenable markers can be used to monitor expression. Exemplary screenable markers include: green fluorescent protein (GFP), luciferase (LUX), a β-glucuronidase or uidA gene (GUS) which encodes an enzyme for which various chromogenic substrates are known; a β-lactamase gene, a gene which encodes an enzyme for which various chromogenic substrates are known (e.g., PAD AC, a chromogenic cephalosporin); a luciferase gene; a tyrosinase gene, which encodes an enzyme capable of oxidizing tyrosine to DOP A and dopaquinone which in turn condenses to melanin; and α-galactosidase, which can turn a chromogenic α-galactose substrate. Included within the terms "selectable or screenable marker genes" are also genes that encode a secretable marker whose secretion can be detected as a means of identifying or selecting for transfonned cells. Examples include markers that encode a secretable antigen that can be identified by antibody interaction, or even secretable enzymes, which can be detected utilizing their inherent properties. Secretable proteins fall into a number of classes, including small, diffusible proteins which are detectable, (e.g., by ELISA), or small active enzymes which are detectable in extracellular solution (e.g., α-amylase, β-lactamase, phosphinothricin transferase). Other possible selectable or screenable marker genes, or both, are apparent to those of skill in the art. A reporter gene can express a fusion protein. As such, the fusion protein can be a fusion of any reporter gene operably linked to another gene, or fragment thereof. For instance, the expressed fusion protein can provide a "tagged" epitope to facilitate detection of the fusion protein, such as GST, GFP, FLAG, or polyHIS. Such fusions preferably encode between 1 and 50 amino acids, more preferably between 5 and 30 additional amino acids, and even more preferably between 5 and 20 amino acids. In one embodiment, a fusion protein can be a fusion protein that includes in whole or in part of a VEGF protein sequence. Alternatively, the fusion can provide regulatory, enzymatic, cell signaling, or intercellular transport functions. For example, a sequence encoding a signal peptide can be added to direct a fusion protein to a particular organelle within a eukaryotic cell. Such fusion partners preferably encode between 1 and 1000 additional amino acids, more preferably between 5 and 500 additional amino acids, and even more preferably between 10 and 250 amino acids. The present invention also provides for a reporter gene flanked by one or more untranslated regions (e.g., the 5' UTR, 3' UTR, or both the 5' UTR and 3' UTR of the target gene). In addition, the present invention provides for a reporter gene flanked by one or more UTRs of a target gene, where the UTR contains one or more mutations (e.g., one or more substitutions, deletions and/or additions). In a preferred embodiment, the reporter gene is flanked by both 5' and 3' UTRs so that compounds that interfere with an interaction between the 5' and 3' UTRs can be identified. In another preferred embodiment, a stable hairpin secondary structure is inserted into the UTR, preferably the 5' UTR of the target gene. For example, in cases where the 5' UTR possesses IRES activity, the addition of a stable hairpin secondary structure in the 5' UTR can be used to separate cap-dependent from cap-independent translation (see, e.g., Muhlrad et al, 1995, Mol Cell. Biol 15(4):2145-56, the disclosure of which is incorporated by reference in its entirety). In another embodiment, an intron is inserted into a UTR (preferably, the 5' UTR) or at the 5' end of an ORF of a target gene. For example, but not by limitation, in cases where an RNA possesses instability elements, an intron, e.g., the human elongation factor one alpha (EF-1 alpha) first intron, can be cloned into a UTR (preferably, the 5' UTR) or a 5' end of the ORF to increase expression (see, e.g., Kim et al, 2002, J Biotechnol 93(2):183-7, the disclosure of which is incorporated by reference in its entirety). In a preferred embodiment, both a stable hairpin secondary structure and an intron are added to the reporter gene construct. In a more preferred embodiment, the stable hairpin secondary structure is cloned into the 5' UTR and the intron is added at the 5' end of the main ORF of the reporter gene. The reporter gene can be positioned such that the translation of that reporter gene is dependent upon the mode of translation initiation, such as, but not limited to, cap-dependent translation or cap-independent translation (i.e., translation via an internal ribosome entry site). Alternatively, where the UTR contains an upstream open reading frame, the reporter gene can be positioned such that the reporter protein is translated only in the presence of a compound that shifts the reading frame of the UTR so that the formerly untranslated open reading frame is then translated. The reporter gene constructs can be monocistronic or multicistronic. A multicistronic reporter gene construct may encode 2, 3, 4, 5, 6, 7, 8, 9, 10 or more, or in the range of 2-5, 5- 10 or 10-20 reporter genes. For example, a dicistronic reporter gene construct comprising, in the following order going downstream, a promoter, a first reporter gene, a 5' UTR of a target gene, a second reporter gene and optionally, a 3' UTR of a target gene. In such a reporter construct, the transcription of both reporter genes is capable of being driven by the promoter. In this example construct, the present invention includes the translation of the mRNA from the first reporter gene by a cap-dependent scanning mechanism and the translation of the mRNA from the second reporter gene by a cap-independent mechanism, for example by an IRES. In such a case, the IRES -dependent translation of a mRNA of the second reporter gene can be normalized against the cap-dependent translation. Reporter genes can be expressed in vitro or in vivo. In vivo expression can be in a suitable bacterial or eukaryotic host. Suitable methods for expression are described by Sambrook et al, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); Haymes et al, Nucleic Acid Hybridization, A Practical Approach, IRL Press, Washington, DC (1985); or similar texts. Fusion protein or peptide molecules of the invention are preferably produced via recombinant means. These proteins and peptide molecules can be derivatized to contain carbohydrate or other moieties (such as keyhole limpet hemocyanin, etc.). Linked As used herein, linked means physically linked, operably linked, flanked, or any of these in combination. As used herein, physically linked means that the physically linked nucleic acid sequences are located on the same nucleic acid molecule, for example a promoter can be physically linked to a reporter gene as part of a construct. A physical linkage can be proximal, and either direct or indirect. In a preferred embodiment, the promoter is operably linked and physically linked to a nucleic acid sequence of the present invention. A preferred embodiment of the present invention also provides for specific nucleic acid molecules containing a reporter gene flanked by one or more UTRs of a target gene. In this preferred embodiment, the one or more UTRs of a target gene can be physically linked, operably linked, or operably and physically linked to the reporter gene. The present invention also provides for a reporter gene flanked by one or more UTRs of a target gene, where one or more of the UTRs contains one or more mutations (e.g., one or more of each substitution, deletion, addition, or any combination of each). In a more preferred embodiment of the present invention, a reporter gene is flanked by a 5' UTR of a VEGF gene containing one or more deletions. In a most preferred embodiment, a reporter gene is flanked by and operably linked to a 5' VEGF UTR in the absence of a NeRP. In a preferred embodiment, the reporter gene is flanked by both 5' and 3' UTRs of one or more target genes so that compounds that interfere with an interaction between the 5' and 3' UTRs can be identified. In a more preferred embodiment, the reporter gene is flanked by a 5' and 3' UTRs of one target gene, and the reporter gene is physically, operably, or physically and operably linked to the UTRs of one target gene. In a most preferred embodiment, a reporter gene is proximally linked, either directly or indirectly, to one or more UTRs of a target gene. If the reporter gene is directly linked to a UTR of a target gene, the last nucleic acid residue of the reporter gene is chemically bonded to the first nucleic acid residue of the UTR of a target gene. If the reporter gene is proximally linked indirectly to a UTR of a target gene, the last nucleic acid residue of the reporter gene is not chemically bonded to the first nucleic acid residue of the UTR of a target gene and the last nucleic acid residue of the reporter gene can be about 3 or greater than 5 but less than 20. If the reporter gene is directly linked to a UTR of a target gene at any time during reporter gene processing, such as after a splicing event, the reporter gene is directly linked to the UTR. UTRs Agents and constructs of the invention include nucleic acid molecules with an untranslated region (UTR). In a preferred aspect, a UTR refers to a UTR of an mRNA, . e. the region of the mRNA that is not translated into protein. In a preferred embodiment, a UTR contains one or more regulatory elements that modulate UTR-dependent regulation of gene expression. In a particularly preferred embodiment, a UTR is a 5' UTR, i.e., upstream of the coding region, or a 3' UTR, i.e., downstream of the coding region. In another particularly preferred embodiment, the 5' UTR includes a VEGF promoter. In a more preferred embodiment, the 5' UTR includes a VEGF promoter and a PTCRE. As used herein, a "main ORF" is a nucleic acid sequence, including sequence contained in deoxyribonucleic acid and ribonucleic acid molecules, having an open reading frame that can be translated. Examples of a main ORF include a reporter gene, a target gene, and a control gene. As used herein, a "target gene" can be any gene. In a preferred embodiment, a target gene is a gene operatively linked downstream of a VEGF 5' UTR containing an upstream open reading frame ("uORF"). In another embodiment, a target gene can be a VEGF main ORF. In a preferred embodiment, a target gene is a gene containing a uORF. In a particularly preferred embodiment, a target gene is a gene having greater than 50% identity greater than 200 residues with respect to a VEGF gene. As used herein, a "control gene" can be any gene. In a preferred embodiment, a control gene is a gene operatively linked downstream of a VEGF 5' UTR that does not contain a NeRP. A UTR of the present invention can be operatively, physically, or operatively and physically linked to a reporter gene. In a preferred embodiment of the present invention, a UTR of the present invention is physically linked to a reporter gene. The physical, operable, or physical and operable linkage may be upstream, downstream, or internal to the reporter gene. As used herein, operably linked means that the operably linked nucleic acid sequences exhibit their deserved function. For example, a promoter can be operably linked to a reporter gene. In a preferred aspect of the present invention, a UTR of the present invention is a VEGF 5' UTR physically linked upstream of a reporter gene. In a particularly preferred embodiment, VEGF 5' UTR contains or consists of SEQ ID NO: 3 and is physically linked downstream of a reporter gene. In another embodiment, a VEGF 5' UTR does not contain or consist of a NeRP and is physically and operatively linked upstream of a reporter gene. In a more particularly preferred embodiment, VEGF 5' UTR does not contain or consist of a NeRP and does contain or consist of a PTCRE and is physically and operatively linked upstream of a reporter gene. In a preferred embodiment of the present invention, a UTR of the present invention is physically linked upstream to a reporter gene and another UTR is physically linked downstream of the reporter gene. In a particularly preferred embodiment, a UTR of the present invention contains or consists of SEQ ID NO: 3 and is physically and operatively linked upstream of a reporter gene and a VEGF 3' UTR is physically and operatively linked downstream of a reporter gene. In a preferred embodiment of the present invention, a UTR of the present invention is physically linked to reporter gene containing an intron. In a more preferred embodiment of the present invention, a UTR of the present invention containing SEQ ID NO: 3 is physically linked to a reporter gene containmg an intron. In a preferred embodiment of the present invention, a UTR of the present invention is physically linked upstream of a reporter gene and contains an intron internal to the UTR. In a preferred embodiment of the present invention, a UTR of the present invention is physically linked upstream of a reporter gene and a UTR is physically linked downstream of the reporter gene. In a more preferred embodiment of the present invention, a VEGF 5' UTR of the present invention containing a SEQ ID NO: 3 is physically linked upstream of a reporter gene and a VEGF 3' UTR is physically linked downstream of the reporter gene. PTCREs and NeRPs As referred to herein, a PTCRE is a post-transcriptional regulatory element that modulates expression of a target gene. In one aspect, a PTCRE is not a full-length sequence of a target UTR. In a preferred aspect, a PTCRE is not a full-length VEGF 5' UTR. In one embodiment, a PTCRE in one target gene can have primary nucleic acid sequence similarity to a PTCRE in a different target gene. Alternatively, there may not be any primary nucleic acid sequence similarity in PTCREs of similar function. In a preferred embodiment, a PTCRE in one target gene can have a secondary, tertiary, or secondary and tertiary structure similar to a PTCRE in a different target gene. Examples of PTCREs include, but are not limited to, IRES elements, upstream ORFs, and AREs. In one embodiment, a PTCRE is a nucleic acid sequence in a UTR, which modulates UTR-dependent expression. A PTCRE can be a nucleic acid sequence selected from the group consisting of an iron response element ("IRE"), Internal ribosome entry site ("IRES"), upstream open reading frame ("uORF"), male specific lethal element ("MSL-2"), G quartet element, and 5 '-terminal oligopyrimidine tract ("TOP"), AU-rich element ("ARE"), selenocysteine insertion sequence ("SECIS"), histone stem loop, cytoplasmic polyadenylation element ("CPE"), nanos translational control element, amyloid precursor protein element ("APP"), translational regulation element ("TGE")/direct repeat element ("DRE"), Bruno element ("BRE"), or a 15-lipoxygenase differentiation control element ("15-LOX-DICE"). In an alternative embodiment, a PTCRE is not an IRES from VEGF. In another embodiment, PTCRE is not be an IRES. In a preferred embodiment, a PTCRE is SEQ ID NO: 3. In a most preferred embodiment, a PTCRE is not a NeRP and the PTCRE does not contain or consist of a NeRP. A NeRP is a nucleic acid sequence in a UTR, which modulates PTCRE-dependent expression in a NeRP-dependent mechanism. In one embodiment of the present invention, a NeRP regulates an IRES. In a preferred embodiment, a NeRP suppresses IRES-dependent expression of a gene. In a most preferred embodiment, a NeRP is SEQ ID NO: 4. Alternatively, a NeRP can modulate PTCRE-dependent expression, where the PTCRE suppresses gene expression, so that the NeRP is capable of increasing gene expression by a NeRP-dependent mechanism. In an alternative embodiment of the invention, a NeRP mimics an IRES. A NeRP of the present invention can differ from any of the residues in SEQ ID NO: 4 in that the nucleic acid sequence has been deleted, substituted, or added in a manner that does not alter the function. In another aspect of the present invention, a NeRP of the present invention consists or comprises SEQ ID NO: 9, and fragments and complements of all. In another aspect of the present invention, a NeRP of the present invention consists or comprises SEQ ID NOs: 10-12, and fragments and complements of all. While the present invention is directed, in part, to VEGF 5' UTRs, PTCREs of the present invention can be located in any position within a construct and not limited to the 5' UTR region of a construct. A PTCRE of the present invention can be operatively, physically, or operatively and physically linked to a UTR. In an alternative embodiment of the present invention, a PTCRE of the present invention is a UTR of the present invention. While the present invention is directed, in part, to a NeRP in the VEGF 5' UTR, NeRPs of the present invention can be located in any position within a construct and not limited to the VEGF 5' UTR region of a construct. A NeRP of the present invention can be operatively, physically, or operatively and physically linked to a UTR. In an alternative embodiment of the present invention, a NeRP of the present invention is upstream of a PTCRE of the present invention. In a preferred embodiment, a PTCRE of the present invention is located between about 1 to about 100 residues upstream from the initiation codon of an open reading frame in a mRNA, between about 150 to about 250 residues upstream from the initiation codon, or between about 300 to about 500 residues upstream from the initiation codon. In a most preferred embodiment, the untranslated region is about 1 residue upstream from the initiation codon. In a preferred embodiment, a NeRP of the present invention is between about 1000 to about 500 residues upstream from a PTCRE, between about 500 to about 100 residues upstream from a PTCRE, or between about 100 to about 60 residues upstream from a PTCRE. In another embodiment, a PTCRE is within about 1000 residues upstream from the 5' end of a main ORF, about 500 residues upstream from the 5' end of a main ORF, or within about 200 residues upstream from the 5' end of a main ORF, or about 100 residues upstream from the 5' end of a main ORF. In another embodiment, a PTCRE is within the main ORF and between about 1000 to about 500 residues upstream from the 3' end of a main ORF, between about 500 to about 100 residues upstream from the 3' end of a main ORF, or between about 100 to about 60 residues upstream from the 3 ' end of a main ORF. In a most preferred embodiment, the PTCRE is within 30 residues upstream from the 5' end of a main ORF. Constructs of the present invention can have more or fewer components than described above. For example, constructs of the present invention can include genetic elements, including but not limited to, 3' transcriptional terminators, 3' polyadenylation signals, other untranslated nucleic acid sequences, transit or targetmg sequences, selectable or screenable markers, promoters, enhancers, and operators, as desired. Constructs of the present invention can also contain a promoterless gene that may utilize an endogenous promoter upon insertion into a host cell chromosome. Alternatively, sequences encoding nucleic acid molecules of the present invention can be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and can be used to synthesize RNA probes in vitro by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (for example, Amersham Biosciences Inc., Piscataway, NJ; and Promega Co, Madison, WI).
Modulation of Gene Expression by Nucleic Acid Molecules of the Present Invention Modulation of gene expression can result in more or less gene expression. Many approaches for modulating gene expression using nucleic acid molecules of the present invention are known to one skilled in the art. For example, over-expression of a gene product can be the result from transfection of a construct of the present invention into a mammalian cell. Similarly, down-regulation can be the result from transfection of a construct of the present invention into a mammalian cell. Other non-limiting examples include anti-sense techniques like RNA interference (RNAi), transgenic animals, hybrids, and ribozymes. The following examples are provided by way of illustration, and are not intended to be limiting of the present invention. Cellular Mechanisms As used herein, the term "UTR-dependent expression" refers to the regulation of gene expression through UTRs at the level of mRNA expression, i.e., after transcription of the gene has begun until the protein or the RNA product(s) encoded by the gene has degraded. In a preferred embodiment, the term "UTR-dependent expression" refers to the regulation of mRNA stability or translation. In a more preferred embodiment, the term "UTR-dependent expression" refers to the regulation of gene expression through regulatory elements present in an UTR(s). Altering the sequence of a PTCRE within a UTR of target gene may change the amount of UTR-dependent expression observed for that target gene. As used herein, a "UTR-affected mechanism" is a cellular mechanism that discriminates between UTRs based on their nucleic acid sequence or based on properties that are a function of their sequence such as the secondary, tertiary, or quaternary structure or other associated factors. Modulation of the UTR-dependent expression of a target gene can be due to a change in how a UTR-affected mechanism acts on the target gene. For example, a UTR in a target gene can contain an IRES, which affects target gene expression via a UTR- affected mechanism. In a preferred embodiment, a UTR-affected mechanism can be a main ORF- independent mechanism. As used herein, a "main ORF-independent mechanism" refers to a cellular pathway or process, wherein at least one step relates to gene expression and is not dependent on the nucleic acid sequence of the main open reading frame. In a preferred embodiment, a UTR-affected mechanism is a main ORF-independent, UTR-affected mechanism. In order to exclude the possibility that a particular compound is functioning solely by modulating the expression of a target gene in an UTR-independent manner, one or more mutations may be introduced into the UTRs operably linked to a reporter gene and the effect on the expression of the reporter gene in a reporter gene-based assay described herein can be determined. For example, a reporter gene construct comprising the 5' UTR of a target gene may be mutated by deleting a fragment of the 5' UTR of the target gene or substituting a fragment of the 5' UTR of the target gene with a fragment of the 5' UTR of another gene and measuring the expression of the reporter gene in the presence and absence of a compound that has been identified in a screening assays of the present invention or of an assay well known to the skilled artisan. If the deletion of a fragment of the 5' UTR of the target gene or the substitution of a fragment of the 5' UTR of the target gene with a fragment of the 5' UTR of another gene affects the ability of the compound to modulate the expression of the reporter gene, then the fragment of the 5' UTR deleted or substituted plays a role in the regulation of the reporter gene expression and the regulation, at least in part, in an UTR-dependent manner. Alternatively or in conjunction with tests described above, the possibility that a particular compound is functioning solely by modulating the expression of a target gene in an UTR-independent manner can be determined by changing the vector utilized as a reporter construct. The UTRs flanked by a reporter gene from the first reporter construct in which an effect on reporter gene expression was detected following exposure to a compound may be inserted into a new reporter construct that has, e.g., different transcriptional regulation elements (e.g., a different promoter) and a different selectable marker. The level of reporter gene expression in the presence of the compound can be compared to the level of reporter gene expression in the absence of the compound or in the presence of a control (e.g., PBS). If there is no change in the level of expression of the reporter gene in the presence of the compound relative to the absence of the compound or in the presence of a control, then the compound probably is functioning in an UTR-independent manner. Compounds, identified in assays of the present invention, that are capable of modulating UTR-dependent expression of a target gene (for convenience referred to herein as a "lead" compound) can be further tested for UTR-dependent binding to the target RNA (which contains at least one UTR, and preferably at least one element of an UTR, for example a PTCRE). Furthermore, by assessing the effect of a compound on target gene expression, cw-acting elements, i.e., specific nucleotide sequences, that are involved in UTR- dependent expression may be identified. RNA binding assays, subtraction assays, and expressed protein concentration and activity assays are examples of methods to determine UTR-dependent expression of a gene. Hybrids In one aspect of the present invention, a hybrid of a compound and a PTCRE or a NeRP of the present invention is a hybrid formed between two non-identical molecules. In a preferred aspect, a hybrid can be formed between two nucleic acid molecules. For example, a hybrid can be formed between two ribonucleic acid molecules, between a ribonucleic acid molecule and a deoxyribonucleic acid molecule, or between derivatives of either. In alternative embodiment, a hybrid can be formed between a nucleic acid of the present invention and a non-nucleic acid molecule. In a preferred embodiment, a hybrid can be formed between a nucleic acid molecule and a non-nucleic acid molecule, for example, a polypeptide or a non-peptide therapeutic agent. Ribozymes In one aspect of the present invention, the activity or expression of a gene is regulated by designing trans-cleaving catalytic RNAs (ribozymes) specifically directed to a nucleic acid molecule of the present invention, for example, SEQ ID NO: 3 and SEQ ID NOs: 5-8. In an alternate aspect, the activity or expression of a gene is regulated by designing trans- cleaving catalytic RNAs (ribozymes) specifically directed to a nucleic acid molecule of the present invention, for example, SEQ ID NO: 4 and SEQ ID NOs: 9-12. Ribozymes are RNA molecules possessing endoribonuclease activity. Ribozymes are specifically designed for a particular target, and the target message contains a specific nucleotide sequence. They are engineered to cleave any RNA species site-specifically in the background of cellular RNA. The cleavage event renders the mRNA unstable and prevents protein expression. Importantly, ribozymes can be used to inhibit expression of a gene of unknown function for the purpose of determining its function in an in vitro or in vivo context, by detecting a phenotypic effect. One commonly used ribozyme motif is the hammerhead, for which the substrate sequence requirements are minimal. Design of the hammerhead ribozyme, and the therapeutic uses of ribozymes, are disclosed in Usman et al, Current Opin. Strict. Biol 6:527-533 (1996). Ribozymes can also be prepared and used as described in Long et al, FASEBJ. 7:25 (1993); Symons, .4 Rev. Biochem. 61:641 (1992); Perrotta et al, Biochem. 31 :16-17 (1992); Ojwang et al, PNAS 89:10802-10806 (1992); and U.S. Patent No. 5,254,678. Ribozyme cleavage of HIV-I RNA, methods of cleaving RNA using ribozymes, methods for increasing the specificity of ribozymes, and the preparation and use of ribozyme fragments in a hammerhead structure are described in U.S. Patent Nos. 5,144,019; 5,116,742; and 5,225,337 and Koizumi et al, Nucleic Acid Res. 17:7059-7071 (1989). Preparation and use of ribozyme fragments in a hairpin structure are described by Chowrira and Burke, Nucleic Acids Res. 20:2835 (1992). Ribozymes can also be made by rolling transcription as described in Daubendiek and Kool, Nat. Biotechnol 15(3):273-277 (1997). The hybridizing region of the ribozyme may be modified or may be prepared as a branched structure as described in Horn and Urdea, Nucleic Acids Res. 11:6959-61 (1989). The basic structure of the ribozymes may also be chemically altered in ways familiar to those skilled in the art, and chemically synthesized ribozymes can be administered as synthetic oligonucleotide derivatives modified by monomeric units. In a therapeutic context, liposome mediated delivery of ribozymes improves cellular uptake, as described in Birikli et al, Eur. J. Biochem. 245:1-16 (1997). Ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one which occurs naturally in Tetrahymena thermophila (known as the IVS, or L-19 IVS RNA) and which has been extensively described by Thomas Cech and collaborators (Zaug et al, Science 224:574-578 (1984); Zaug and Cech, Science 231:470-475 (1986); Zaug et al, Nature, 324:429-433 (1986); W0 88/04300; Been and Cech, Cell 47:207-216 (1986)). The Cech-type ribozymes have an eight base pair active site which hybridizes to a target RNA sequence whereafter cleavage of the target RNA takes place. The invention encompasses those Cech-type ribozymes which target eight base-pair active site sequences that are present in a target gene. Ribozymes can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.) and should be delivered to cells which express the target gene in vivo. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Because ribozymes, unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency. Using the nucleic acid sequences of the invention and methods known in the art, ribozymes are designed to specifically bind and cut the corresponding mRNA species. Ribozymes thus provide a means to inhibit the expression of any of the proteins encoded by the disclosed nucleic acids or their full-length genes. The full-length gene need not be known in order to design and use specific inhibitory ribozymes. In the case of a nucleic acid or cDNA of unknown function, ribozymes corresponding to that nucleotide sequence can be tested in vitro for efficacy in cleaving the target transcript. Those ribozymes that effect cleavage in vitro are further tested in vivo. The ribozyme can also be used to generate an animal model for a disease, as described in Birikh et al, Eur. J. Biochem. 245:1-16 (1997). An effective ribozyme is used to determine the function of the gene of interest by blocking its transcription and detecting a change in the cell. Where the gene is found to be a mediator in a disease, an effective ribozyme is designed and delivered in a gene therapy for blocking transcription and expression of the gene. Therapeutic and functional genomic applications of ribozymes begin with knowledge of a portion of the coding sequence of the gene to be inhibited. Thus, for many genes, a partial nucleic acid sequence provides adequate sequence for constructing an effective ribozyme. A target cleavage site is selected in the target sequence, and a ribozyme is constructed based on the 5' and 3' nucleotide sequences that flank the cleavage site. Retroviral vectors are engineered to express monomeric and multimeric hammerhead ribozymes targetmg the mRNA of the target coding sequence. These monomeric and multimeric ribozymes are tested in vitro for an ability to cleave the target mRNA. A cell line is stably transduced with the retroviral vectors expressing the ribozymes, and the transduction is confirmed by Northern blot analysis and reverse-transcription polymerase chain reaction
(RT-PCR). The cells are screened for inactivation of the target mRNA by such indicators as reduction of expression of disease markers or reduction of the gene product of the target mRNA.
Cells and Organisms Nucleic acid molecules that may be used in cell transformation or transfection can be any of the nucleic acid molecules of the present invention. Nucleic acid molecules of the present invention can be introduced into a cell or organism. In a preferred aspect, the cell is selected from the group consisting of cells that do not express VEGF, cells that express VEGF, or cells that express VEGF conditionally. In a more preferred aspect, the cell is a cancer cell, more preferably a cancer cell where VEGF is overexpressed relative to a non- transformed cell. A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences, to process an expressed reporter gene in the desired fashion, or based on the expression levels of an endogenous or heterologous VEGF gene. Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC, Manassas, VA), such as HeLa cells, Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells and a number of other cell lines. Non-limiting examples of suitable mammalian host cell lines include those shown below in Table 1. Table 1 : Mammalian Host Cell Lines
Figure imgf000035_0001
Figure imgf000036_0001
In a preferred aspect, cells of the present invention can be cells of an organism. In a more preferred aspect, the organism is a mammal. In a most preferred aspect, the mammal is a human. In another more preferred aspect, the organism is a non-human mammal, preferably a mouse, rat, or a chimpanzee. In one aspect of the present invention, cells can be pluripotent or differentiated. A nucleic acid of the present invention can be naturally occurring in the cell or can be introduced using techniques such as those described in the art. There are many methods for introducing transforming DNA segments into cells, but not all are suitable for delivering DNA to eukaryotic cells. Suitable methods include any method by which DNA can be introduced into a cell, such as by direct delivery of DNA, by desiccation/inhibition-mediated DNA uptake, by electroporation, by agitation with silicon carbide fibers, by acceleration of DNA coated particles, by chemical transfection, by lipofection or liposome-mediated transfection, by calcium chloride-mediated DNA uptake, etc. For example, without limitation, Lipofectamine® (Invitrogen Co., Carlsbad, CA) and Fugene® (Hoffmann-La Roche Inc., Nutley, NJ) can be used for transfection of nucleic acid molecules, such as constructs and siRNA, into several mammalian cells. Alternatively, in certain embodiments, acceleration methods are preferred and include, for example, microprojectile bombardment and the like. Within the scope of this invention, the transfected nucleic acids of the present invention may be expressed transciently or stably. Such transfected cells can be in a two- or three-dimensional cell culture system or in an organism. For example, without limitation, the construct may be an autonomously replicating construct, i.e., a construct that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The construct may contain any means for assuring self-replication. For autonomous replication, the construct may further comprise an origin of replication enabling the construct to replicate autonomously in the host cell in question. Alternatively, the construct may be one which, when introduced into the cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. This integration may be the result of homologous or non-homologous recombination. Integration of a construct or nucleic acid into the genome by homologous recombination, regardless of the host being considered, relies on the nucleic acid sequence of the construct. Typically, the construct contains nucleic acid sequences for directing integration by homologous recombination into the genome of the host. These nucleic acid sequences enable the construct to be integrated into the host cell genome at a precise location or locations in one or more chromosomes. To increase the likelihood of integration at a precise location, there should be preferably two nucleic acid sequences that individually contain a sufficient number of nucleic acids, preferably 400 residues to 1500 residues, more preferably 800 residues to 1000 residues, which are highly homologous with the corresponding host cell target sequence. This enhances the probability of homologous recombination. These nucleic acid sequences may be any sequence that is homologous with a host cell target sequence and, furthermore, may or may not encode proteins. Stable expression is preferred for long-term, high-yield production of recombinant proteins. For example, cell lines that stably express a reporter gene can be transformed using expression constructs that can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate construct. Following the introduction of the construct, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to a selective medium. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells that successfully express the introduced construct. Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. See, for example, Animal Cell Culture, R.I. Freshney, ed., 1986. Any number of selection systems can be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler et al, 1977. Cell vol.11:223-32) and adenine phosphoribosyltransferase (Lowy etal, 1980 Cell vol. 22:817-23.) genes which can be employed in tk' or aprf cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dhfr confers resistance to methotrexate (Wigler et al, 1980. Proc. Natl. Acad. Sci. vol. 77:3567-70), npt confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin et al, 1981. J Mol. Biol vol.150: 1-14), and als and at confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. Additional selectable genes have been described. For example, trpB allows cells to utilize indole in place of tryptophan, and hisD allows cells to utilize histinol in place of histidine (Hartman & Mulligan, 1988. Proc. Natl Acad. Sci. vol. 85:8047-51). Visible markers such as anthocyanins, β-glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific construct system (Rhodes et al, 1995. Methods Mol. Biol. vol. 55:121-131). Although the presence of marker gene expression suggests that a reporter gene is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding a reporter gene is inserted within a marker gene sequence, transformed cells containing sequences that encode a reporter gene can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a reporter gene under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of a reporter gene. Alternatively, host cells which contain a reporter gene and which express a reporter gene e can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques that include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein. For example, the presence of a reporter gene can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding a reporter gene. Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding a reporter gene to detect transformants that contain a reporter gene. Screening Methods of the Present Invention Compound The present invention includes methods for screening compounds capable of modulating gene expression. Any compound can be screened in an assay of the present invention. In an embodiment, a compound includes a nucleic acid or a non-nucleic acid, such as a polypeptide or a non-peptide therapeutic agent. In a preferred embodiment, a nucleic acid can be a polynucleotide, a polynucleotide analog, a nucleotide, or a nucleotide analog. In a more preferred embodiment, a compound can be an antisense oligonucleotide, which are nucleotide sequences complementary to a specific DNA or RNA sequence of the present invention. Preferably, an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used. Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Nucleic acid molecules, including antisense oligonucleotide molecules, can be provided in a DNA construct and introduced into a cell. Nucleic acid molecules can be anti- sense or sense and double- or single-stranded. In a preferred embodiment, nucleic acid molecules can be interfering RNA (RNAi) or microRNA (miRNA). In a preferred embodiment, the dsRNA is 20-25 residues in length, termed small interfering RNAs (siRNA). Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non- phosphodiester internucleotide linkages such alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters. See Brown, 1994 Meth. Mol. Biol vol. 20:1-8; Sonveaux, 1994. Meth Mol. Biol. Vol. 26:1-72; and Uhlmann et al, 1990. Chem. Rev. vol. 90:543-583. Salts, esters, and other pharmaceutically acceptable forms of such compounds are also encompassed. In a preferred embodiment, a compound can be a peptide, polypeptide, polypeptide analog, amino acid, or amino acid analog. Such a compound can be synthesized manually or by an automated synthesizer. A compound can be a member of a library of compounds. In a specific embodiment, the compound is selected from a combinatorial library of compounds comprising peptoids; random biooligomers; diversomers such as hydantoins, benzodiazepines and dipeptides; vinylogous polypeptides; nonpeptidal peptidomimetics; oligocarbamates; peptidyl phosphonates; peptide nucleic acid libraries; antibody libraries; carbohydrate libraries; and small organic molecule libraries. In a preferred embodiment, the small organic molecule libraries are libraries of benzodiazepines, isoprenoids, thiazolidinones, metathiazanones, pyrrolidines, morpholino compounds, or diazepindiones. In another embodiment, a compound can have a molecular weight less than about 10,000 grams per mole, less than about 5,000 grams per mole, less than about 1,000 grams per mole, less than about 500 grams per mole, less than about 100 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds. Compounds can be evaluated comprehensively for cytotoxicity. The cytotoxic effects of the compounds can be studied using cell lines, including for example 293 (kidney), HuH7 (liver), and Hela cells over about 4, 10, 16, 24, 36 or 72-hour periods. In addition, a number of primary cells such as normal fibroblasts and peripheral blood mononuclear cells (PBMCs) can be grown in the presence of compounds at various concentrations for about 4 days. Fresh compound can be added every other day to maintain a constant level of exposure with time. The effect of each compound on cell-proliferation can be determined by CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega Co, Madison, WI) and [3H]- Thymidine incorporation. Treatment of some cells with some of the compounds may have cytostatic effects. A selective index (ratios of CC50 in cytotoxicity assays to the EC50 in ELISA or FACS or the reporter gene assays) for each compound can be calculated for all of the UTR-reporters and protein inhibition assays. Compounds exhibiting substantial selective indices can be of interest and can be analyzed further in the functional assays. The structure of a compound can be determined by any well-known method such as mass spectroscopy, NMR, vibrational spectroscopy, or X-ray crystallography as part of a method of the present invention. Compounds can be pharmacologic agents already known in the art or can be compounds previously unknown to have any pharmacological activity. The compounds can be naturally occurring or designed in the laboratory. They can be isolated from microorganisms, animals, or plants, and can be produced recombinantly, or synthesized by chemical methods known in the art. If desired, compounds can be obtained using any of the numerous combinatorial library methods known in the art, including but not limited to, biological libraries, spatially addressable parallel solid phase or solution phase libraries, synthetic library methods requiring deconvolution, the "one-bead one-compound" library method, and synthetic library methods using affinity chromatography selection. Methods for the synthesis of molecular libraries are well known in the art (see, for example, DeWitt et al., Proc. Natl. Acad. Sci. U.S.A. 90, 6909, 1993; Erb et al. Proc. Natl. Acad. Sci. U.S.A. 91, 11422, 1994; Zuckermann et al, J. Med. Chem. 37, 2678, 1994; Cho et al., Science 261, 1303, 1993; Carell et al, Angew. Chem. Int. Ed. Engl. 33, 2059, 1994; Carell et al., Angew. Chem. Int. Ed. Engl. 33, 2061; Gallop et al., J. Med. Chem. 37, 1233, 1994). Libraries of compounds can be presented in solution (see, e.g., Houghten, BioTechniques 13, 412-421, 1992), or on beads (Lam, Nature 354, 82-84, 1991), chips (Fodor, Nature 364, 555-556, 1993), bacteria or spores (Ladner, U.S. Pat. No. 5,223,409), plasmids (Cull et al., Proc. Natl. Acad. Sci. U.S.A. 89, 1865-1869, 1992), or phage (Scott & Smith, Science 249, 386-390, 1990; Devlin, Science 249, 404-406, 1990); Cwirla et al., Proc. Natl. Acad. Sci. 97, 6378- 6382, 1990; Felici, J. Mol. Biol. 222, 301-310, 1991; and Ladner, U.S. Pat. No. 5,223,409). Methods of the present invention for screening compounds can select for compounds capable of modulating gene expression, which are capable of directly binding to a ribonucleic acid molecule transcribed from a target gene. In a preferred embodiment, a compound identified in accordance with the methods of the present invention may be capable of binding to one or more trans-acting factors (such as, but not limited to, proteins) that modulate UTR- dependent expression of a target gene. In another preferred embodiment, a compound identified in accordance with the methods of invention may disrupt an interaction between the 5' UTR and the 3' UTR. Compounds can be tested using in vitro assays (e.g., cell-free assays) or in vivo assays (e.g., cell-based assays) well known to one of skill in the art or as provided in the present invention. A compound that modulates expression of a target gene can be determined from the methods provided in the present invention. A UTR of the present invention includes UTRs capable of modulating gene expression in the presence, in the absence, or in the presence and absence of a compound. In a preferred embodiment, the effect of a compound on the expression of one or more genes can be determined utilizing assays well known to one of skill in the art or provided by the present invention to assess the specificity of a particular compound's effect on the UTR-dependent expression of a target gene. In a more preferred embodiment, a compound has specificity for a plurality of genes. In another more preferred embodiment, a compound identified utilizing the methods of the present invention is capable of specifically effect the expression of only one gene or, alternatively, a group of genes within the same signaling pathway. Compounds identified in the assays of the present invention can be tested for biological activity using host cells containing or engineered to contain the target RNA element involved in UTR-dependent gene expression coupled to a functional readout system. Screening assays The present invention includes and provides for assays capable of screening for compounds capable of modulating gene expression. In a preferred aspect of the present invention, an assay is an in vitro assay. In another aspect of the present invention, an assay is an in vivo assay. In another preferred aspect of the present invention, an assay measures translation. In a preferred aspect of the present invention, the assay includes a nucleic acid molecule of the present invention or a construct of the present invention. A nucleic acid molecule or construct of the present invention include, without limitation, SEQ ID NOs: 3- 12, or a sequence that differs from any of the residues in SEQ ID NOs: 3-12 in that the nucleic acid sequence has been deleted, substituted, or added in a manner that does not alter the function. The present invention also provides fragments and complements of all the nucleic acid molecules of the present invention. In one embodiment of the present invention, the activity or expression of a reporter gene is modulated. Modulated means increased or decreased during any point before, after, or during translation. In a preferred embodiment, activity or expression of a reporter gene is modulated during translation. For example, inhibition of translation of the reporter gene would modulate expression. In an alternative example, expression level of a reporter gene is modulated if the steady-state level of the expressed protein decreased even though translation was not inhibited. For example, a change in the half-life of a mRNA can modulate expression. In an alternative embodiment, modulated activity or expression of a reporter gene means increased or decreased during any point before or during translation. In a more preferred aspect, the activity or expression of a reporter gene or a target gene is modulated by greater than 30%, 40%, 50%, 60%, 70%, 80% or 90%) in the presence of a compound. In a highly preferred aspect, more of an effect is observed in VEGF- dependent cancer cells. In a most preferred aspect, the activity or expression of a reporter gene is modulated without altering the activity of a control gene for general, indiscriminate translation activity. As used herein, indiscriminate translation activity refers to modulation in translation levels or activity that is random or unsystematic. One assay for modulation in general, indiscriminate translation activity uses a general translational inhibitor, for example puromycin, which is an inhibitor that causes release of nascent peptide and mRNA from ribosomes. Expression of a reporter gene can be detected with, for example, techniques know in the art. Translation or transcription of a reporter gene can be detected in vitro or in vivo. In detection assays, either the compound or the reporter gene can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase. High-throughput screening can be done by exposing nucleic acid molecules of the present invention to a library of compounds and detecting gene expression with assays known in the art, including, for example without limitation, those described above. In one embodiment of the present invention, cancer cells, such as HeLa cells, expressing a nucleic acid molecule of the present invention are treated with a library of compounds. Percent inhibition of reporter gene activity can be obtained with all the library compounds can be analyzed using, for example without limitation, a scattergram generated by SpotFire® (SpotFire, Inc., Somerville, MA). The high-throughput screen can be followed by subsequent selectivity screens. In a preferred embodiment, a subsequent selectivity screen can include detection of reporter gene expression in cells expressing, for example, a reporter gene linked to a PTCRE or flanked by a 5' and 3' UTR of the same gene, either of which contains a PTCRE or a NeRP or both of the present invention. In an alternative preferred embodiment, a subsequent selectivity screen can include detection of reporter gene expression in cells in the presence of a various concentrations of compounds. Once a compound has been identified to modulate UTR-dependent expression of a target gene and preferably, the structure of the compound has been identified by the methods described in the present invention and well known in the art, the compounds are tested for biological activity in further assays and/or animal models. Further, a lead compound may be used to design congeners or analogs. A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to PTCREs or NeRPs of the present invention include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like. In vitro The present invention includes and provides for assays capable of screening for compounds capable of modulating gene expression. In a preferred aspect of the present invention, an assay is an in vitro assay. In a preferred aspect of the present invention, an in vitro assay that measures translation. In a preferred aspect of the present invention the in vitro assay includes a nucleic acid molecule of the present invention or a construct of the present invention. In one embodiment, a reporter gene of the present invention can encode a fusion protein or a fusion protein comprising a domain that allows the expressed reporter gene to be bound to a solid support. For example, glutathione-S -transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, which are then combined with the compound or the compound and the non-adsorbed expressed reporter gene; the mixture is then incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components. Binding of the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can be dissociated from the solid support before binding is determined. Other techniques for immobilizing an expressed reporter gene or compound on a solid support also can be used in the screening assays of the invention. For example, either an expressed reporter gene or compound can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated expressed reporter genes or compounds can be prepared from biotin-NHS(N-hydroxysuccinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL) and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemicals, Rockford, IL). Alternatively, antibodies which specifically bind to an expressed reporter gene or compound, but which do not interfere with a desired binding or catalytic site, can be derivatized to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies which specifically bind to an expressed reporter gene or compound, enzyme-linked assays which rely on detecting an activity of an expressed reporter gene, electrophoretic mobility shift assays (EMSA), and SDS gel electrophoresis under reducing or non-reducing conditions. In one embodiment, translation of a reporter gene in vitro can be detected following the use of a reticulocyte lysate translation system, for example the TNT Coupled Reticulocyte Lysate System (Promega Co., Madison, WI). In this aspect, for example, without limitation, RNA (100 ng) can be translated at 30° C in reaction mixtures containing 70% reticulocyte lysate, 20 μM amino acids and RNase inhibitor (0.8 units/μl). After 45 minutes of incubation, 20 μl of Luclite can be added and luminescence can be read on the View-Lux. Different concentrations of compounds can be added to the reaction in a final DMSO concentration of 2%> and the EC50 values calculated. Puromycin can be used as control for general indiscriminate translation inhibition. In vitro transcripts encoding a reporter gene linked to specific UTRs from target genes, including GAPDH, XIAP, TNF-α, and HIF-lα, can also be used. To study the influence of cell-type specific factors, capped RNA can be translated in translation extracts prepared from specialized cells or cancer cell lines, for example without limitation, HT1080 cells (a human fibrosarcoma cell line). Briefly, the cells can be washed with PBS and swollen in hypotonic buffer (10 mM Hepes, pH 7.4, 15 mM KC1, 1.5 mM Mg(OAc)2, 2 mM DTT and 0.5 mM Pefabloc (Pentapharm Ltd. Co., Switzerland) for 5 minutes on ice. The cells can be lysed using a Dounce homogenizer (100 strokes), and the extracts can be spun for 10 minutes at 10,000 x g. These clarified extracts can then be flash- frozen in liquid nitrogen and stored in aliquots at -70°C. The translation reaction can be capped RNA (50 ng) in a reaction mixture containing 60%» clarified translation extract, 15 μM total amino acids, 0.2 mg/ml Creatine phosho-kinase, which are all in IX translation buffer (15 mM Hepes, pH 7.4, 85 mM KOAc, 1.5 mM Mg(OAc)2, 0.5 mM ATP, 0.075 mM GTP, 18 mM creatine diphosphate and 1.5 mM DTT). After incubation of the translation reaction for 90 min at 37°C, activity of the protein encoded by the reporter gene can be detected. For activity of luciferase, encoded by the luciferase gene serving as the reporter gene, addition of 20 μl of LucLite® (Packard Instrument Co., Inc., Meriden, CT) can be used. Capped and uncapped RNAs can be synthesized in vitro using the T7 polymerase transcription kits (Ambion Inc., Austin, TX). Capped RNAs from a variety of nucleic acid molecules of the present invention, including without limitation, constructs with VEGF linked to a PTCRE of the present invention, constructs with a reporter gene linked only to a vector, constructs with GAPDH linked to a PTCRE, constructs with a HIF-lα linked to a PTCRE, and constructs with a HIF-lα not linked to a PTCRE, can be used in a similar in vitro system to study the influence of cell-type specific factors on translation. In vivo The present invention includes and provides for assays capable of screening for compounds capable of modulating gene expression. In a preferred aspect of the present invention, an assay is an in vivo assay. A preferred aspect of the present invention is an assay that measures translation. In a preferred embodiment of the present invention, an in vivo assay includes a nucleic acid molecule of the present invention or a construct of the present invention and can include the use of a cell or a cell or tissue within an organism. In a more preferred embodiment, an in vivo assay includes a nucleic acid molecule of the present invention present in a cell or a cell or tissue within an organism. In another embodiment, in vivo translation of a reporter gene can be detected. In a preferred embodiment, a reporter gene is transfected into a cancer cell obtained from a cell line available at the (American Type Culture Collection (ATCC), Manassas, VA), for example HeLa, MCF-7, and COS-7, BT474. In a more preferred embodiment, a cancer cell has an altered genome relative to a similarly derived normal, primary cell, and the mammalian cancer cell proliferates under conditions where such a primary cell would not. Screening for compounds that modulate reporter gene expression can be carried out in an intact cell. Any cell that comprises a reporter gene can be used in a cell-based assay system. A reporter gene can be naturally occurring in the cell or can be introduced using techniques such as those described above (see Cells and Organisms). In one embodiment, a cell line is chosen based on its expression levels of naturally occurring VEGF. Modulation of reporter gene expression by a compound can be determined in vitro as described above or in vivo as described below. To detect expression of endogenous protein, a variety of protocols for detecting and measuring the expression of a reporter gene are known in the art. For example, Enzyme- Linked Immunosorbent Assays (ELIS As), western blots using either polyclonal or monoclonal antibodies specific for an expressed reporter gene, Fluorescence-Activated Cell Sorter (FACS), electrophoretic mobility shift assays (EMSA), or radioimmunoassay (RIA) can be performed to quantify the level of specific proteins in lysates or media derived from cells treated with the compounds. In a preferred embodiment, a phenotypic or physiological readout can be used to assess UTR-dependent activity of the target RNA in the presence and absence of the lead compound. A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides having a PTCRE or a NeRP of the present invention include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, sequences having a PTCRE or a NeRP of the present invention can be cloned into a vector for the production of a mRNA probe. Such vectors are known in the art, are commercially available, and can be used to synthesize RNA probes in vitro by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Biosciences Inc., Piscataway, NJ; and Promega Co, Madison, WI). Suitable reporter molecules or labels which can be used for ease of detection include radionucleotides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like. Therapeutic Uses The present invention also provides for methods for treating, preventing or ameliorating one or more symptoms of a disease or disorder associated with the aberrant expression of a target gene, said method comprising administering to a subject in need thereof a therapeutically or prophylactically effective amount of a compound, or a pharmaceutically acceptable salt thereof, identified according to the methods described herein. In one embodiment of the present invention, a target gene is aberrantly expressed. A target gene can be aberrantly overexpressed or expressed at an aberrantly low level. In particular, the invention provides for a method of treating or preventing a disease or disorder or ameliorating a symptom thereof, said method comprising administering to a subject in need thereof an effective amount of a compound, or a pharmaceutically acceptable salt thereof, identified according to the methods described herein, wherein said effective amount increases the expression of a target gene beneficial in the treatment or prevention of said disease or disorder. The invention also provides for a method of treating or preventing a disease or disorder or ameliorating a symptom thereof, said method comprising administering to a subject in need thereof an effective amount of a compound, or a pharmaceutically acceptable salt thereof, identified according to the methods described herein, wherein said effective amount decreases the expression of a target gene whose expression is associated with or has been linked to the onset, development, progression or severity of said disease or disorder. In a specific embodiment, the disease or disorder is a proliferative disorder, an inflammatory disorder, an infectious disease, a genetic disorder, an autoimmune disorder, a cardiovascular disease, or a central nervous system disorder. In an embodiment wherein the disease or disorder is an infectious disease, the infectious disease can be caused by a fungal infection, a bacterial infection, a viral infection, or an infection caused by another type of pathogen. In addition, the invention provides pharmaceutical compositions that can be administered to a patient to achieve a therapeutic effect. Pharmaceutical compositions of the invention can comprise, for example, ribozymes or antisense oligonucleotides, antibodies that specifically bind to a PTCRE or NeRP of the present invention, or mimetics, activators, inhibitors of PTCRE or NeRP activity, or a nucleic acid molecule of the present invention. The compositions can be administered alone or in combination with at least one other agent, such as stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones. In addition to the active ingredients, these pharmaceutical compositions can contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Pharmaceutical compositions of the invention can be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means. Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient. Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents can be added, such as the cross- linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate. Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers. Pharmaceutical formulations suitable for parenteral administration can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions can contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or tiiglycerides, or liposomes. Non-lipid polycationic amino polymers also can be used for delivery. Optionally, the suspension also can contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. The pharmaceutical compositions of the present invention can be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. The pharmaceutical composition can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation can be a lyophilized powder which can contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use. Further details on techniques for formulation and administration can be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.). After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration. Determination of a Therapeutically Effective Dose A therapeutically effective dose refers to that amount of active ingredient that increases or decreases reporter gene activity relative to reporter gene activity that occurs in the absence of the therapeutically effective dose. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dog, or pigs. The animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic efficacy and toxicity, e.g., ED50 (the dose therapeutically effective in 50%) of the population) and LD50 (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD5o/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect. Factors that can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation. Normal dosage amounts can vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc. If the reagent is a single-chain antibody, polynucleotides encoding the antibody can be constructed and introduced into a cell either ex vivo or in vivo using well-established techniques including, but not limited to, transferrin-polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, "gene gun," and DEAE- or calcium phosphate-mediated transfection. Effective in vivo dosages of an antibody are in the range of about 5 μg to about 50 μg/kg, about 50 μg to about 5 mg/kg, about 100 μg to about 500 μg/kg of patient body weight, and about 200 to about 250 μg/kg of patient body weight. For administration of polynucleotides encoding single-chain antibodies, effective in vivo dosages are in the range of about 100 ng to about 200 ng, 500 ng to about 50 mg, about 1 μg to about 2 mg, about 5 μg to about 500 μg, and about 20 μg to about 100 μg of DNA. If the expression product is mRNA, the reagent is preferably an antisense oligonucleotide or a ribozyme. Polynucleotides that express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described above. Preferably, a reagent reduces expression of a reporter gene or the activity of a reporter gene by at least about 10, preferably about 50, more preferably about 75, 90, or 100%) relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of expression of a reporter gene or the activity of a reporter gene can be assessed using methods well known in the art, such as hybridization of nucleotide probes to reporter gene- specific mRNA, quantitative RT-PCR, immunologic detection of an expressed reporter gene, or measurement of activity from an expressed reporter gene. In any of the embodiments described above, any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects. Any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans. Administration of a Therapeutically Effective Dose A reagent which affects translation can be administered to a human cell, either in vitro or in vivo, to specifically reduce translational activity of a specific gene. In a preferred embodiment, the reagent preferably binds to a 5' UTR of a gene. In an alternate embodiment, the present invention the reagent preferably binds to a PTCRE or NeRP of the present invention. In a preferred embodiment, the reagent is a compound. For treatment of human cells ex vivo, an antibody can be added to a preparation of stem cells which have been removed from the body. The cells can then be replaced in the same or another human body, with or without clonal propagation, as is known in the art. In one embodiment, the reagent is delivered using a liposome. Preferably, the liposome is stable in the animal into which it has been administered for at least about 30 minutes, more preferably for at least about 1 hour, and even more preferably for at least about 24 hours. A liposome comprises a lipid composition that is capable of targeting a reagent, particularly a polynucleotide, to a particular site in an animal, such as a human. Preferably, the lipid composition of the liposome is capable of targeting to a specific organ of an animal, such as the lung, liver, spleen, heart brain, lymph nodes, and skin. A liposome useful in the present invention comprises a lipid composition that is capable of fusing with the plasma membrane of the targeted cell to deliver its contents to the cell. Preferably, the transfection efficiency of a liposome is about 0.5 μg of DNA per 16 nmole of liposome delivered to about 106 cells, more preferably about 1.0 μg of DNA per 16 mnole of liposome delivered to about 106 cells, and even more preferably about 2.0 μg of DNA per 16 nmol of liposome delivered to about 106 cells. Preferably, a liposome is between about 100 and 500 nm, more preferably between about 150 and 450 nm, and even more preferably between about 200 and 400 nm in diameter. Suitable liposomes for use in the present invention include those liposomes standardly used in, for example, gene delivery methods known to those of skill in the art. More preferred liposomes include liposomes having a polycationic lipid composition and/or liposomes having a cholesterol backbone conjugated to polyethylene glycol. Optionally, a liposome comprises a compound capable of targeting the liposome to a particular cell type, such as a cell-specific ligand exposed on the outer surface of the liposome. Complexing a liposome with a reagent such as an antisense oligonucleotide or ribozyme can be achieved using methods that are standard in the art (see, for example, U.S. Pat. No. 5,705,151). Preferably, from about 0.1 μg to about 10 μg of polynucleotide is combined with about 8 nmol of liposomes, more preferably from about 0.5 μg to about 5 μg of polynucleotides are combined with about 8 nmol liposomes, and even more preferably about 1.0 μg of polynucleotides is combined with about 8 nmol liposomes. In another embodiment, antibodies can be delivered to specific tissues in vivo using receptor-mediated targeted delivery. Receptor-mediated DNA delivery techniques are taught in, for example, Findeis et al. Trends in Biotechnol. 11, 202-05 (1993); Chiou et al., Gene Therapeutics: Methods And Applications Of Direct Gene Transfer (J. A. Wolff, ed.) (1994); Wu & Wu, J. Biol. Chem. 263, 621-24 (1988); Wu et al., J. Biol. Chem. 269, 542-46 (1994); Zenke et al., Proc. Natl. Acad. Sci. U.S.A. 87, 3655-59 (1990); Wu et al., J. Biol. Chem. 266, 338-42 (1991). Diagnostic Methods Agents of the present invention can also be used in diagnostic assays for detecting diseases and abnormalities or susceptibility to diseases and abnormalities related to the presence of mutations in the nucleic acid sequences that encode a PTCRE or NeRP of the present invention. For example, differences can be determined between the cDNA or genomic sequence encoding a PTCRE or NeRP in individuals afflicted with a disease and in normal individuals. If a mutation is observed in some or all of the afflicted individuals but not in normal individuals, then the mutation is likely to be the causative agent of the disease. For example, the direct DNA sequencing method can reveal sequence differences between a reference gene and a gene having mutations. In addition, cloned DNA segments can be employed as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. For example, a sequencing primer can be used with a double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures using radiolabeled nucleotides or by automatic sequencing procedures using fluorescent tags. Moreover, for example, genetic testing based on DNA sequence differences can be carried out by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Small sequence deletions and insertions can be visualized, for example, by high-resolution gel electrophoresis. DNA fragments of different sequences can be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific melting or partial melting temperatures (see, e.g., Myers et al., Science 230, 1242, 1985). Sequence changes at specific locations can also be revealed by nuclease protection assays, such as RNase and SI protection or the chemical cleavage method (e.g., Cotton et al., Proc. Natl. Acad. Sci. USA 85, 4397-4401, 1985). Thus, the detection of a specific DNA sequence can be performed by methods such as hybridization, RNase protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes and Southern blotting of genomic DNA. In addition to direct methods such as gel-electrophoresis and DNA sequencing, mutations can also be detected by in situ analysis. Altered levels of a PTCRE or NeRP of the present invention can also be detected in various tissues. For example, one or more genes having a PTCRE or a NeRP can be detected by assays used to detect levels of particular nucleic acid sequence, such as Southern hybridization, northern hybridization, and PCR. Alternatively, assays can be used to detect levels of a reporter polypeptide regulated by a PTCRE or a NeRP or of a polypeptide encoded by a gene having a PTCRE or a NeRP. Such assays are well known to those of skill in the art and include radioimmunoassays, competitive binding assays, western blot analysis, and ELISA assays. A sample from a subject, such as blood or a tissue biopsy derived from a host, may be the material on which these assays are conducted. Having now generally described the invention, the same will be more readily understood through reference to the following examples that are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified. Each periodical, patent, and other document or reference cited herein is herein incorporated by reference in its entirety. Examples Example 1. Identification of compounds that specifically inhibit VEGF expression post-transcriptionally. A monocistronic reporter construct (pLuc/vegf5'+3'UTR) is under the transcriptional control of the CMV promoter and contains a VEGF IRES driving the luciferase reporter, which nucleic acid sequences are both upstream of a VEGF 3' -UTR. Stable cell lines are generated by transfecting 293 cells with the pLuc/vegf5'+3'UTR. A stable cell line is cultured under hygromycin B selection to create clonal cell lines consistent with protocols well known in the art. After two weeks of selection, clonal cell lines are screened for luciferase activity. The luciferase activity of several clonal cell lines (hereafter "clones") are compared and normalized against total protein content. Clones are maintained under hygromycin B selection for more than three months with intermittent monitoring of luciferase activity. Clones are stable and maintain a high level of luciferase expression. Many clones, for example, about twenty, may be compared to each other with respect to luciferase activity. In comparison to clones B9, D3, and H6, clone B9 exhibits the highest level of luciferase activity. In addition, semi-quantitative PCR analysis is performed, and the results indicate that multiple copies of the reporter are integrated per cell. Particular parameters for clones are studied prior to selection for use in post-transcriptional, high-throughput screening (PTHTS). Relevant parameters for PTHTS include, but are not limited to, cell number, incubation time, DMSO concentration, and volume of substrate. Chemical libraries in excess of 150,000 compounds are screened by PTHTS with a clone containing the monocistronic reporter construct, pLuc/vegf5'+3'UTR. Screens are performed in duplicate with each molecule at a single concentration of 7.5 μM. Bright-Glow (Promega Co., Madison, WI) is used as a substrate to measure firefly luciferase activity. Active compounds are identified by reporting the average percent inhibition of the duplicate runs followed by rejecting those compounds that did not provide satisfactory reproducibility. The average percent inhibition of compounds that provide satisfactory reproducibility is within a range of about 10%>, about 25% or about 35%> in duplicate runs. Data is analyzed as a normal distribution, which is apparent from graphical and statistical analysis of skewness and kurtosis. Hits are then reported at about a 99% confidence level, usually representing a selection of 3 standard deviations from the mean, or a hit lower limit of observed inhibition about equal to 50%. These selection criteria result in a hit rate of about 1%. Certain compounds that are identified through the PTHTS-screening tier by screening with clone B9 modulate hypoxia-inducible endogenous VEGF expression. Endogenous VEGF protein levels are monitored by an ELISA assay (R&D Systems, Minneapolis, MN). HeLa cells are used to evaluate hypoxia-inducible expression. HeLa cells demonstrate about a three- to five-fold hypoxia-inducible window as compared to normoxic conditions (about 1000 - about 1500 pg/ml under hypoxia compared to about 200 - about 400 pg/ml under normoxia). Cells are cultured overnight under hypoxic conditions (about 1%> O , about 5% CO2, and balanced with nitrogen) in the presence or absence of compounds. The conditioned media is assayed by ELISA. The concentration of VEGF is calculated from the standard ELISA curve of each assay. The assays are performed in duplicate at a compound concentration of about 7 μM. A threshold of about 50%o inl ibition for a compound is selected as a criterion for further investigation. Further evaluation of about 100 to about 150 compounds is conducted from about 700 to about 800 initial PTHTS hits. The activity of the identified compounds is confirmed by repeating the experiments described above. The identified compounds are then acquired as dry powders and analyzed further. The purity and molecular weight of the identified compounds are confirmed by LC-MS. A dose-response analysis is performed using an ELISA assay and using conditions essentially as described above. A series of seven different concentrations are analyzed. In parallel, a dose-response cytotoxicity assay is performed under the same conditions as the ELISA to ensure that the inhibition of VEGF expression is not due to cytotoxicity as measured by CellTiter-Glo® (Promega, Inc., Madison, WI). Dose-response curves are plotted using percentage inliibition versus concentration of the compound. For each compound, the maximal inhibition is set as 100%) and the minimal inhibition is set as 0%> to generate EC50 and CC50 values. A compound from PTHTS shows a sigmoidal curve over a compound concentration range from about lO^nM to about 10 nM when plotted against the percent inhibition of VEGF expression on the y-axis (see Figure 2). The same compound from PTHTS shows a convex curve over the same compound concentration range plotted against the percent of cytotoxicity. The ELISA EC50 (50%> inhibition of VEGF expression) for this particular compound is about 7 nM, while its CC50 (50%> cytotoxicity) is greater than about 2000 nM. Subsets of compounds that show similar efficacy/cytotoxicity windows are also identified. The B9 cell line harbors the firefly luciferase reporter driven by the CMV promoter and flanked by the 5'- and 3 '-UTRs of VEGF transcripts. Use of the B9 cell line with the PTHTS identifies compounds that specifically target the function of VEGF UTRs to modulate expression. Cell line B12 harbors the luciferase reporter in the absence of operably linked VEGF UTRs. Compounds that inhibit luciferase activity in both the B9 and B 12 cell lines are general transcription or general translation inhibitors or luciferase enzyme inhibitors. Several UTR specific compounds are identified in experiments with PTHTS identified compounds as described above. The dose-response curves of an identified compound show a concave curve in B9 cells and a sigmoidal curve in B12 cells when the percent luciferase inhibition of each is plotted over a compound concentration range from about lO^nM to about 104 nM on the x-axis (see Figure 3). The difference between the two cell lines (B9 and B12) shows that inhibition of VEGF production by this compound is through the VEGF UTRs, i.e., by a post-transcriptional control mechanism. A control experiment is performed with a general translation inhibitor, puromycin. Puromycin treatment does not change the difference of inhibition in luciferase expression in these two cell lines. Example 2. Characteristics ofUTR-specific VEGF inhibitors All identified compounds are re-synthesized and shown by LC/MS and combustion analysis to be greater than 95%> pure. Subsequently, the re-synthesized compounds are tested in the dose-response VEGF ELISA and luciferase assays that are used to initially assess UTR specificity. All identified compounds retain UTR specificity and are bonafide inhibitors of VEGF expression. PTHTS using B9 cells identified compounds that specifically inhibit hypoxia inducible VEGF expression for the treatment of ocular neovascular diseases. Compounds that target multiple angiogenesis factors (including VEGF) for the treatment of cancers are also identifiable. Several targets are used for these purposes, including TNF-α, FGF-2, G- CSF, IGF-1, PDGF, and HIF-lα. ELISA assays analyze levels of expression of these factors using commercially available kits from R&D Systems (Minneapolis, MN). UTR-specific PTHTS identified compounds are tested for their ability to inhibit the expression of a subset of these proteins, including G-CSF, TNFα, FGF-2, and IGF-1. Identified compounds that are very potent inhibitors of VEGF production as assayed in HeLa cells have EC50 values ranging from low nM to high nM. Treatment with a general translation inhibitor (puromycin) results in similar inhibition for all these cytokines, with EC50 values ranging from about 0.2 to about 2 μM. Lead compounds are further characterized and optimized. Analogs are synthesized and identified compounds exhibit excellent potency in the VEGF ELISA assay (EC50 values ranging from 0.5 nM to 50 nM). In another embodiment, an analog exhibits low nM potency. In an additional embodiment, several analogs are synthesized and a subset of identified compounds are very active (EC50 values ranging from 1 to 50 nM) in the VEGF ELISA assay. Activity of a very potent analog is improved about 500-fold compared to its parent (EC50 of 1 nM vs. 500 nM). Further characterization and optimization for selectivity and pharmaceutical properties (ADMET) of the most active compounds will develop a drug candidate(s) for clinical trials. Example 3. Identified compounds are active as inhibitors of hypoxia-inducible VEGF production in retinal pigment epithelial cells and macrophage cells. PTHTS identified compounds are VEGF-specific inhibitors for the treatment of ocular neo vascular disorders. The effect of the identified compounds on retinal pigment epithelial cells and macrophage cells are tested in two cell lines: ARPE-19, a human retinal pigment epithelial cell line, and RAW264, a mouse macrophage cell line. Both cell lines produce high levels of VEGF under hypoxic conditions. A subset of identified compounds is active in these two cell lines. Compound 1 inhibits VEGF production in both macrophage (a non-limiting example of which is RAW264.7) and retinal pigment epithelial cells (a non-limiting example of which is ARPE-19). In selectivity studies, as shown in Table 2, Compound 1 specifically inhibits VEGF expression relative to that of other factors (FGF-2, IGF-1, GCSF, TNFα).
Figure imgf000059_0001
Example 4. Identified compounds are active in inhibition of VEGF expression and tumor growth in vivo. A pharmacodynamic model assesses intratumor VEGF levels and selects compounds for in vivo efficacy. Preliminary data demonstrates that several of our compounds effectively inhibit VEGF production in tumor tissues (see Figure 4A). Briefly, HT1080 cells (a human fibrosarcoma cell line) are implanted subcutaneously in nude mice. After seven days, mice are administrated compounds orally at 20mg/kg/day for two weeks. The tumors are then excised from the mice and homogenized in Tris-HCl buffer containing proteinase inhibitors (Moulder, S.L., et al, Cancer Res. 61(24):8887-95, 2001). Intratumor VEGF levels are subsequently measured using a human VEGF ELISA kit (R&D System, Minneapolis, MN). Protein concentrations of the homogenates are measured with a Bio-Rad™ Protein assay kit and intratumor VEGF levels are normalized to the protein concentrations. Treatment with the identified compounds significantly reduces intratumor VEGF protein levels compared to the vehicle control. In addition, treatment with the identified compound for two weeks inhibits tumor growth as compared to the vehicle-treated control groups (see Figure 4B). Example 5. Mapping of Functional Domains in a 5' VEGF UTR. VEGF-5UTR1 and 5UTR2 are amplified from human genomic DNA. The full-length 5' UTR is generated by ligation of the two fragments (see Figure 5). P21uc/VEGF5UTR-FL is generated by inserting the full-length 5' UTR into a dicistronic plasmid (p21uc) between Sal land Smαl I sites. Other vectors are derived from p21uc/VEGF5UTR-FL by deleting relevant sequences. All these plasmids are tested in 293 cells by transient transfection. Figure 6 shows the relative fire-fly luciferase activity (normalized against Renilla luciferase) for each of the VEGF 5' UTR fragments. Similar results are obtained from repeating such experiments.

Claims

WHAT IS CLAIMED:
1. A nucleic acid construct comprising a nucleic acid sequence encoding a reporter polypeptide, wherein said nucleic acid sequence encoding a reporter polypeptide is operably linked to a NeRP, said NeRP is operably linked to a PTCRE, said PTCRE is not SEQ ID NO: 3, and expression of said reporter polypeptide is capable of being modulated relative to in an absence of said NeRP.
2. The nucleic acid construct according to claim 1, wherein a NeRPl (SEQ ID NO: 4) is located within said nucleic acid sequence encoding a reporter polypeptide.
3. The nucleic acid construct according to claim 1, wherein a NeRPl (SEQ ID NO: 4) is located downstream of said nucleic acid sequence encoding a reporter polypeptide.
4. The nucleic acid construct according to claim 1, wherein a NeRPl (SEQ ID NO: 4) is located within an intron and said intron is located within said nucleic acid sequence encoding a reporter polypeptide.
5. A nucleic acid molecule comprising a nucleic acid sequence encoding a reporter polypeptide and a VEGF 5' UTR nucleic acid sequence in an absence of SEQ ID NO: 4.
6. The nucleic acid molecule according to claim 5, wherein said VEGF 5' UTR in an absence of SEQ ID NO: 4 contains an internal ribosome entry site ("IRES").
7. The nucleic acid molecule according to claim 5, further comprising a high-level mammalian expression vector capable of integrating randomly into the genome.
8. The nucleic acid molecule according to claim 5, further comprising a high-level mammalian expression vector capable of integrating site-selectively into the genome.
9. The nucleic acid molecule according to claim 5, further comprising an episomal mammalian expression vector.
10. The nucleic acid molecule according to claim 5, wherein said nucleic acid sequence encoding a reporter polypeptide contains an intron.
11. The nucleic acid molecule according to claim 5, wherein said VEGF 5' UTR in an absence of SEQ ID NO: 4 contains an intron.
12. A nucleic acid molecule comprising a nucleic acid sequence encoding a reporter polypeptide operably linked to a VEGF 5' UTR in an absence of SEQ ID NO: 4.
13. The nucleic acid molecule according to claim 12, wherein said nucleic acid sequence encoding a reporter polypeptide contains an intron.
14. A nucleic acid molecule comprising a nucleic acid sequence encoding a reporter polypeptide, wherein said nucleic acid sequence encoding a reporter polypeptide is operably linked downstream of a UTR containing a NeRP, and said UTR is not operably upstream of SEQ ID NO: 3.
15. A heterogeneous population of nucleic acid molecules, wherein said heterogeneous population comprises a reporter nucleic acid sequence, and said nucleic acid sequence encoding a reporter polypeptide is operably linked to a VEGF 5' UTR in an absence of NeRPl (SEQ ID NO: 4).
16. The heterogeneous population of nucleic acid molecules according to claim 15, wherein said heterogeneous population is isolated from a stable cell line.
17. The heterogeneous population of nucleic acid molecules according to claim 15, wherein said population is produced in vitro.
18. The heterogeneous population of nucleic acid molecules according to claim 15, wherein said population is used to produce polypeptides.
19. The heterogeneous population of nucleic acid molecules according to claim 15, wherein said heterogeneous population is selected to exclude molecules with a 5' cap.
20. The heterogeneous population of nucleic acid molecules according to claim 15, wherein said heterogeneous population is poly-adenylated.
21. The heterogeneous population of nucleic acid molecules according to claim 15, wherein said heterogeneous population is not poly-adenylated.
22. A substantially purified nucleic acid molecule comprising between 95% and 99% sequence identity with a nucleic acid molecule of SEQ ID NO: 3, a fragment thereof, or a complement of either.
23. A substantially purified nucleic acid molecule consisting of SEQ ID NO: 3, a fragment thereof, or a complement of either.
24. A substantially purified nucleic acid molecule consisting of a first nucleic acid sequence linked to a heterologous nucleic acid sequence encoding a polypeptide, wherein said first nucleic acid sequence is selected from the group consisting of SEQ ID NO: 3, a fragment thereof, and a complement of either.
25. A substantially purified nucleic acid molecule comprising between 95% and 99%> sequence identity with a nucleic acid molecule of SEQ ID NO: 4, a fragment thereof, or a complement of either.
26. A substantially purified nucleic acid molecule of a nucleic acid sequence selected from a group consisting of SEQ ID NO: 4, a fragment thereof, and a complement of either.
27. A substantially purified nucleic acid molecule consisting of a first nucleic acid sequence linked to a heterologous nucleic acid sequence encoding a polypeptide, wherein said first nucleic acid sequence is selected from the group consisting of SEQ ID NO: 4, a fragment thereof, and a complement of either.
28. A method of making a nucleic acid construct to screen for a compound comprising: a) providing a main ORF downstream of a promoter in said nucleic acid construct; b) operably linking a VEGF 5' UTR in an absence of SEQ ID NO: 4 upstream of said main ORF; and c) operably linking a VEGF 3 ' UTR downstream of said main ORF.
29. The method according to claim 28, wherein said main ORF encodes a reporter polypeptide.
30. A method of screening in vivo for a compound that modulates UTR-dependent expression comprising: a) providing a cell having a nucleic acid molecule comprising a promoter upstream from a VEGF 5' UTR in an absence of SEQ ID NO: 4, wherein said VEGF 5' UTR in an absence of SEQ ID NO: 4 is upstream from a nucleic acid sequence encoding a reporter polypeptide, and said nucleic acid sequence encoding a reporter polypeptide is upstream from a VEGF 3' UTR; b) contacting said cell with a compound; c) producing a nucleic acid molecule that contains a nucleic acid sequence encoding a reporter polypeptide and does not contain SEQ ID NO: 4; and d) detecting said reporter polypeptide.
31. The method according to claim 30, wherein said nucleic acid sequence encoding a reporter polypeptide is VEGF.
32. A method of screening in vitro for a compound that modulates UTR-affected expression comprising: a) providing an in vitro translation system; b) contacting said in vitro translation system with a compound and a nucleic acid molecule comprising a VEGF 5' UTR in an absence of SEQ ID NO: 4, wherein said VEGF 5' UTR in an absence of SEQ ID NO: 4 is upstream from a nucleic acid sequence encoding a reporter polypeptide and said nucleic acid sequence encoding a reporter polypeptide is upstream from a VEGF 3' UTR; and c) detecting said reporter polypeptide in vitro.
33. A method of expressing a nucleic acid molecule in a cell comprising: a) providing a nucleic acid molecule to a cell, wherein said nucleic acid molecule comprises a nucleic acid sequence encoding a reporter polypeptide flanked by VEGF UTRs in an absence of SEQ ID NO: 4; and b) detecting said reporter polypeptide.
34. The method according to claim 33, wherein said nucleic acid molecule is produced by in vitro transcription.
35. The method according to claim 33, wherein said nucleic acid molecule is a synthetically produced RNA molecule.
36. A method of screening for a compound that modulates protein expression through a main ORF-independent, UTR-affected mechanism comprising: a) growing a stable cell line having a reporter gene operably linked to a VEGF 5' UTR in an absence of SEQ ID NO: 4; b) comparing said stable cell line in a presence of a compound relative to said stable cell line in an absence of said compound; and c) selecting for said compound that modulates protein expression through a main ORF- independent, UTR-affected mechanism.
37. A method of screening for a compound that modulates protein expression through a main ORF-independent, UTR-affected mechanism comprising: a) growing a stable cell line having a main ORF operably linked to a VEGF 5' UTR in an absence of SEQ ID NO: 4; b) comparing said stable cell line in the presence of a compound relative to said stable cell line in the absence of said compound; and c) selecting for said compound that modulates protein expression through a main ORF- independent, UTR-affected mechanism.
38. A method of screening for a compound that modulates protein expression through a VEGF-independent, UTR-affected mechanism comprising: a) substituting in vivo a VEGF gene with a reporter gene, wherein a UTR consisting of SEQ ID NO: 3 is operably linked to said reporter gene, and said substitution occurs in a differentiated cell; b) growing said differentiated cell; and c) selecting for said compound that modulates protein expression of said reporter gene through a main ORF-independent, UTR-affected mechanism.
39. A method of screening for a compound that modulates protein expression through a main ORF-independent, UTR-affected mechanism comprising: a) substituting in vivo a main ORF with a reporter gene, wherein a 5' UTR is operably linked to said reporter gene and consists of SEQ ID NO: 3, and said substitution occurs in a differentiated cell; b) growing said differentiated cell; and c) selecting for said compound that modulates protein expression of said reporter gene through a main ORF-independent, UTR-affected mechanism.
40. A method of screening for a compound that modulates protein expression through a UTR-affected mechanism comprising: a) providing a stable cell line having a reporter gene operably linked to a VEGF 5' UTR in an absence of SEQ ID NO: 4, wherein said stable cell line mimics post- transcriptional regulation of a VEGF gene found in vivo in presence of said compound; b) maintaining said stable cell line; and c) selecting for said compound that modulates protein expression of said reporter gene through a UTR-affected mechanism.
41. The method according to claim 40, wherein said stable cell line is a transformed cell.
42. A method of screening for a compound that modulates protein expression through a UTR-affected mechanism comprising: a) providing a stable cell line having a main ORF encoding a reporter polypeptide operably linked to a VEGF 5' UTR in an absence of SEQ ID NO: 4, wherein said stable cell line mimics post-transcriptional regulation of a VEGF gene found in vivo in a presence of a compound; b) maintaining said stable cell line; and c) selecting for said compound that modulates protein expression of said main ORF through a UTR-affected mechanism.
43. A method of screening for a compound that modulates protein expression through a UTR-affected mechanism mediating the effect of a NeRP comprising: a) growing a stable cell line having a reporter gene operably linked to a 5' VEGF UTR in an absence of a NeRPl (SEQ ID NO: 4); b) comparing said stable cell line in a presence of a compound relative to in an absence of said compound, wherein said compound does not modulate UTR-dependent expression if said 5' VEGF UTR in an absence of a NeRPl (SEQ ID NO: 4) is operably linked to a reporter gene; and c) selecting for said compound that modulates protein expression of said reporter gene through a UTR-affected mechanism mediating the effect of a NeRP.
44. The method according to claim 43, wherein said c) selecting for said compound comprises comparing said stable cell line in the presence of a compound relative to in the absence of said compound, wherein said compound modulates UTR-dependent expression if said reporter gene is operably linked to said 5' VEGF UTR.
45. A method of screening for a compound that modulates protein expression through a UTR-affected mechanism mediating the effect of a NeRP comprising: a) growing a stable cell line having a main ORF encoding a reporter polypeptide operably linked to a 5' VEGF UTR in an absence of a NeRPl (SEQ ID NO: 4); b) comparing said stable cell line in the presence of a compound relative to in the absence of said compound, wherein said compound does not modulate UTR-dependent expression if said 5' VEGF UTR in an absence of a NeRPl (SEQ ID NO: 4) is operably linked to a main ORF; and c) selecting for said compound that modulates protein expression of said main ORF through a UTR-affected mechanism mediating the effect of a NeRP.
46. A method of screening for a compound that modulates protein expression through a UTR-affected mechanism mediating the effect of a NeRP comprising: a) growing a stable cell line having a reporter gene operably linked to a UTR having a NeRPl (SEQ ID NO: 4); b) comparing said stable cell line in a presence of a compound relative to in an absence of said compound, wherein said compound modulates UTR-dependent expression if a NeRPl (SEQ ID NO: 4) is operably linked to a reporter gene; and c) selecting for said compound that modulates protein expression of said reporter gene through a UTR-affected mechanism mediating the effect of a NeRP.
47. A method of screening for a compound that modulates protein expression through a UTR-affected mechanism mediating the effect of a NeRP comprising: a) growing a stable cell line having a main ORF encoding a reporter polypeptide operably linked to a UTR having a NeRPl (SEQ ID NO: 4); b) comparing said stable cell line in a presence of a compound relative to in an absence of said compound, wherein said compound modulates UTR-dependent expression if a NeRPl (SEQ ID NO: 4) is operably linked to a main ORF encoding a reporter polypeptide; and c) selecting for said compound that modulates protein expression of said main ORF encoding a reporter polypeptide through a UTR-affected mechanism mediating the effect of said NeRP.
PCT/US2004/020751 2004-05-24 2004-06-28 Methods and agents for screening for compounds capable of modulating vegf expression WO2005118857A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2567111A CA2567111C (en) 2004-05-24 2004-06-28 Methods and agents for screening for compounds capable of modulating vegf expression
EP04809465A EP1761638A4 (en) 2004-05-24 2004-06-28 Methods and agents for screening for compounds capable of modulating vegf expression
JP2007515026A JP2008507953A (en) 2004-05-24 2004-06-28 Methods and agents for screening for compounds capable of modulating VEGF expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/851,074 2004-05-24
US10/851,074 US8426194B2 (en) 2003-01-21 2004-05-24 Methods and agents for screening for compounds capable of modulating VEGF expression

Publications (2)

Publication Number Publication Date
WO2005118857A2 true WO2005118857A2 (en) 2005-12-15
WO2005118857A3 WO2005118857A3 (en) 2008-01-03

Family

ID=35463461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/020751 WO2005118857A2 (en) 2004-05-24 2004-06-28 Methods and agents for screening for compounds capable of modulating vegf expression

Country Status (5)

Country Link
US (1) US8426194B2 (en)
EP (3) EP1761638A4 (en)
JP (2) JP2008507953A (en)
CA (2) CA2872701A1 (en)
WO (1) WO2005118857A2 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2198891A1 (en) * 2007-09-07 2010-06-23 The University of Tokushima Method for promoting the expression of p53, and p53 expression promoter for use in the method
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
US8460864B2 (en) 2003-01-21 2013-06-11 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
WO2013151668A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of secreted proteins
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US9181319B2 (en) 2010-08-06 2015-11-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
US9255129B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9587003B2 (en) 2012-04-02 2017-03-07 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9657295B2 (en) 2010-10-01 2017-05-23 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9950068B2 (en) 2011-03-31 2018-04-24 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US10022425B2 (en) 2011-09-12 2018-07-17 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US10653712B2 (en) 2016-09-14 2020-05-19 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
US11912982B2 (en) 2017-08-18 2024-02-27 Modernatx, Inc. Methods for HPLC analysis
US11926817B2 (en) 2019-08-09 2024-03-12 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598079B2 (en) * 1998-12-24 2009-10-06 Novation Pharmaceuticals, Inc. Assay for identifying compounds which affect stability of mRNA
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
KR20120073287A (en) * 2004-03-15 2012-07-04 피티씨 테라퓨틱스, 인크. Carboline derivatives useful in the inhibition of angiogenesis
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
JP2014510140A (en) 2011-04-07 2014-04-24 ザ プロクター アンド ギャンブル カンパニー Conditioner composition with increased adhesion of polyacrylate microcapsules
EP2694017B1 (en) 2011-04-07 2019-05-22 The Procter and Gamble Company Personal cleansing compositions with increased deposition of polyacrylate microcapsules
US8927026B2 (en) 2011-04-07 2015-01-06 The Procter & Gamble Company Shampoo compositions with increased deposition of polyacrylate microcapsules
CN110511939A (en) 2011-10-03 2019-11-29 现代泰克斯公司 Nucleosides, nucleotide and nucleic acid of modification and application thereof
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
JP2013220090A (en) * 2012-04-19 2013-10-28 Tohoku Univ Drug screening method for use in eye disease treatment
PT2922554T (en) 2012-11-26 2022-06-28 Modernatx Inc Terminally modified rna
CA2964161A1 (en) * 2014-10-10 2016-04-14 Dana-Farber Cancer Institute, Inc. Methods for discovering therapeutics that alter the stability of target proteins
WO2018053006A1 (en) 2016-09-13 2018-03-22 Dana-Farber Cancer Institute, Inc. Methods and compositions for the positive selection of protein destabilizers

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3346381A (en) 1964-07-30 1967-10-10 Rca Corp Electrostatic recording element
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5144019A (en) 1989-06-21 1992-09-01 City Of Hope Ribozyme cleavage of HIV-I RNA
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
EP0537270B1 (en) 1990-07-02 1998-09-09 The Regents Of The University Of California Detection of analytes using fluorescent energy transfer
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5444149A (en) 1992-05-11 1995-08-22 Duke University Methods and compositions useful in the recognition, binding and expression of ribonucleic acids involved in cell growth, neoplasia and immunoregulation
US6824976B1 (en) 1993-04-02 2004-11-30 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
US5700660A (en) 1993-05-24 1997-12-23 University Of Masachusetts Medical Center Positional control of selenium insertion in polypeptides for X-ray crystallography
US5849520A (en) 1993-05-24 1998-12-15 University Of Massachusetts Medical Center Post transcriptional gene regulation by selenium
US5908779A (en) 1993-12-01 1999-06-01 University Of Connecticut Targeted RNA degradation using nuclear antisense RNA
US5587300A (en) 1994-04-26 1996-12-24 Wisconsin Ulumni Research Foundation Method to increase regulatory molecule production
CA2191583C (en) 1994-06-07 2007-03-27 Engin Ozkaynak Methods and compositions for modulating morphogenic protein expression
US5731343A (en) 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US5922852A (en) 1995-06-07 1999-07-13 Oklahoma Medical Research Foundation 3' untranslated region of the human prohibitin gene
US6303295B1 (en) 1995-07-14 2001-10-16 University Of Georgia Research Foundation, Inc. Selenoproteins, coding sequences and methods
WO1997025860A1 (en) 1996-01-19 1997-07-24 Allegheny University Of The Health Sciences Cellular immunogens useful as cancer vaccines
US5843770A (en) 1996-03-11 1998-12-01 The Immune Response Corporation Antisense constructs directed against viral post-transcriptional regulatory sequences
US6004749A (en) 1996-07-31 1999-12-21 Message Pharmaceuticals Method for identifying compounds affecting RNA/RNA binding protein interactions
US6107029A (en) 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
US5859227A (en) 1996-07-31 1999-01-12 Bearsden Bio, Inc. RNA sequences which interact with RNA-binding proteins
US5691145A (en) 1996-08-27 1997-11-25 Becton, Dickinson And Company Detection of nucleic acids using G-quartets
JP4100712B2 (en) * 1996-09-20 2008-06-11 アスビオファーマ株式会社 Screening method for compounds that regulate the expression of human inducible nitric oxide synthase
US5928888A (en) 1996-09-26 1999-07-27 Aurora Biosciences Corporation Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
EP1012268A4 (en) * 1997-02-25 2001-11-28 Qbi Entpr Ltd Ires sequences with high translational efficiency and expression vectors containing the sequence
WO1998039484A1 (en) 1997-03-05 1998-09-11 Scriptgen Pharmaceuticals, Inc. Screen employing fluorescence anisotropy to identify compounds with affinity for nucleic acids
JPH1142091A (en) * 1997-07-25 1999-02-16 Toagosei Co Ltd Anti-sense nucleic acid compound
US6221612B1 (en) 1997-08-01 2001-04-24 Aurora Biosciences Corporation Photon reducing agents for use in fluorescence assays
US6214563B1 (en) 1997-08-01 2001-04-10 Aurora Biosciences Corporation Photon reducing agents for reducing undesired light emission in assays
US5990298A (en) 1997-09-12 1999-11-23 The University Of Connecticut CIS-acting cellular nucleic acid molecules
US6521433B1 (en) 1997-09-17 2003-02-18 E. I. Du Pont De Nemours And Company cDNA sequences from plants that encode activities associated with isoflavone biosynthesis
US7598361B2 (en) 1997-11-24 2009-10-06 Monsanto Technology Llc Nucleic acid molecules and other molecules associated with the sucrose pathway
US6265546B1 (en) 1997-12-22 2001-07-24 Genset Prostate cancer gene
US6221587B1 (en) 1998-05-12 2001-04-24 Isis Pharmceuticals, Inc. Identification of molecular interaction sites in RNA for novel drug discovery
JP2002519027A (en) 1998-06-30 2002-07-02 ジェンセット Nucleic acids encoding retinoblastoma binding protein (RBP-7) and polymorphic markers associated with said nucleic acids
EP1097233B1 (en) 1998-07-15 2008-12-03 Metamorphix, Inc. Growth differentiation factor promoter and uses therefor
US6159709A (en) 1998-07-24 2000-12-12 Apoptogen, Inc. XIAP IRES and uses thereof
US6171821B1 (en) * 1998-07-24 2001-01-09 Apoptogen, Inc. XIAP IRES and uses thereof
AU2342900A (en) 1998-09-23 2000-05-01 Cleveland Clinic Foundation, The Novel interferon stimulated and repressed genes
US6465176B1 (en) 1998-10-02 2002-10-15 Message Pharmaceuticals, Inc. Method for identifying compounds RNA/RNA binding protein interactions
AU1201600A (en) 1998-10-08 2000-04-26 University Of Massachusetts Controlling gene expression in living cells
US6476208B1 (en) 1998-10-13 2002-11-05 Genset Schizophrenia associated genes, proteins and biallelic markers
US6232070B1 (en) 1998-11-09 2001-05-15 Stewart Shuman Pharmacological targeting of mRNA cap formation
JP2002531515A (en) 1998-12-11 2002-09-24 ファーマソリューションズ・インコーポレイテッド Self-emulsifying compositions for poorly water soluble drugs
US6455280B1 (en) 1998-12-22 2002-09-24 Genset S.A. Methods and compositions for inhibiting neoplastic cell growth
GB9828709D0 (en) 1998-12-24 1999-02-17 Novartis Ag Assay
US6635671B1 (en) 1998-12-24 2003-10-21 Novation Pharmaceuticals Inc. Compounds which affect mRNA stability and uses therefor
US7598079B2 (en) 1998-12-24 2009-10-06 Novation Pharmaceuticals, Inc. Assay for identifying compounds which affect stability of mRNA
WO2000046247A1 (en) 1999-02-05 2000-08-10 Merck & Co., Inc. Methods of use for dna molecules encoding m68, a tnf receptor-related protein
US6284882B1 (en) * 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof
US6448007B1 (en) 1999-07-02 2002-09-10 Message Pharmaceuticals Functional genomic screen for post-transcriptional 5′ and 3′ regulatory elements
US6645747B1 (en) 1999-09-21 2003-11-11 E. I. Du Pont De Nemours And Company Cis-prenyltransferases from plants
US6528060B1 (en) * 2000-03-16 2003-03-04 Genzyme Corporation Therapeutic compounds
US6627797B1 (en) 2000-03-21 2003-09-30 The Texas A&M University System Maize lipoxygenase polynucleotide and methods of use
JP2001340080A (en) * 2000-03-31 2001-12-11 Hochi Oka Searching system for insulin-resistant ameliorant without possibility of exacerbating diabetic retinopathy and without edema inducing action
WO2001084155A1 (en) 2000-04-28 2001-11-08 Message Pharmaceuticals, Inc. Methods for identifying novel nucleic acid regulatory elements and compounds that affect the regulation
US6331170B1 (en) 2000-06-05 2001-12-18 Griffin Ordway Adjustable back support
EP1176196A1 (en) 2000-07-24 2002-01-30 Message Pharmaceuticals, Inc. Functional genomic screen for post-transcriptional 5' and 3' regulatory elements
CA2465534C (en) 2000-11-02 2009-10-27 Nigel H. Greig Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
EP1229134A3 (en) 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2002077609A2 (en) 2001-03-26 2002-10-03 Message Pharmaceuticals, Inc. Identification of compounds for the treatment or prevention of proliferative diseases
WO2002083842A2 (en) 2001-04-10 2002-10-24 Message Pharmaceuticals, Inc. Small molecule inhibitors of secretion of proteins encoded by are-mrnas
CA2443711A1 (en) 2001-04-11 2002-10-24 Ptc Therapeutics, Inc. Methods for identifying small molecules that bind specific rna structural motifs
WO2003087815A2 (en) 2002-04-17 2003-10-23 Novartis Ag Method for the identification of inhibitors of the binding of are-containing mrn a and an hur protein
WO2004005891A2 (en) 2002-07-10 2004-01-15 The Regents Of The University Of Michigan Expression profile of lung cancer
US8460864B2 (en) 2003-01-21 2013-06-11 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
US20070072186A1 (en) * 2003-11-17 2007-03-29 Anuradha Mehta Methods and agents for screening for compounds capable of modulating her2 expression
UA93855C2 (en) * 2003-12-31 2011-03-25 Шеринг-Плау Лтд. Neutralizing epitope-based growth enhancing vaccine
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
KR20120073287A (en) * 2004-03-15 2012-07-04 피티씨 테라퓨틱스, 인크. Carboline derivatives useful in the inhibition of angiogenesis
US8076353B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1761638A4 *

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493845B2 (en) 2003-01-21 2016-11-15 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
US8460864B2 (en) 2003-01-21 2013-06-11 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US9376725B1 (en) 2007-06-20 2016-06-28 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using human ALPHA7 integrin mRNA translation regulation
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8741572B1 (en) 2007-06-20 2014-06-03 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using mIGF1 mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
US9394539B1 (en) 2007-06-22 2016-07-19 Ptc Therapeutics, Inc. Survival motor neuron gene (SMN2) mRNA constructs for post-transcription regulation
EP2198891A1 (en) * 2007-09-07 2010-06-23 The University of Tokushima Method for promoting the expression of p53, and p53 expression promoter for use in the method
EP2198891A4 (en) * 2007-09-07 2011-12-21 Univ Tokushima Method for promoting the expression of p53, and p53 expression promoter for use in the method
US9181319B2 (en) 2010-08-06 2015-11-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9937233B2 (en) 2010-08-06 2018-04-10 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9657295B2 (en) 2010-10-01 2017-05-23 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US10064959B2 (en) 2010-10-01 2018-09-04 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9950068B2 (en) 2011-03-31 2018-04-24 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US10022425B2 (en) 2011-09-12 2018-07-17 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US10751386B2 (en) 2011-09-12 2020-08-25 Modernatx, Inc. Engineered nucleic acids and methods of use thereof
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151668A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of secreted proteins
US9255129B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding SIAH E3 ubiquitin protein ligase 1
US9089604B2 (en) 2012-04-02 2015-07-28 Moderna Therapeutics, Inc. Modified polynucleotides for treating galactosylceramidase protein deficiency
US9061059B2 (en) 2012-04-02 2015-06-23 Moderna Therapeutics, Inc. Modified polynucleotides for treating protein deficiency
US9587003B2 (en) 2012-04-02 2017-03-07 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9050297B2 (en) 2012-04-02 2015-06-09 Moderna Therapeutics, Inc. Modified polynucleotides encoding aryl hydrocarbon receptor nuclear translocator
US9782462B2 (en) 2012-04-02 2017-10-10 Modernatx, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9814760B2 (en) 2012-04-02 2017-11-14 Modernatx, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9827332B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of proteins
US9828416B2 (en) 2012-04-02 2017-11-28 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2013151736A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics In vivo production of proteins
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
US10653712B2 (en) 2016-09-14 2020-05-19 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
US11202793B2 (en) 2016-09-14 2021-12-21 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
US11866696B2 (en) 2017-08-18 2024-01-09 Modernatx, Inc. Analytical HPLC methods
US11912982B2 (en) 2017-08-18 2024-02-27 Modernatx, Inc. Methods for HPLC analysis
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
US11926817B2 (en) 2019-08-09 2024-03-12 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof

Also Published As

Publication number Publication date
EP1761638A4 (en) 2009-01-14
US8426194B2 (en) 2013-04-23
EP2400038A1 (en) 2011-12-28
WO2005118857A3 (en) 2008-01-03
US20040214223A1 (en) 2004-10-28
CA2872701A1 (en) 2005-12-15
EP2400038B1 (en) 2014-06-25
JP2011041579A (en) 2011-03-03
CA2567111C (en) 2015-02-17
CA2567111A1 (en) 2005-12-15
JP2008507953A (en) 2008-03-21
EP2806036A1 (en) 2014-11-26
EP1761638A2 (en) 2007-03-14

Similar Documents

Publication Publication Date Title
EP2400038B1 (en) Methods and nucleic acid constructs for screening for compounds capable of modulating VEGF expression
US9476870B2 (en) Methods and agents for screening for compounds capable of modulating gene expression
US20050208486A1 (en) Brca-1 regulators and methods of use
JPH06511386A (en) Methods for identifying ligands and antagonists of ligands
US7105656B2 (en) Compositions and methods for treating hematologic malignancies and multiple drug resistance
US20070072186A1 (en) Methods and agents for screening for compounds capable of modulating her2 expression
US20150330981A1 (en) PGC-1beta-Protein-Function Regulator, Mitochondria-Function Regulator, Anti-Obesity Agent, And Screening Method Therefor
EP2307573B1 (en) Methods for screening for compounds for treating cancer
JP2014006195A (en) Screening method of compound for increasing expression level of chip
US8084434B2 (en) Runx2 isoforms in angiogenesis
WO2009084668A1 (en) Method of inhibiting cancer cell proliferation, proliferation inhibitor and screening method
JP2002541760A (en) c-myc is activated by β-catenin and TCF-4
KR102040362B1 (en) Markers for diagnosing ocular marginal zone lymphoma and uses thereof
JP2003527860A (en) BRCA-1 regulatory factors and methods of use
JPWO2005052150A1 (en) Insulin gene transcription regulation method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2567111

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007515026

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2004809465

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004809465

Country of ref document: EP